<SEC-DOCUMENT>0001295345-16-000646.txt : 20160822
<SEC-HEADER>0001295345-16-000646.hdr.sgml : 20160822
<ACCEPTANCE-DATETIME>20160822170736
ACCESSION NUMBER:		0001295345-16-000646
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		48
CONFORMED PERIOD OF REPORT:	20160630
FILED AS OF DATE:		20160822
DATE AS OF CHANGE:		20160822

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emerald Medical Applications Corp.
		CENTRAL INDEX KEY:			0000797542
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				680080601
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15746
		FILM NUMBER:		161845853

	BUSINESS ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141
		BUSINESS PHONE:		97237444505

	MAIL ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19950916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INFERGENE CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mrla06302016.htm
<DESCRIPTION>FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2016
<TEXT>
<html>

<body>
<div style="text-align: left">

<hr SIZE="2" NOSHADE COLOR="#000000">

	<div style="text-align: center">

<b><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="4">UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</font><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="3">Washington, D.C. 20549<br>
</font></b><font SIZE="4" FACE="Times New Roman, Times, Serif">___________________<br>
<br>
<strong>FORM 10-Q<br>
</strong>___________________</font></div>
	</p>

<p style="MARGIN: 0in 0in 0pt 0.5in; COLOR: windowtext; TEXT-INDENT: -0.5in"
align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 12pt" face="Wingdings"
size="3">&#253</font><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="FONT-WEIGHT: bold; FONT-SIZE: 12pt" size="3">QUARTERLY REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></p>

<p style="MARGIN: 0in 0in 0pt; COLOR: windowtext" align="center"><font size="1">&nbsp; </font></p>

<p style="MARGIN: 0in 0in 0pt; COLOR: windowtext; TEXT-ALIGN: center" align="center"><font
style="FONT-SIZE: 10pt" face="Times New Roman" size="2">For the quarterly period ended
June 30, 2016</font></p>

<p style="MARGIN: 0in 0in 0pt; COLOR: windowtext" align="center"><font size="1">&nbsp;&nbsp;
</font></p>

<p style="FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt; COLOR: windowtext; TEXT-ALIGN: center"
align="center"><font style="FONT-SIZE: 10pt" face="Times New Roman" size="2">Commission
file number: 0-15476</font></p>

<p style="FONT-SIZE: 10pt; MARGIN: 0in 0in 0pt; COLOR: windowtext; TEXT-ALIGN: center"
align="center"><font size="1">&nbsp; </font></p>

<p ALIGN="center"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="5"><b><u>
EMERALD MEDICAL APPLICATIONS CORP.</u><br>
</b></font><font face="TIMES NEW ROMAN, TIMES, SERIF" size="1">(Exact Name Of Registrant
As Specified In Its Charter)</font></p>

<p ALIGN="center">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td width="50%" align="center"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>Delaware</u></font></td>
    <td width="50%" align="center"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>68-0080601</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff"><font size="1">(State of Incorporation)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff"><font size="1">(I.R.S. Employer
    Identification No.)</font></td>
  </tr>
  <tr>
    <td width="50%" align="center"><font size="1">&nbsp; </font></td>
    <td width="50%" align="center"><font size="1">&nbsp; </font></td>
  </tr>
  <tr>
    <td width="50%" align="center">
<font SIZE="2"><u>

	7 Imber Street, Petach Tivka, Israel</u></font></td>
    <td width="50%" align="center">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>4951141</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff"><font size="1">(Address of Principal
    Executive Offices)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff"><font size="1">(ZIP Code)</font></td>
  </tr>
</table>

<p align="center"><font SIZE="2">Registrant's
Telephone Number, Including Area Code: +(972) 3-744-4505</p>

	</font>

	<div style="text-align: left">

<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">Indicate by check
mark whether the registrant (1) has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.&nbsp;Yes&nbsp;</font><font
size="2" FACE="WINGDINGS">&#120</font><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">&nbsp;No&nbsp;</font><font
size="2" FACE="WINGDINGS">&#168</font><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><br>
</font><font size="2">Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). </font><font
FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">Yes&nbsp;</font><font size="2"
FACE="WINGDINGS">&#168</font><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">&nbsp;No&nbsp;</font><font
size="2" FACE="WINGDINGS">&#120</font></div>

<font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer </font><font style="FONT-SIZE: 10pt" face="Times New Roman" size="2">(as
defined in Rule&nbsp;12b-2 of the Exchange Act)</font><font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> or a smaller
reporting company.<br></font>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td width="25%" align="center"><font
    style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Large accelerated
    filer <font style="FONT-FAMILY: Wingdings">&#168</font></font></td>
    <td width="25%" align="center"><font
    style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Accelerated filer <font
    style="FONT-FAMILY: Wingdings">&#168</font></font></td>
    <td width="25%" align="center"><font
    style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Non-Accelerated
    filer <font style="FONT-FAMILY: Wingdings">&#168</font></font></td>
    <td width="25%" align="center"><font
    style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Smaller reporting
    company </font><font face="WINGDINGS" size="2">&#120</font></td>
  </tr>
</table>

<p><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">On August 22, 2016,
the Registrant had 19,505,711 shares of common stock outstanding.</font></p>

<hr SIZE="2" NOSHADE COLOR="#000000">

<p Style='page-break-before:always'>

&nbsp;</p>

	<div style="text-align: center">

		<strong><font size="2"><a name="TABLE_OF_CONTENTS">TABLE OF CONTENTS</a></font></strong></div>
	</p>

<table ALIGN="CENTER" CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="100%" height="68">
  <tr VALIGN="BOTTOM">
    <th nowrap ALIGN="LEFT" height="55"><font size="2">Item</font><hr SIZE="1" NOSHADE
    COLOR="#000000" ALIGN="left">
    </th>
    <th height="55"></th>
    <th nowrap ALIGN="LEFT" height="55"><font size="2">Description</font><hr SIZE="1" NOSHADE
    COLOR="#000000" ALIGN="left">
    </th>
    <th COLSPAN="3" nowrap height="55"><font size="2">Page</font><hr SIZE="1" NOSHADE
    COLOR="#000000" WIDTH="60%">
    </th>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px">&nbsp;&nbsp;</td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px">&nbsp;</td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="75%" bgcolor="#ffffff" style="text-align: center; height: 1px;"><font size="2"><strong>PART
    I - FINANCIAL INFORMATION</strong></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp; </font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 1.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_1.&nbsp;FINANCIAL_STATEMENTS">FINANCIAL STATEMENTS</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">3</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 2.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_2._MANAGEMENTS_DISCUSSION_AND_ANALYSIS_AND_PLAN_OF_OPERATION">MANAGEMENT'S
    DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">17</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 3.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_3._QUANTITATIVE_AND_QUALITATIVE_DISCLOSURES_ABOUT_MARKET_RISK">QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">20</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 4.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_4._CONTROLS_AND_PROCEDURES">CONTROLS AND PROCEDURES</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">20</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp; </font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp; </font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="75%" bgcolor="#ffffff" style="text-align: center; height: 1px;"><font size="2"><strong>PART
    II - OTHER INFORMATION</strong></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp; </font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp; </font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 1.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_1._LEGAL_PROCEEDINGS">LEGAL PROCEEDINGS</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">20</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 1A.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_1A._RISK_FACTORS">RISK FACTORS</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">20</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 2.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_2._UNREGISTERED_SALES_OF_EQUITY_SECURITIES_AND_USE_OF_PROCEEDS">UNREGISTERED
    SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">20</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 3.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_3.&nbsp;DEFAULTS_UPON_SENIOR_SECURITIES">DEFAULT UPON SENIOR SECURITIES</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">21</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 4.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_4.&nbsp;MINE_SAFETY_DISCLOSURE_">MINE SAFETY DISCLOSURE</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">21</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 5.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_5.&nbsp;OTHER_INFORMATION">OTHER INFORMATION</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">21</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
  <tr>
    <td ALIGN="left" WIDTH="12%" bgcolor="#ffffff" style="height: 1px"><font size="2">ITEM 6.</font></td>
    <td WIDTH="3%" bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="left" WIDTH="75%" bgcolor="#ffffff" style="height: 1px"><font size="2">&nbsp;&nbsp;
	<a href="#ITEM_6.&nbsp;EXHIBITS">EXHIBITS</a></font></td>
    <td WIDTH="5%" ALIGN="RIGHT" nowrap bgcolor="#ffffff" style="height: 1px"></td>
    <td ALIGN="RIGHT" bgcolor="#ffffff" style="height: 1px"><font size="2">21</font></td>
    <td WIDTH="5%" ALIGN="LEFT" bgcolor="#ffffff" style="white-space: nowrap; height: 1px;"></td>
  </tr>
</table>

<p>&nbsp;</p>
<b><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="3">

<hr SIZE="1" NOSHADE COLOR="#000000">
</font></b>

<p Style='page-break-before:always; text-align: center;'>

<font size="2"><b>PART I - FINANCIAL INFORMATION</b></font></p>

<font size="2"><a name="ITEM_1.&nbsp;FINANCIAL_STATEMENTS">ITEM
1.&nbsp;FINANCIAL STATEMENTS</a> </font><font size="1">
	<a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <td style="width: 90%; height: 1px"><font size="2">&nbsp;&nbsp;&nbsp;
	  <a href="#Balance_Sheets">Balance Sheets -
      June 30, 2016 (Unaudited) and December 31, 2015</a></font></td>
    <td align="center" style="width: 10%; height: 1px"><font size="2">3</font></td>
  </tr>
  <tr>
      <td style="width: 90%; height: 1px"><font size="2">&nbsp;&nbsp;&nbsp;
	  <a href="#Statements_of_Operations">Statements
    of Operations - Three and Six Months Ended June 30, 2016 and 2015 (Unaudited)</a></font></td>
    <td align="center" style="width: 10%; height: 1px"><font size="2">4</font></td>
  </tr>
  <tr>
      <td style="width: 90%; height: 1px"><font face="Times New Roman" size="2">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">&nbsp;&nbsp;&nbsp;
	  <a href="#Statements_of_Comprehensive_Income_(Loss)">Statements
    of Comprehensive Income (Loss)<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'"> - Three
	  and Six Months Ended June 30, 2016 and 2015 (Unaudited)</font></a></font></font></td>
    <td align="center" style="width: 10%; height: 1px">5</td>
  </tr>
  <tr>
      <td style="width: 90%; height: 1px"><font size="2">&nbsp;&nbsp;&nbsp;
	  <a href="#Statements_of_Cash_Flows">Statements
    of Cash Flows - Six Months Ended June 30, 2016 and 2015 (Unaudited)</a></font></td>
    <td align="center" style="width: 10%; height: 1px"><font size="2">6</font></td>
  </tr>
  <tr>
      <td style="width: 90%; height: 1px"><font size="2">&nbsp;&nbsp;&nbsp;
	  <a href="#Notes_to_Unaudited_Interim_Financial_Statements">Notes to Unaudited Interim
    Financial Statements</a></font></td>
    <td align="center" style="width: 10%; height: 1px"><font size="2">7</font></td>
  </tr>
</table>

&nbsp;</p>

<font face="Times New Roman" size="2"><font size="2">



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
	<tr>
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="6"><b>Emerald Medical
	Applications Corp.</b></TD>

	</font>
		</font>
	</tr>
	<tr>
		<font SIZE="2">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="6">
	<a name="Balance_Sheets">Balance Sheets</a></TD>

	</font></font>
		</font>
	</tr>
	<tr>
		<font SIZE="2">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="6">As of June 30,
	2016 (Unaudited) and December 31,
	2015</TD>

	</font></font>
		</font>
	</tr>
	<tr>
		<font SIZE="2">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="6"><font size="1">
	<a href="#ITEM_1.&nbsp;FINANCIAL_STATEMENTS">Back to Table of
	Contents</a></TD>

	</font></font>
		</font>
	</tr>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; height: 1px;" colspan="6">&nbsp;&nbsp;</TD>
	</TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; height: 0%; width: 70%;"></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2016 (Unaudited)</FONT></TD>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px;"></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">December
    31, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="text-align: center; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Assets</FONT></TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">Current assets:</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; height: 0%;">&nbsp;&nbsp; Cash and cash equivalents</TD>
    <TD STYLE="width: 1%; text-align: left; height: 1px;">$</TD>
	<TD STYLE="width: 14%; text-align: right; height: 1px;">
	274,759</TD><TD STYLE="width: 2%; height: 1px;">
	</TD>
    <TD STYLE="width: 1%; text-align: left; height: 1px;">$</TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="width: 14%; text-align: right; height: 1px;">
	115,449</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">&nbsp;&nbsp; Other receivable</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	8,212</TD>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px;"></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	25,797</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp; Total current
    assets</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"><B>&nbsp;</B></TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	282,971</TD>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px;"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"><B>&nbsp;</B></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	141,246</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="height: 0%; width: 70%;">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD>
	<TD style="height: 1px"></TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;"></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fixed
	assets, net</FONT></TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;"></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">&nbsp;&nbsp; Fixed assets, net of accumulated depreciation of $10,751 and $6,536, respectively</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	17,735</TD><TD STYLE="padding-bottom: 1.5pt; height: 1px;">
	</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	21,120</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp; Total
	assets</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; height: 1px;">$</TD>
	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	300,706</TD>
	<TD STYLE="padding-bottom: 2.5pt; height: 1px;"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; height: 1px;">$</TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	162,366</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="height: 0%; width: 70%;">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;"></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
	Liabilities and Stockholders' Equity (Deficit)</FONT></TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;"></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current
	liabilities:</FONT></TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;"></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Accounts payable and accrued liabilities</TD>
    <TD STYLE="text-align: left; height: 1px;">$</TD>
	<TD STYLE="text-align: right; height: 1px;">48,204</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;">$</TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;">90,705</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp;
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	Employee payable

	</font>
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">22,786</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;">25,612</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Employee payable
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	- related party</font></TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">3,081</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;">3,480</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Accrued interest payable</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">21,887</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;">19,285</TD>

	</font>
	</TR>
	<tr>
		<font SIZE="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Short-term notes payable</TD>

    <TD STYLE="text-align: left; height: 1px;"></TD>
		<TD STYLE="text-align: right; height: 1px;">
		186,336</TD>

		<TD style="height: 1px"></TD>

    <TD STYLE="text-align: left; height: 1px;"></TD>
		<font SIZE="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

		<TD STYLE="text-align: right; height: 1px;">
		119,974</TD>

	</font>

		</font>

	</font>

		</font>
	</tr>
	<tr>

    <TD STYLE="text-align: left; height: 0%; width: 70%;">

<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">&nbsp;&nbsp;
	Convertible note payable, default</font></TD>

    <TD STYLE="text-align: left; height: 1px;">&nbsp;</TD>
		<TD STYLE="text-align: right; height: 1px;">
		29,719</TD>

		<TD style="height: 1px">&nbsp;</TD>

    <TD STYLE="text-align: left; height: 1px;">&nbsp;</TD>

		<TD STYLE="text-align: right; height: 1px;">
		-</TD>

	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">&nbsp;&nbsp;
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	Convertible note payable, net of discount of $412,628 and $0, respectively</font></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	222,377</TD>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px;"></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	29,719</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp; Total
	current liabilities</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	534,390</TD>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px;"></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	288,775</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp; Total
	liabilities</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"><B>&nbsp;</B></TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	<font size="2">
	534,390</font></TD>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px;"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"><B>&nbsp;</B></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	<font size="2">
	288,775</font></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="height: 0%; width: 70%;">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;"></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stockholders'
	equity (deficit)</FONT></TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;"></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;"><font SIZE="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none
	issued.</font></TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"><font SIZE="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	-</font></TD><TD style="height: 1px"></TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;"><font SIZE="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	-</font></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;"><font SIZE="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	Common stock, $0.0001 par value; 490,000,000 shares authorized;

	</font>
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;"></TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; 19,474,461 and
	15,325,889 shares
	issued and outstanding at June 30, 2016 and December 31, 2015 </TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">1,948</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;">1,533</TD>

	</font>
	</TR>
	<tr>
		<font SIZE="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: left; height: 0%; width: 70%;">Accumulated other comprehensive income</TD>

    <TD STYLE="text-align: left; height: 1px;"></TD>

		<TD STYLE="text-align: right; height: 1px;">(24,178)</TD>

		<TD style="height: 1px"></TD>

    <TD STYLE="text-align: left; height: 1px;"></TD>

		<font SIZE="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

		<TD STYLE="text-align: right; height: 1px;">(19,337)</TD>

	</font>

		</font>

	</font>

		</font>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">Additional paid-in capital</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">11,738,066</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; height: 1px;">8,752,711</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">Accumulated deficit</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	(11,949,520)</TD>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px;"></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	(8,861,316)</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
	stockholders' deficit</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"><B>&nbsp;</B></TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	(233,684)</TD>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px;"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; height: 1px;"><B>&nbsp;</B></TD>
<font face="Times New Roman" size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	(126,409)</TD>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 0%; width: 70%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
	liabilities and stockholders' equity (deficit)</FONT></TD>
	<font size="2" face="Times New Roman">



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; height: 1px;">$</TD>

	</font>
	<font size="2">



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	300,706</TD>

	<TD STYLE="padding-bottom: 2.5pt; height: 1px;"><B>&nbsp;</B></TD>

    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; height: 1px;">$</TD>

	<font size="2" face="Times New Roman">



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	162,366</TD>

	</font>

	</font>

	</font>

	</font>

	</font>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 1px;" colspan="6"></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 1px;" colspan="6">
	The accompanying notes are an integral part of these financial statements.</TD>
    </TR>
</TABLE>

	</font>
<hr SIZE="4" NOSHADE COLOR="#000000">
<p Style='page-break-before:always; text-align: center;'>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; height: 0%;">
<TR STYLE="vertical-align: bottom">
    <TD style="height: 1px; text-align: center;" colspan="9"><b>Emerald Medical
	Applications Corp.</b></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD style="height: 1px; text-align: center;" colspan="9">
	<a name="Statements_of_Operations">Statements of
	Operations</a></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD style="height: 1px; text-align: center;" colspan="9">For the Three and
	Six Months Ended
	June 30, 2016 and 2015</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD style="height: 1px; text-align: center;" colspan="9">(Unaudited)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD style="height: 1px; text-align: center;" colspan="9">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="1">
	<a href="#ITEM_1.&nbsp;FINANCIAL_STATEMENTS">Back to Table of
	Contents</a></font></font></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD style="height: 1px; text-align: center;" colspan="9">&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD style="width: 40%; height: 0%"></TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: center; height: 1; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Three months</FONT></TD>
	</font></font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Three months</FONT></TD>
	</font></font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Six months</FONT></TD>
	</font><TD style="height: 1px; width: 2%"></TD>
    <font size="2">
    <TD STYLE="text-align: center; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Six months</FONT></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 40%; height: 0%;" class="auto-style1"></TD><font size="2">
	<TD STYLE="text-align: center; height: 1px; width: 2%;">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD>
	</font></font>
	<TD STYLE="text-align: center; height: 1px; width: 2%;">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD>
	</font></font>
	<TD STYLE="text-align: center; height: 1px; width: 2%;"></TD>
    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD>
	</font><TD STYLE="text-align: center; height: 1px; width: 2%;"></TD>
    <font size="2">
    <TD STYLE="text-align: center; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 40%; height: 0%;">
	</TD><font size="2">
	<TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 1px; width: 2%;">
	&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2016</FONT></TD></font>
	</font>
	<TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 1px; width: 2%;">
	&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2015</FONT></TD></font>
	</font>
	<TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 1px; width: 2%;">
	</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2016</FONT></TD></font>
	<TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 1px; width: 2%;">
	</TD>
    <font size="2">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px;">
	<FONT STYLE="font: 8pt Times New Roman, Times, Serif">June 30, 2015</FONT></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom">
    <TD style="width: 40%; height: 0%">&nbsp;&nbsp;</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: center; height: 1px; width: 13%;"></TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2">
    <TD STYLE="text-align: center; height: 1px;"></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 0%">Revenues</TD><font size="2">
	<TD class="auto-style1" style="height: 1px; width: 2%; text-align: right;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	$</font></TD>
	<TD class="auto-style1" style="height: 1px; width: 2%; text-align: right;">-</TD>
	<TD class="auto-style1" style="height: 1px; width: 2%; text-align: right;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	$</font></TD>
	<TD class="auto-style1" style="height: 1px; width: 2%; text-align: right;">-</TD>
	<TD class="auto-style1" style="height: 1px; width: 2%; text-align: right;">$</TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;">-</TD></font>
	<TD style="height: 1px; width: 2%; text-align: right;">$</TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px;">-</TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 0%">&nbsp;&nbsp;</TD>
	<TD class="auto-style1" style="height: 1px; width: 2%">&nbsp;</TD>
	<TD class="auto-style1" style="height: 1px; width: 2%">&nbsp;</TD>
	<TD class="auto-style1" style="height: 1px; width: 2%">&nbsp;</TD>
	<TD class="auto-style1" style="height: 1px; width: 2%">&nbsp;</TD>
	<TD class="auto-style1" style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>
	<TD class="auto-style1" style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px;"></TD>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 1px">Expenses:</TD>
	<TD class="auto-style1" style="height: 1px; width: 2%"></TD>
	<TD class="auto-style1" style="height: 1px; width: 2%"></TD>
	<TD class="auto-style1" style="height: 1px; width: 2%"></TD>
	<TD class="auto-style1" style="height: 1px; width: 2%"></TD>
	<TD class="auto-style1" style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>
	<TD class="auto-style1" style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px;"></TD>
	</TR>
	<tr>
		<font size="2" face="Times New Roman">


	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="width: 40%; height: 0%">&nbsp;&nbsp; Research and development</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"><font SIZE="2">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	(192,002)</font></font></TD></font>
		</font>
		<font size="2" face="Times New Roman">


	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	<TD style="height: 1px; width: 2%"></TD>

	</font>

	</font>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'"><TD STYLE="text-align: right; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	(237,095)</font></font></font></font></font></TD>
    </font>

		</font></font>
		</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"><font SIZE="2">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	(295,350)</font></font></TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px;"><font SIZE="2">


    	<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
		(247,400)</font></font></TD>
    </font>

	</font>

	</font>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; width: 40%; height: 1px;">&nbsp;&nbsp; General
	and administrative expenses</TD><font size="2">
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;"></TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(969,214)</TD></font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;">
	</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(5,570)</TD>
    </font></font></font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;"></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(2,768,736)</TD></font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;">
	</TD>
    <font size="2">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(174,391)</TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; width: 40%; height: 0%;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
	operating
    expenses</FONT></TD><font size="2">
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(1,161,218)</TD></font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;"></TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(242,665)</TD>
    </font></font></font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;"></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(3,064,086)</TD></font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;"></TD>
    <font size="2">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(421,791)</TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 0%">&nbsp;&nbsp;</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 40%; height: 0%;">Loss from operations</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	(1,161,218)</font></font></TD></font>
	</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	(242,665)</font></font></TD></font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	(3,064,086)</font></font></TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px; width: 13%;">
	(421,791)</TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 0%">&nbsp;&nbsp;</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 40%; height: 0%;">Other income (expense):</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 40%; height: 0%;">&nbsp;&nbsp; Interest expense</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;">(14,128)</TD></font>
	</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;">(4,346)</TD></font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;">(21,887)</TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px; width: 13%;">
	(11,829)</TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 40%; height: 0%;">&nbsp;&nbsp; Change in fair value of derivative</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;">-</TD></font>
	</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;">-</TD></font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;">-</TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px; width: 13%;">
	367</TD>
    </font></TR>
	<tr>
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">


	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: left; width: 40%; height: 0%;">&nbsp;&nbsp;
	Depreciation and amortization expense</TD>

	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">


	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: right; height: 1px; width: 13%;">(47,718)</TD>

	</font>

	</font>

	</font>
		</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">


	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: right; height: 1px; width: 13%;">-</TD>

	</font>

	</font>

	</font>
		</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;">(51,665)</TD>
	<TD style="height: 1px; width: 2%"></TD>
    	<TD STYLE="text-align: right; height: 1px; width: 13%;">-</TD>

	</font>

	</font>

	</font>

	</tr>
	<tr>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">


	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: left; width: 40%; height: 0%;">&nbsp;&nbsp; Other income
	(expenses)</TD>

	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">


	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: right; height: 1px; width: 13%;">28,587</TD>

	</font>

	</font>

	</font>
		</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">


	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: right; height: 1px; width: 13%;">-</TD>

	</font>

	</font>

	</font>
		</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;">28,587</TD>
	<TD style="height: 1px; width: 2%"></TD>
    	<TD STYLE="text-align: right; height: 1px; width: 13%;">-</TD>

	</font>

	</font>

	</font>
		</font>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; width: 40%; height: 0%;">&nbsp;&nbsp;
	<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	Gain/(loss) from foreign currency</font></font></TD><font size="2">
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	6,503</TD></font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(4,110)</TD></font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;"></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	20,847</TD></font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;"></TD>
    <font size="2">
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	1,808</TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; width: 40%; height: 0%;">
	Financial income (expense)</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;">(26,756)</TD>
	</font></font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;">(8,456)</TD>
	</font></font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;">(24,118)</TD>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;">(9,654)</TD>
	</font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 0%">&nbsp;&nbsp;</TD><font size="2">
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>
    </font></TR>
	<tr>
		<font SIZE="2">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: left; padding-bottom: 1.5pt; width: 40%; height: 0%;">&nbsp;&nbsp;
	Provision for income taxes</TD>

	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;">&nbsp;</TD>

    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	-</TD>

	</font></font>


		</font>
		</font>

	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;">&nbsp;</TD>

    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	-</TD>

	</font></font>


		</font>
		</font>

	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;"></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	-</TD>

	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%;"></TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">-</TD>

	</font></font>


		</font>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 0%">&nbsp;&nbsp;</TD>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>

	</font>
	</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>

	</font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; width: 40%; height: 0%;">Net loss</TD><font size="2">
	<TD STYLE="padding-bottom: 2.5pt; text-align: right; height: 1px; width: 2%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	$</font></TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (1,187,974)</font></font></font></font></TD>
	</font>
	</font>
	<TD STYLE="padding-bottom: 2.5pt; text-align: right; height: 1px; width: 2%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	$</font></TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (251,121)</font></font></font></font></TD>
	</font>
	</font>
	<TD STYLE="padding-bottom: 2.5pt; text-align: right; height: 1px; width: 2%;">
	$</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (3,088,204)</font></font></font></font></TD>
	</font>
	<TD STYLE="padding-bottom: 2.5pt; text-align: right; height: 1px; width: 2%;">
	$</TD>
    <font size="2">
	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (431,445)</font></font></font></font></font></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 1px">&nbsp;&nbsp;</TD><font size="2">
	<TD style="height: 1px; width: 2%"></TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: right; height: 1px; width: 13%;"></TD></font>
	<TD style="height: 1px; width: 2%"></TD>
    <font size="2"><TD STYLE="text-align: right; height: 1px; width: 13%;"></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; width: 40%; height: 0%;">Basic and diluted
	(net loss
	per share)</TD><font size="2">
	<TD STYLE="padding-bottom: 2.5pt; text-align: right; height: 1px; width: 2%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	$</font></TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">(0.06)</TD>
	</font>
	</font>
	<TD STYLE="padding-bottom: 2.5pt; text-align: right; height: 1px; width: 2%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	$</font></TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">(1.18)</TD>
	</font>
	</font>
	<TD STYLE="padding-bottom: 2.5pt; text-align: right; height: 1px; width: 2%;">
	$</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">(0.17)</TD>
	</font>
	<TD STYLE="padding-bottom: 2.5pt; text-align: right; height: 1px; width: 2%;">
	$</TD>
    <font size="2">
	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;"><font SIZE="2">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	(2.03)</font></font></TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; width: 40%; height: 0%;">Weighted average shares outstanding
	- basic and diluted</TD><font size="2">
	<TD STYLE="padding-bottom: 2.5pt; height: 1px; width: 2%;">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">
	18,890,670</TD>
	</font></font>
	<TD STYLE="padding-bottom: 2.5pt; height: 1px; width: 2%;">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">
	213,001</TD>
	</font></font>
	<TD STYLE="padding-bottom: 2.5pt; height: 1px; width: 2%;"></TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">
	18,121,314</TD>
	</font><TD STYLE="padding-bottom: 2.5pt; height: 1px; width: 2%;"></TD>
    <font size="2">
	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px; width: 13%;">
	213,001</TD>
    </font></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; height: 1px;" colspan="9">&nbsp;&nbsp;</TD></TR>
	<tr>
	<font size="2" face="Times New Roman">



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 1px;" colspan="9">
	The accompanying notes are an integral part of these financial statements.</TD>

	</font>

	</font>
	</tr>
</TABLE>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<hr SIZE="4" NOSHADE COLOR="#000000">
	</font>
<p Style='page-break-before:always'>

    <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; height: 0%;">


    <TD style="height: 1px; text-align: center;" colspan="9"><font size="2"><b>Emerald Medical
	Applications Corp.</b></TD>

		</tr>
		<tr>


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="9">
	<a name="Statements_of_Comprehensive_Income_(Loss)">Statements of
	Comprehensive Income (Loss)</a></TD>

	</font></font>
		</tr>
		<tr>


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="9">For the Three and
	Six Months Ended
	June 30, 2016 and 2015</TD>

	</font></font>
		</tr>
		<tr>


    <TD style="height: 1px; text-align: center;" colspan="9">(Unaudited)</TD>

		</tr>
		<tr>


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="9">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


	<font size="1">
	<a href="#ITEM_1.&nbsp;FINANCIAL_STATEMENTS">Back to Table of
	Contents</a></font></TD>

	</font></font>
		</tr>
<TR STYLE="vertical-align: bottom">
    <TD style="height: 1px" colspan="9">&nbsp;&nbsp;</TD>
    	</TR>
<TR STYLE="vertical-align: bottom">
    <TD style="width: 40%; height: 0%"></TD>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Three months</FONT></TD>

	</font>
	</font>
	<TD style="height: 1px; width: 2%">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Three months</FONT></TD>

	</font>
	</font>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Six months</FONT></TD>
	<TD style="height: 1px; width: 2%"></TD>
    <TD STYLE="text-align: center; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Six months</FONT></TD>
    	</TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 40%; height: 0%;"></TD>
	<TD STYLE="text-align: center; height: 1px; width: 2%;">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD>

	</font>
	</font>
	<TD STYLE="text-align: center; height: 1px; width: 2%;">&nbsp;</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD>

	</font>
	</font>
	<TD STYLE="text-align: center; height: 1px; width: 2%;"></TD>
    <TD STYLE="text-align: center; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD>
	<TD STYLE="text-align: center; height: 1px; width: 2%;"></TD>
    <TD STYLE="text-align: center; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD>
		</TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 40%; height: 0%;">
	</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	<TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 1px; width: 2%;">
	</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2016</FONT></TD>

	</font>
	</font>
	<TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 1px; width: 2%;">
	</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2015</FONT></TD>

	</font>
	</font>
	<TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 1px; width: 2%;">
	</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px; width: 13%; font-weight: bold;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2016</FONT></TD>
	<TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 1px; width: 2%;">
	</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2015</FONT></TD>
    	</TR>
		<tr>


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: left; padding-bottom: 2.5pt; width: 40%; height: 0%;">
	Net loss</TD>

			<font SIZE="2">
    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

			<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

			<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	$</TD>

    <TD STYLE="text-align: right; height: 1px; width: 13%;"><font size="2" face="Times New Roman">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (1,187,974)</font></font></font></font></TD>
			</font>

    		</font>


		</font>
			</font>


	</font>
			</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	$</TD>

    <TD STYLE="text-align: right; height: 1px; width: 13%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (251,121)</font></font></font></font></font></TD>
			</font>

    		</font>


		</font>
			</font>


	</font>
			</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	$</TD>
    </font></font>

    <TD STYLE="text-align: right; height: 1px; width: 13%;"><font size="2" face="Times New Roman">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (3,088,204)</font></font></font></font></TD>
			<font SIZE="2">
    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	$</TD>
    </font></font>
    <TD STYLE="text-align: right; height: 1px; width: 13%;">(431,445)</TD>

	</font></font>


		</font>
			</font>


		</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 0%"><font size="2">Change in unrealized foreign currency translation gain (loss)</TD>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	</TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(3)</TD>

	</font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	</TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(15,771)</TD>

	</font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	</TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(4,841)</TD>
	<TD class="auto-style1" style="height: 1px; width: 2%; text-align: right;"></TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	(25,550)</TD>
    	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="width: 40%; height: 0%"><font size="2">&nbsp;&nbsp; Total comprehensive
	loss</TD>
    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	$</TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (1,187,977)</font></font></font></font></font></font></TD>

	</font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	$</TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (266,892)</font></font></font></font></font></TD>

	</font>
	</font>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	$</TD>
    </font>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (3,093,045)</font></font></font></font></font></font></TD>
    <font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<TD STYLE="padding-bottom: 1.5pt; height: 1px; width: 2%; text-align: right;">
	$</TD>
    </font>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px; width: 13%;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (456,995)</font></font></font></font></TD>
    	</TR>
		<tr>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 1px;" colspan="9">
	&nbsp;&nbsp;</TD>
    	</tr>
		<tr>
	<font size="2" face="Times New Roman">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 1px;" colspan="9">
	The accompanying notes are an integral part of these financial statements.</TD>

	</font>

	</font>

	</font>
		</tr>
</TABLE>

	</font>
<hr SIZE="4" NOSHADE COLOR="#000000">
<p Style='page-break-before:always; text-align: center;'>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
	<tr>
			<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="6"><b>Emerald Medical
	Applications Corp.</b></TD>

	</font></font>
			</font>
	</tr>
	<tr>
			<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="6">
	<a name="Statements_of_Cash_Flows">Statements of
	Cash Flows</a></TD>

	</font></font>
			</font>
	</tr>
	<tr>
			<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="6">For the
	Six Months Ended June 30, 2016 and 2015</TD>

	</font></font>
			</font>
	</tr>
	<tr>

    <TD style="height: 1px; text-align: center;" colspan="6">(Unaudited)</TD>

	</tr>
	<tr>
			<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD style="height: 1px; text-align: center;" colspan="6">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


	<font size="1">
	<a href="#ITEM_1.&nbsp;FINANCIAL_STATEMENTS">Back to Table of
	Contents</a></font></TD>

	</font></font>
			</font>
	</tr>
<TR STYLE="vertical-align: bottom">
    <TD colspan="6">&nbsp;&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD style="height: 0%; width: 70%;"></TD>
    <TD COLSPAN="2" STYLE="text-align: center; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Six months</FONT></TD><TD STYLE="text-align: center; height: 1px;"></TD>
    <TD COLSPAN="2" STYLE="text-align: center; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	Six months</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; height: 0%; width: 70%;"></TD>
    <TD COLSPAN="2" STYLE="text-align: center; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD>
	<TD STYLE="text-align: center; height: 1px;">
	</TD>
    <TD COLSPAN="2" STYLE="text-align: center; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ended</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 0%; width: 70%;"></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2016</FONT></TD>
	<TD STYLE="text-align: center; padding-bottom: 1.5pt; height: 1px;">
	</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px;"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">
	June 30, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">Operating Activities:</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; height: 0%;">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: right; height: 0%;">&nbsp;</TD>
	<TD STYLE="width: 12%; text-align: right; height: 1px;">&nbsp;</TD>
	<TD STYLE="width: 2%; height: 1px;">
	&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right; height: 1px;">&nbsp;</TD>
	<TD STYLE="width: 14%; text-align: right; height: 1px;">
	&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; height: 0%;">Net loss</TD>
    <TD STYLE="width: 2%; text-align: right; height: 0%;">$</TD>
	<TD STYLE="width: 12%; text-align: right; height: 1px;">(3,088,204)</TD>
	<TD STYLE="width: 2%; height: 1px;">
	</TD>
    <TD STYLE="width: 1%; text-align: right; height: 1px;">$</TD>
	<TD STYLE="width: 14%; text-align: right; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
		<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    (431,445)</font></font></font></font></font></TD></TR>
	<tr>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="text-align: left; height: 0%; width: 70%;">Adjustments to reconcile net (loss) to net cash (used in) operating activities:</TD>

    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>

		<TD STYLE="text-align: right; height: 1px;"></TD>

		<TD style="height: 1px">
		</TD>

    <TD STYLE="text-align: left; height: 1px;"></TD>

		<TD STYLE="text-align: right; height: 1px;"></TD>

	</font>
		</font>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Depreciation expense</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;">8,293</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    1,878</font></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Amortization of debt discount</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;">43,373</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">4,399</TD></TR>
	<tr>
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Change in
	fair value of derivative liabilities</TD>


    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;">-</TD>
    	</font>
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


	<TD style="height: 1px">
	</TD>
    	</font>
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">(367)</TD></font>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Shares issued for services</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;"><font SIZE="2">
	<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	2,074,736</TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"><font SIZE="2">
	<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Options issued for services</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;"><font SIZE="2">
	<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	455,032</TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"><font SIZE="2">
	<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">Increase (decrease) in
	cash resulting from change in:</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">&nbsp;</TD><TD style="height: 1px">
	&nbsp;</TD>
    <TD STYLE="text-align: left; height: 1px;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Due from
	related party&nbsp;</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">-</TD><TD style="height: 1px">
	&nbsp;</TD>
    <TD STYLE="text-align: left; height: 1px;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">(6,443)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Decrease
	(increase) in other receivable</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;">
	17,585</TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">(25,689)</TD></TR>
	<tr>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; (Decrease)
	increase in accounts payable</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;">(1,777)</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">(2,577)</TD></font>
	</tr>
	<tr>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; (Decrease)
	increase in accounts payable - related party</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;">-</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">1,087</TD></font>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Employee
	payable&nbsp;</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">
	-</TD><TD style="height: 1px">
	&nbsp;</TD>
    <TD STYLE="text-align: left; height: 1px;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">23,800</TD></TR>
	<tr>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; (Decrease)
	increase in other current liabilities</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;">-</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">14,202</TD></font>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">&nbsp;&nbsp;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    (Decrease) increase
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    in accrued expenses</font></font></TD>



    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    (45,779)</font></TD><TD STYLE="padding-bottom: 1.5pt; height: 1px;"></TD>



    <TD STYLE="text-align: left; height: 1px;"></TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    7,430</font></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">Net cash used in operating activities</TD>



    <TD STYLE="text-align: right; height: 0%; width: 2%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">(536,741)</TD>
	<TD STYLE="padding-bottom: 1.5pt; height: 1px;">
	</TD>



    <TD STYLE="text-align: right; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	(413,725)</TD></TR>
	<tr>
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">&nbsp;</TD><TD style="height: 1px">
		&nbsp;</TD>
    <TD STYLE="text-align: left; height: 1px;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">&nbsp;</TD>
	</tr>
	<tr>
    <TD STYLE="text-align: left; height: 0%; width: 70%;">Investing Activities:</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD>
	</tr>
	<tr>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">&nbsp;&nbsp;
	Cash paid for fixed assets</TD>
	<font size="2" face="Times New Roman">



    <TD STYLE="text-align: right; height: 0%; width: 2%;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</font></TD>

	</font>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	(474)</TD><TD STYLE="padding-bottom: 1.5pt; height: 1px;">
	</TD>
	<font size="2" face="Times New Roman">



    <TD STYLE="text-align: right; height: 1px;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</font></TD>

	</font>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	25,317</TD>
	</tr>
	<tr>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">Net cash provided by investing activities</TD>
	<font size="2" face="Times New Roman">



    <TD STYLE="text-align: right; height: 0%; width: 2%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</TD>

	</font>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	(474)</TD><TD STYLE="padding-bottom: 1.5pt; height: 1px;">
	</TD>
	<font size="2" face="Times New Roman">



    <TD STYLE="text-align: right; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</TD>

	</font>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	25,317</TD>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="height: 4px; width: 70%;">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left; height: 4px; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 4px;"></TD><TD style="height: 4px">
	</TD>
    <TD STYLE="text-align: left; height: 4px;"></TD>
	<TD STYLE="text-align: right; height: 4px;"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


	Financing Activities:</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD></TR>
	<tr>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    <TD STYLE="text-align: left; height: 0%; width: 70%;"><font SIZE="2">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

&nbsp;&nbsp; Borrowings on debt</font></TD>


    <TD STYLE="text-align: right; height: 0%; width: 2%;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</font></TD>

	<TD STYLE="text-align: right; height: 1px;">735,913</TD>


	<TD style="height: 1px">
	</TD>


    <TD STYLE="text-align: right; height: 1px;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</font></TD>

	<TD STYLE="text-align: right; height: 1px;">531,798</TD>

    	</font>
		</font>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">&nbsp;&nbsp;
	<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	  <font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	Principal payments on debt</TD>



    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


    (34,547)</font></TD><TD STYLE="padding-bottom: 1.5pt; height: 1px;">
	</TD>



    <TD STYLE="text-align: left; height: 1px;"></TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


	Net cash provided by financing activities</TD>



    <TD STYLE="text-align: right; height: 0%; width: 2%;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</font></TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	701,366</TD><TD STYLE="padding-bottom: 1.5pt; height: 1px;">
	</TD>



    <TD STYLE="text-align: right; height: 1px;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; text-align: right;">
	  $</font></TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	531,798</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="height: 0%; width: 70%;">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp; Foreign currency adjustment</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;">(4,841)</TD>
	<TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">(25,550)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="height: 0%; width: 70%;">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">Net increase (decrease) in cash</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;">
	159,310</TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;">67,206</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 0%; width: 70%;">Cash and cash equivalents - beginning of period</TD>



    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	115,449</TD><TD STYLE="padding-bottom: 1.5pt; height: 1px;"></TD>



    <TD STYLE="text-align: left; height: 1px;"></TD>

	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	14,411</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 0%; width: 70%;">Cash and cash equivalents - end of period</TD>



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    <TD STYLE="width: 2%; text-align: right; height: 0%;">$</TD>

	</font>

	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	274,759</TD><TD STYLE="padding-bottom: 2.5pt; height: 1px;"></TD>



    <TD STYLE="text-align: right; height: 1px;"><font SIZE="2">
	<font SIZE="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">$</TD>

	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	81,617</TD></TR>
	<tr>
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <TD style="height: 0%; width: 70%;">&nbsp;&nbsp; </TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD></font>
	</tr>
	<tr>
    <TD style="height: 0%; width: 70%;">Non-cash transactions:</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">&nbsp;</TD><TD style="height: 1px">
		&nbsp;</TD>
    <TD STYLE="text-align: left; height: 1px;">&nbsp;</TD>
	<TD STYLE="text-align: right; height: 1px;">&nbsp;</TD>
	</tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 0%; width: 70%;">
	&nbsp;&nbsp; BCF due to convertible note payable&nbsp;</TD>



    <TD STYLE="width: 2%; text-align: right; height: 0%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    $</font></TD>

	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	456,000</TD><TD STYLE="padding-bottom: 2.5pt; height: 1px;">&nbsp;</TD>



    <TD STYLE="text-align: right; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    $</font></TD>

	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 0%; width: 70%;">
	&nbsp;&nbsp; Cashless conversion of class B warrants&nbsp;</TD>



    <TD STYLE="width: 2%; text-align: right; height: 0%;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    $</font></TD>

	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	193</TD><TD STYLE="padding-bottom: 2.5pt; height: 1px;">&nbsp;</TD>



    <TD STYLE="text-align: right; height: 1px;">
    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

    $</font></TD>

	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; height: 0%; width: 70%;">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left; height: 0%; width: 2%;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD><TD style="height: 1px">
	</TD>
    <TD STYLE="text-align: left; height: 1px;"></TD>
	<TD STYLE="text-align: right; height: 1px;"></TD></TR>
	<tr>



	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">



    <TD STYLE="text-align: left; padding-bottom: 2.5pt; height: 1px;" colspan="5">
	The accompanying notes are an integral part of these financial statements.</TD>

	</font>

	</font>

	</font>

	</tr>
</TABLE>

<hr SIZE="4" NOSHADE COLOR="#000000">
<p Style='page-break-before:always; text-align: center;'>


<font SIZE="2">

	<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<b>Emerald Medical Applications Corp <br></b>
	<a name="Notes_to_Unaudited_Interim_Financial_Statements">Notes to Unaudited Interim Financial
	Statements</a><br>June 30, 2016</font><br>
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">


	<font size="1">
	<a href="#ITEM_1.&nbsp;FINANCIAL_STATEMENTS">Back to Table of
	Contents</a></font></font></p>

<p><font size="2"><b>Note 1. The Company</b></p>

	<p><i>Organizational Background</i></p>
	<p>Emerald Medical Applications Corp. (&quot;the Company&quot;) (f/k/a Zaxis
	International Inc.) was incorporated in Ohio in 1989, it's fiscal year end
	is December 31st. On August 25, 1995, The Company merged with a subsidiary
	of The InFerGene Company (&quot;InFerGene&quot;) and InFerGene changed its name to The
	Company International Inc. InFerGene was incorporated in California in 1984
	and subsequently changed its domicile in connection with the merger into The
	Company to Delaware in 1985. Operations ceased operations in 2002. In
	November 2002, the Company and its subsidiaries filed a petition for
	bankruptcy in the U.S. Bankruptcy Court Northern District of Ohio. On
	October 13, 2004, the Company emerged from bankruptcy. </p>
	<p>On July 14, 2015 the closing of the Share Exchange Agreement was held
	(the &quot;Closing&quot;) and as a result, Emerald Medical Applications Ltd. became a
	wholly-owned subsidiary of the Registrant. Pursuant to the Closing of the
	Share Exchange Agreement, the Company issued 5,474,545 shares of its common
	stock, par value $0.0001 (the &quot;Shares&quot; or &quot;Common Stock&quot;) to Lior Wayn,
	Emerald's CEO and the sole holder of Emerald Medical Applications Ltd.'s
	ordinary Shares, representing 40.58% of the company's 13,489,905 outstanding
	Shares, in exchange for 100% of Emerald Medical Applications Ltd.'s ordinary
	Shares. </p>
	<p>Subsequently to the Closing Mr. Lior Wayn has been appointed as the
	Company's CEO, and has been granted considerable influence on the
	appointment of new directors thereby creating a new management structure for
	the company replacing the old management. Additionally Mr. Wayn is to
	receive additional shares in the future contingent on the Company achieving
	commercial milestone. Thus the new management, headed by Mr. Wayn, is
	considered to be in control of more than 50% of the company and with the
	ability to make all management decisions.</p>
	<p>Emerald is a company organized under the laws of the State of Israel on
	February 17, 2010. Emerald is digital health Startup Company engaged in the
	development, sale and service of imaging solutions utilizing its proprietary
	DermaCompare software that it developed for use in derma imaging and
	analytics (&quot;DermaCompare&quot;). Emerald believes that its proprietary
	DermaCompare software represents an advancement in skin cancer screening
	that should enable physicians to more readily identify and monitor changes
	in their patients' skin characteristics. </p>
	<p>Emerald's DermaCompare solution allows dermatologists and other medical
	care professionals, using a set of 25 total body photography (&quot;TBP&quot;), to
	capture sets of skin lesion images with, among other devices, digital
	cameras, camera-equipped smartphones or tablets. These images are then
	transmitted online and are remotely analyzed by professionals using our
	DermaCompare software.</p>
	<p>Emerald's sales and marketing plan is to sell licenses for our imaging
	software to: NHSs, HMOs, health insurance companies, hospitals and medical
	clinics through distributers, health care channel partners or directly
	through independent salespersons and/or web purchase to dermatologists and
	other physicians (GPs) that we expect to purchase licenses based on the
	number of potential numbers of patients.</p>
	<p><i>Basis of Presentation</i></p>
	<p>The accompanying financial statements have been prepared in conformity
	with accounting principles generally accepted in the United States of
	America, which contemplate continuation of the Company as a going concern.
	The Company has not established any source of revenue to cover its operating
	costs, and as such, has incurred operating losses since inception. Further,
	as of June 30, 2016, the cash resources of the Company were insufficient to
	meet its current business plan, and the Company had negative working
	capital. These and other factors raise substantial doubt about the Company's
	ability to continue as a going concern. The accompanying financial
	statements do not include any adjustments to reflect the possible future
	effects on the recoverability and classification of assets or the amounts
	and classification of liabilities that may result from the possible
	inability of the Company to continue as a going concern.</p>
	<p>The Company elected December 31 as its fiscal year end.</p>
	<p><i>Significant Accounting Policies</i></p>
	<p><i>Use of Estimates</i></p>
	<p>The preparation of financial statements in conformity with generally
	accepted accounting principles requires management to make estimates and
	assumptions that affect reported amounts of assets and liabilities and
	disclosure of contingent assets and liabilities at the date of the financial
	statement and the reported amounts of revenues and expenses during the
	reporting period. Actual results could differ from the estimates.</p>
	<p><i>Cash and Cash Equivalents</i></p>
	<p>For financial statement presentation purposes, the Company considers
	those short-term, highly liquid investments with original maturities of
	three months or less to be cash or cash equivalents. There were no cash
	equivalents as of June 30, 2016 and December 31, 2015.</p>
	<p><i>Other Receivables</i></p>
	<p>The company treats VAT refunds claimed resulting from excess VAT paid
	over VAT received as other receivables, amount shown as other receivables as
	of June 30, 2016 was $8,212.</p>
	<p><i>Currency Translation and other Comprehensive Income</i></p>
	<p>Balance sheet items are translated using all current translation method
	for self-contained foreign operations (where functional currency = foreign
	currency) whereby assets and liabilities are translated using the exchange
	rate on the date of the balance sheet. It translates revenues, expenses, and
	net income using the average exchange rate during the period. The foreign
	exchange adjustment that results from applying the all-current method
	appears in other comprehensive income, a separate shareholders' equity
	account, and does not affect net income each period.</p>
	<p><i>Property and Equipment</i></p>
	<p>New property and equipment are recorded at cost. Depreciation is computed
	using the straight-line method over the estimated useful lives of the
	assets, generally 5 years. Expenditures for renewals and betterments are
	capitalized. Expenditures for minor items, repairs and maintenance are
	charged to operations as incurred. Gain or loss upon sale or retirement due
	to obsolescence is reflected in the operating results in the period the
	event takes place.</p>
	<p><i>Valuation of Long-Lived Assets</i></p>
	<p>We review the recoverability of our long-lived assets including
	equipment, goodwill and other intangible assets, when events or changes in
	circumstances occur that indicate that the carrying value of the asset may
	not be recoverable. The assessment of possible impairment is based on our
	ability to recover the carrying value of the asset from the expected future
	pre-tax cash flows (undiscounted and without interest charges) of the
	related operations. If these cash flows are less than the carrying value of
	such asset, an impairment loss is recognized for the difference between
	estimated fair value and carrying value. Our primary measure of fair value
	is based on discounted cash flows. The measurement of impairment requires
	management to make estimates of these cash flows related to long-lived
	assets, as well as other fair value determinations.</p>
	<p><i>Stock Based
	Compensation</i></p>
	<p>Stock-based awards are accounted for using the fair value
	method in accordance with ASC 718,&nbsp;Share-Based Payments. Our primary type of
	share-based compensation consists of stock options. We use the Black-Scholes
	option pricing model in valuing options. The inputs for the valuation
	analysis of the options include the market value of the Company's common
	stock, the estimated volatility of the Company's common stock, the exercise
	price of the warrants and the risk free interest rate.</p>
	<p><i>Accounting For Obligations And Instruments Potentially To Be Settled
	In The Company's Own Stock: </i></p>
	<p>We account for obligations and instruments potentially to be settled in
	the Company's stock in accordance with FASB ASC 815,&nbsp;Accounting for
	Derivative Financial Instruments.&nbsp;This issue addresses the initial balance
	sheet classification and measurement of contracts that are indexed to, and
	potentially settled in, the Company's own stock.</p>
	<p><i>Fair Value Measurements</i></p>
	<p>The Company adopted the FASB standard related to fair value measurement
	at inception. The standard defines fair value, establishes a framework for
	measuring fair value and expands disclosure of fair value measurements. The
	standard applies under other accounting pronouncements that require or
	permit fair value measurements and, accordingly, does not require any new
	fair value measurements. The standard clarifies that fair value is an exit
	price, representing the amount that would be received to sell an asset or
	paid to transfer a liability in an orderly transaction between market
	participants. As such, fair value is a market-based measurement that should
	be determined based on assumptions that market participants would use in
	pricing an asset or liability.</p>
	<p>As a basis for considering such assumptions, the standard established a
	three-tier fair value hierarchy, which prioritizes the inputs used in
	measuring fair value as follows.</p>
	<p>Level 1. Observable inputs such as quoted prices in active markets;<br>
	Level 2. Inputs, other than quoted prices in active markets, that are
	observable either directly or indirectly; and<br>Level 3. Unobservable
	inputs in which there is little or no market data, which require the
	reporting entity to develop its own assumptions.</p>
	<p>The Company values its derivative instruments related to embedded
	conversion features and warrants from the issuance of convertible debentures
	in accordance with the Level 3 guidelines. For the six-month period ended
	June 30, 2016 and the twelve month period ending December 31, 2015, the
	following table reconciles the beginning and ending balances for financial
	instruments that are recognized at fair value in these consolidated
	financial statements. The fair value of embedded conversion features that
	have floating conversion features and tainted common stock equivalents
	(warrants and convertible debt) are estimated using a Binomial Lattice
	model. The key inputs to this valuation model as of December 31, 2015, were:
	Volatility of 143.9% for the six-month period ended June 30, 2016 and
	132.4% for the twelve months period ending December 31, 2015, inherent term
	of instruments equal to the remaining contractual term, quoted closing stock
	prices on valuation dates, and various settlement scenarios and probability
	percentages summing to 100%.</p>

	<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair
Value Measurements at June 30, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">Level 3 - Derivative liabilities from:</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Balance at<BR>
    June 30, 2016</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">New Issuances</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Settlements</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Change in Fair Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 27%; text-align: left">Convertible Note</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 16%; text-align: right; border-bottom: Black 1.5pt solid">
	-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 6%; text-align: right; border-bottom: Black 1.5pt solid">
	-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 6%; text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 1.5pt solid">
	-</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

	<font size="2" face="Times New Roman">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair
Value Measurements at December 31, 2015</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">Level 3 - Derivative liabilities from:</TD><TD STYLE="text-align: center">
	&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Balance at<BR>
    December 31, 2015</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">New Issuances</TD><TD STYLE="text-align: center">
	&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">
	Extinguishment</TD><TD STYLE="text-align: center">
	&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Change in Fair Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 27%; text-align: left">Convertible Note</TD><TD STYLE="width: 2%">
	&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 16%; text-align: right; border-bottom: Black 1.5pt solid">
	-</TD><TD STYLE="width: 1%; text-align: left">
	&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 6%; text-align: right; border-bottom: Black 1.5pt solid">
	-</TD><TD STYLE="width: 1%; text-align: left">
	&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 6%; text-align: right; border-bottom: Black 1.5pt solid">
	(20,532)</TD><TD STYLE="width: 1%; text-align: left">
	&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; border-bottom: Black 1.5pt solid">
	-</TD></TR>
</TABLE>



<P>
&nbsp;</P>
	<P>
Changes in the unobservable input values would likely cause material changes in
the fair value of the Company's Level 3 financial instruments. The significant
unobservable input used in the fair value measurement is the estimation for
probability percentages assigned to future expected settlement possibilities. A
significant increase (decrease) in this distribution of percentages would result
in a higher (lower) fair value measurement.</P>

	<P>
	The following schedule summarizes the valuation of financial instruments at
	fair value on a recurring basis in the balance sheets as of June 30, 2016
	and December 31, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair
Value Measurements at June 30, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp; </FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font-style: normal; font-variant: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, Serif;">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
    3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Assets</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total Assets</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">
	&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Liabilities</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 78%; text-align: left; padding-bottom: 1.5pt">Derivative liability</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 18%; text-align: right; border-bottom: Black 1.5pt solid">
	-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total Liabilities</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">
	-</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp; </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair
Value Measurements at December 31, 2015</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp; </FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; height: 1px;"></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; height: 1px;"></TD>
	<TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px;"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
                                         3</FONT></TD>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><font size="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Assets</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 78%; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
    Assets</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 18%; text-align: right; border-bottom: Black 1.5pt solid">-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><font size="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Liabilities</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Derivative liability</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">
	<font size="2" face="Times New Roman">



	-</font></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total Liabilities</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">
	<font size="2" face="Times New Roman">



	-</font></TD></TR>
</TABLE>

	<P>
	The fair values of our debts are deemed to approximate book value, and are
	considered Level 2 inputs as defined by ASC Topic 820-10-35.</P>
	<P>
	There were no transfers of financial assets or liabilities between Level 1,
	Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the
	year ended December 31, 2015.</P>
	<P>
	The Company had no other assets or liabilities valued at fair value on a
	recurring or non-recurring basis as of June 30, 2016 or December 31, 2015.</P>
	<P>
	<i>Earnings per Common Share</i></P>
	<P>
	We compute net income (loss) per share in accordance with ASC 260,&nbsp;Earning
	per Share. ASC 260 requires presentation of both basic and diluted earnings
	per share (EPS) on the face of the income statement. Basic EPS is computed
	by dividing net income (loss) available to common shareholders (numerator)
	by the weighted average number of shares outstanding (denominator) during
	the period. Diluted EPS gives effect to all dilutive potential common shares
	outstanding during the period using the treasury stock method and
	convertible preferred stock using the if-converted method. In computing
	Diluted EPS, the average stock price for the period is used in determining
	the number of shares assumed to be purchased from the exercise of stock
	options or warrants. Diluted EPS excludes all dilutive potential shares if
	their effect is anti-dilutive. All per share disclosures retroactively
	reflect shares outstanding or issuable as though the reverse split had
	occurred January 1, 2012.</P>
	<P>
	<i>Income Taxes</i></P>
	<P>
	We have adopted FASB ASC 740,&nbsp;Accounting for Income Taxes.&nbsp;Pursuant to ASC
	740, we are required to compute tax asset benefits for net operating losses
	carried forward. The potential benefits of net operating losses have not
	been recognized in these financial statements because the Company cannot be
	assured it is more likely than not it will utilize the net operating losses
	carried forward in future years.</P>
	<P>
	We must make certain estimates and judgments in determining income tax
	expense for financial statement purposes. These estimates and judgments
	occur in the calculation of certain tax assets and liabilities, which arise
	from differences in the timing of recognition of revenue and expense for tax
	and financial statement purposes.</P>
	<P>
	Deferred tax assets and liabilities are determined based on the differences
	between financial reporting and the tax basis of assets and liabilities
	using the tax rates and laws in effect when the differences are expected to
	reverse. ASC 740 provides for the recognition of deferred tax assets if
	realization of such assets is more likely than not to occur. Realization of
	our net deferred tax assets is dependent upon our generating sufficient
	taxable income in future years in appropriate tax jurisdictions to realize
	benefit from the reversal of temporary differences and from net operating
	loss, or NOL, carryforwards. We have determined it more likely than not that
	these timing differences will not materialize and have provided a valuation
	allowance against substantially all of our net deferred tax asset.
	Management will continue to evaluate the realizability of the deferred tax
	asset and its related valuation allowance. If our assessment of the deferred
	tax assets or the corresponding valuation allowance were to change, we would
	record the related adjustment to income during the period in which we make
	the determination. Our tax rate may also vary based on our results and the
	mix of income or loss in domestic and foreign tax jurisdictions in which we
	operate.</P>
	<P>
	In addition, the calculation of our tax liabilities involves dealing with
	uncertainties in the application of complex tax regulations. We recognize
	liabilities for anticipated tax audit issues in the U.S. and other tax
	jurisdictions based on our estimate of whether, and to the extent to which,
	additional taxes will be due. If we ultimately determine that payment of
	these amounts is unnecessary, we will reverse the liability and recognize a
	tax benefit during the period in which we determine that the liability is no
	longer necessary. We will record an additional charge in our provision for
	taxes in the period in which we determine that the recorded tax liability is
	less than we expect the ultimate assessment to be.</P>
	<P>
	ASC 740 which requires recognition of estimated income taxes payable or
	refundable on income tax returns for the current period and for the
	estimated future tax effect attributable to temporary differences and
	carry-forwards. Measurement of deferred income tax is based on enacted tax
	laws including tax rates, with the measurement of deferred income tax assets
	being reduced by available tax benefits not expected to be realized.</P>
	<P>
	<i>Uncertain Tax Positions</i></P>
	<P>
	When tax returns are filed, it is highly certain that some positions taken
	would be sustained upon examination by the taxing authorities, while others
	are subject to uncertainty about the merits of the position taken or the
	amount of the position that would be ultimately sustained. In accordance
	with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax
	Positions, the benefit of a tax position is recognized in the financial
	statements in the period during which, based on all available evidence,
	management believes it is more likely than not that the position will be
	sustained upon examination, including the resolution of appeals or
	litigation processes, if any. Tax positions taken are not offset or
	aggregated with other positions. Tax positions that meet the
	more-likely-than-not recognition threshold are measured as the largest
	amount of tax benefit that is more than 50 percent likely of being realized
	upon settlement with the applicable taxing authority. The portion of the
	benefits associated with tax positions taken that exceeds the amount
	measured as described above should be reflected as a liability for
	unrecognized tax benefits in the accompanying consolidated balance sheets
	along with any associated interest and penalties that would be payable to
	the taxing authorities upon examination.</P>
	<P>
	Our federal and state income tax returns are open for fiscal years ending on
	or after December 31, 2011. We are not under examination by any jurisdiction
	for any tax year. At June 30, 2016 we had no material unrecognized tax
	benefits and no adjustments to liabilities or operations were required under
	FIN&nbsp;48.</P>
	<P>
	<i>Recent Accounting Pronouncements</i></P>
	<P>
	In September, 2015, the FASB issued ASU No. 2015-16, Business Combinations
	(Topic 805) ("ASU 2015-16"). Topic 805 requires that an acquirer
	retrospectively adjust provisional amounts recognized in a business
	combination, during the measurement period. To simplify the accounting for
	adjustments made to provisional amounts, the amendments in the Update
	require that the acquirer recognize adjustments to provisional amounts that
	are identified during the measurement period in the reporting period in
	which the adjustment amount is determined. The acquirer is required to also
	record, in the same period's financial statements, the effect on earnings of
	changes in depreciation, amortization, or other income effects, if any, as a
	result of the change to the provisional amounts, calculated as if the
	accounting had been completed at the acquisition date. In addition an entity
	is required to present separately on the face of the income statement or
	disclose in the notes to the financial statements the portion of the amount
	recorded in current-period earnings by line item that would have been
	recorded in previous reporting periods if the adjustment to the provisional
	amounts had been recognized as of the acquisition date. ASU 2015-16 is
	effective for fiscal years beginning December 15, 2015. The adoption of ASU
	2015-016 is not expected to have a material effect on the Company's
	consolidated financial statements.</P>
	<P>
	In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts
	with Customers (Topic 606): Deferral of the Effective Date ("ASU 2015-14").
	The amendment in this ASU defers the effective date of ASU No. 2014-09 for
	all entities for one year. Public business entities, certain not-for-profit
	entities, and certain employee benefit plans should apply the guidance in
	ASU 2014-09 to annual reporting periods beginning December 15, 2017,
	including interim reporting periods within that reporting period. Earlier
	application is permitted only as of annual reporting periods beginning after
	December 31, 2016, including interim reporting periods with that reporting
	period.</P>
	<P>
	In April 2015, the Financial Accounting Standards Board ("FASB") issued
	Accounting Standards Update ("ASU") No. 2015-03, Interest-Imputation of
	Interest (Subtopic 835-30) ("ASU 2015-03"), which changes the presentation
	of debt issuance costs in financial statements. ASU 2015-03 requires an
	entity to present such costs in the balance sheet as a direct deduction from
	the related debt liability rather than as an asset. Amortization of the
	costs will continue to be reported as interest expense. It is effective for
	annual reporting periods beginning after December 15, 2016. Early adoption
	is permitted. The new guidance will be applied retrospectively to each prior
	period presented. The Company is currently in the process of evaluating the
	impact of adoption of ASU 2015-03 on its balance sheets</P>
	<P>
	<i>Going Concern</i></P>
	<P>
	The accompanying financial statements have been prepared in conformity with
	accounting principles generally accepted in the United States of America,
	which contemplate continuation of the Company as a going concern. The
	Company has not established any source of revenue to cover its operating
	costs, and as such, has incurred an operating loss since inception. Further,
	as of June 30, 2016, the cash resources of the Company were insufficient to
	meet its current business plan, and the Company had negative working
	capital. These and other factors raise substantial doubt about the Company's
	ability to continue as a going concern. The accompanying financial
	statements do not include any adjustments to reflect the possible future
	effects on the recoverability and classification of assets or the amounts
	and classification of liabilities that may result from the possible
	inability of the Company to continue as a going concern.</P>
	<P>
	<b>Note 2. Stockholders' Equity.</b></P>
	<P>
	On January 8, 2015 the shareholders approved a resolution to increase the
	authorized common shares from 100,000,000 to 490,000,000 shares. All other
	provisions of the common shares remain unchanged. Also on that date, the
	Company declared a reverse split of common stock at the ration of 1:4. The
	stock split was effective January 8, 2015 for holders of record as of that
	date. Except as otherwise noted, all share, option and warrant numbers have
	been restated to give retroactive effect to this split. All per share
	disclosures retroactively reflect shares outstanding or issuable as though
	the reverse split had occurred at January 1, 2012.</P>
	<P>
	<i>Recent Issuances of Common Stock</i></P>
	<P>
	Between January 15, 2015 and March 15, 2015, the Company sold a total of
	2,052,000 units for cash consideration of $780,000 at a price of $0.40 (the
	&quot;Units&quot;), each unit comprised of one share of common stock and one Class A
	warrant exercisable at $0.80 per share with a term 24 month. The relative
	fair value of the stock with embedded warrants was $351,433 for the common
	stock and $428,567 for the class A warrants. The warrants were valued using
	the Black-Scholes model with 153% volatility and discount rates ranging
	between 0.44% to 0.7%. These units were issued as stock payable and the cash
	from sale of units was not received for the sale of stock pre-reverse
	merger. </P>
	<P>
	Between April 1, 2015 and June 29, 2015, the Company sold a total of
	1,012,500 units for cash consideration of $405,000 at a price of $0.40 (the
	&quot;Units&quot;), each unit comprised of one share of common stock and one Class A
	warrant exercisable at $0.80 per share with a term 24 month. The relative
	fair value of the stock with embedded warrants was $158,123 for the common
	stock and $246,877 for the class A warrants. The warrants were valued using
	the Black-Scholes model with volatility ranging between163% - 177% and
	discount rates ranging between 0.54% to 0.71%. These units were issued as
	stock payable and the cash from sale of units was not received for the sale
	of stock pre-reverse merger. </P>
	<P>
	Between July 1, 2015 and September 30, 2015, the Company sold a total of
	140,000 units for cash consideration of $15,000 at price of $0.107 (the
	&quot;Units&quot;), each unit comprised of one share of common stock and one Class A
	warrant exercisable at $0.80 per share with a term 24 month. The relative
	fair value of the stock with embedded warrants was $4,294 for the common
	stock and $10,706 for the class A warrants. The warrants were valued using
	the Black-Scholes model with volatility of 153% and discount rates of 0.61%.
	These units were issued as stock payable and the cash from sale of units was
	not received for the sale of stock pre-reverse merger. </P>
	<P>
	Between July 1, 2015 and September 30, 2015, the Company sold a total of
	862,500 units for cash consideration of $345,000 at price of $0.40 (the
	&quot;Units&quot;), each unit comprised of one share of common stock and one Class A
	warrant exercisable at $0.80 per share with a term 24 month. The relative
	fair value of the stock with embedded warrants was $118,415 for the common
	stock and $226,585 for the class A warrants. The warrants were valued using
	the Black-Scholes model with volatility ranging between 153% - 182% and
	discount rates ranging between 0.54% to 0.71%. Of these units $65,000 were
	issued as stock payable and the cash from sale of units was not received for
	the sale of stock pre-reverse merger and $280,000 cash was received
	subsequent to Closing of the reverse merger. </P>
	<P>
	On July 16, 2015 and August 6, 2015, the company issue 517,900 shares to one
	service provider and 100,000 shares to two service providers, respectively,
	for services valued at a total value of $617,900, arrived at using the stock
	price on date of grant of $1.00 per Nasdaq.com. </P>
	<P>
	On July 16, 2015, 5 Emerald debt holders in amount of $87,910 converted their
	debt into 274,719 units at a conversion price of $0.32 per unit, each unit
	comprised of one share of common stock and one Class A warrant exercisable
	at $0.80 per share with a term 24 month. The Loss on Settlement of Debt
	recorded was $678,027. </P>
	<P>
	On July 14, 2015 the Company issued Emerald's CEO and founder, Lior Wayn,
	5,474,545 shares as per the share purchase agreement valued at $877,380,
	valued on the date of grant for the price of common stock. </P>
	<P>
	On July 16, 2015 consultants were issued 2,500,000 Class B Warrants
	exercisable for a two-year period to acquire one (1) share of Common Stock
	at a price of $0.40 per share&#894; The fair value of these warrants is
	$2,199,507. The warrants were valued using the Black-Scholes model with
	volatility of 182% and discount rate of 0.67%. The Class B warrants are
	fully vested and were accordingly included in expenses as stock based
	compensation. </P>
	<P>
	On July 16, 2015 consultants were issued 2,536,247 Class C Warrants
	exercisable for a 90 day period, commencing 90 days after the effective date
	of this Registration Statement, at an exercise price of $0.40 to acquire one
	(1) share of Common Stock and one (1) Class A Warrant at an exercise price
	of $0.80. The fair value of these warrants is $3,143,581. The warrants were
	valued using the Black-Scholes model with volatility of 182% and discount
	rate of 0.67%. The Class C warrants are fully vested and were accordingly
	included in expenses as stock based compensation.</P>
	<P>
	On November 17, 2015 the Company sold 250,000 units for cash consideration
	of $100,000 at price of $0.40 (the &quot;Units&quot;), each unit comprised of one
	share of common stock and one Class A warrant exercisable at $0.80 per share
	with a term 24 month. The relative fair value of the stock with embedded
	warrants was $41,304 for the common stock and $58,696 for the class A
	warrants. The warrants were valued using the Black-Scholes model with
	volatility ranging between 149% and discount rate of 0.50%. These warrants
	are fully vested and the fair value and included as stock based compensation
	on the prior year retained earnings. </P>
	<P>
	Between November 5, 2015 and November 16, 2015 the company issue 268,084
	shares to three service provider and for services valued at a total value of
	$268,084, arrived at using the stock price on date of grant of $1.00 per
	Nasdaq.com. </P>
	<P>
	On October 1, 2015, the Company granted a total of 534,400 stock options (the
	&quot;Options&quot;) to three company employees. The options vest over 5 quarters and
	are exercisable at prices ranging from $0.01 to $0.40 per Share. The options
	were valued using the Black-Scholes model with 149% volatility and 0.67%
	discount rate for a total value of $528,857. Of this amount, $397,547 was
	expensed as of December 31, 2015 and $42,394 as of March 31, 2016. An
	additional $42,394 was expensed during the three-month period ended June 30,
	2016.</P>
	<P>
	On January 26, 2016 and March 17, 2016, the Company issued 125,000 shares to
	one service provider and 50,000 shares to two service providers,
	respectively, for services valued at a total value of $251,250, arrived at
	using the stock price on date of grant of $1.75 and $0.65, respectively, per Nasdaq.com. </P>
	<P>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	On February 18, 2016, the Company issued 1,195,000 shares to three acting
	directors, for services valued at a total value of $1,194,403, arrived at
	using the stock price on date of grant of $1.00 per Nasdaq.com.
	</font>
	</P>
	<P>
	On January 26, 2016, consultants that were previously issued 2,500,000 Class
	B Warrants exercisable for a two-year period to acquire one (1) share of
	Common Stock at a price of $0.40 per share, exercised the warrants on a
	cashless basis resulting in 1,928,572 shares issued with no additional
	related expense booked. </P>
	<p>On February 11 and 18, 2016, the Company granted a total of 403,333 stock
	options (the &quot;Options&quot;) to three company employees. The options vest over
	periods of between 1 and 8 quarters and are exercisable at prices ranging
	from $0.01 to $0.40 per Share. The options were valued using the
	Black-Scholes model with 157% volatility and 0.56% discount rate for a total
	value of $400,914. Of this amount, $231,920 was expensed during the
	three-months ended March 31, 2016 and $48,711 during the three-months ended
	June 30, 2016.</p> <p>On March 24, 2016, a
	convertible note payable was issued to GoldMed Ltd. The warrants were valued
	at a fair value of $56,030. The note included a beneficial conversion
	feature which resulted in a $75,000 discount recorded as a reduction of debt
	and an increase to additional paid in capital.</p>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<P>

	On April 5, 2016, the Company issued 150,000 shares to one service provider
	for services valued at $105,000 based on the Company's stock price of $0.70

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	per share
	</font>
	on the date of issuance.</P>
	<P>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	On May 10, 2016, the Company issued 41,667 shares to one service provider
	for services valued at $72,911 based on the Company's stock price of $1.75
	per share on the date of issuance.</font></P>
	<P>

	On May 18, 2016, the Company issued 150,000 shares to one service provider
	for services valued at $102,000 based on the Company's stock price of $0.68

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	per share
	</font>
	on the date of issuance.</P>
	<P>

	On June 28, 2016, the Company issued 175,000 shares to one service provider
	for services valued at $122,500 based on the Company's stock price of $0.70
	per share on the date of issuance.</P>
	<P>

	On June 30, 2016, the Company issued 333,333 shares to one service provider
	for services valued at $226,666 based on the Company's stock price of $0.68
	per share on the date of issuance.</P>
	<P>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	On June 6, 2016, a
	convertible note payable was issued to Alpha Capital. The attached warrants were valued
	at a fair value of $440,000. The note included a beneficial conversion
	feature which resulted in a $300,000 discount recorded as a reduction of debt
	and an increase to additional paid in capital.</font></P>
	<P>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	On April 11, 2016, a
	convertible note payable was issued to Maz Partner. The attached warrants were valued
	at a fair value of $80,000. The note included a beneficial conversion
	feature which resulted in a $46,000 discount recorded as a reduction of debt
	and an increase to additional paid in capital.</font></P>
	<P>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	On June 30, 2016, a
	convertible note payable was issued to Ilan Malka. The attached warrants were valued
	at a fair value of $40,000. The note included a beneficial conversion
	feature which resulted in a $35,000 discount recorded as a reduction of debt
	and an increase to additional paid in capital.</font></P>
	</font>
	<p>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	On April 14, 2016, the Company granted a total of 450,000 stock options (the
	&quot;Options&quot;) to one Company director. The options vest over periods of
	between 1 and 3 quarters and are exercisable at $0.60 per share. The options were valued using the Black-Scholes model with
	233% volatility and 0.56% discount rate for a total value of $268,839. The
	Company expensed $89,613 during the three-months ended June 30, 2016 related
	to these options.</font></p>
	<P>
	<b>Note 3. Related Party Transactions </b></P>
	<P>
	On July 16, 2015 5 Emerald debt holders in amount of $87,910 converted their
	debt into 274,719 units at a conversion price of $0.32 per unit, each unit
	comprised of one share of common stock and one Class A warrant exercisable
	at $0.80 per share with a term 24 month. The Loss on Settlement of Debt
	recorded was $678,027. </P>
	<P>
	On July 14, 2015 the Company issued Emerald's CEO and founder, Lior Wayn,
	5,474,545 shares as per the share purchase agreement valued at $877,380,
	valued on the date of grant for the price of common stock. </P>
	<P>
	The company's CEO, Lior Wayn was owed $3,310 and $3,480 payable as of June
	30, 2016 and December 31, 2015, respectively. </P>
	<P>
	Following Closing of the reverse merger, $490,000 loan from Zaxis
	International Inc. to Emerald Medical Applications Ltd. was rendered an
	intercompany loan and as such was written off.</P>
	<P>
	On February 18, 2016, the Company issued 1,195,000 shares to three acting
	directors, for services valued at a total value of $1,194,403, arrived at
	using the stock price on date of grant of $1.00 per Nasdaq.com. </P>
	<P>
	<b>Note 4. Employee Payable.</b></P>
	<P>
	For the periods ended June 30, 2016 and December 31, 2015 the Company had
	$25,867 and $25,612, respectively, in employee payable related to the
	monthly wages payable to the company's employees. </P>
	<P>
	<b>Note 5. Notes Payable.</b></P>
	<P>
	<i>Convertible Notes Payable</i></P>
	<P>
	On March 24, 2016, the Company issued a convertible promissory note to GoldMed Ltd. in the amount of $75,000. The Convertible Note
	is convertible
	to 187,500 units at $0.40 (the &quot;Units&quot;), each unit comprised of one share of
	common stock and one Class A warrant exercisable at $0.80 per share with a
	term 24 months. Since the market price on the date of issuance was higher
	than the conversion price, a beneficial conversion feature was calculated at
	$78,750, but only $75,000 was recorded. $20,137 was recorded as amortization expense
	of for the period ending June 30, 2016, compared to amortization expense of $0
	as of December 31, 2015. </P>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<P>

	On June 20, 2016, a
	$400,000 convertible note payable and 200,000 warrants exercisable at $0.80
	per share with a term of 24 months was issued to Alpha Capital. The note included a beneficial conversion
	feature which resulted in a $300,000 discount recorded as a reduction of debt
	and an increase to additional paid in capital. The Company recorded an
	amortization expense of $8,219 related to this note.
	</P>
	<P>

	On March 31, 2016, a
	$80,000 convertible note payable

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	and 200,000 warrants exercisable at $0.80 per share with a term of 24 months
	</font>
	was issued to Maz Partner. The note included a beneficial conversion
	feature which resulted in a $46,000 discount recorded as a reduction of debt
	and an increase to additional paid in capital.<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	The Company recorded an amortization expense of $11,468 related to this
	note.
	</font>
	</P>
	<P>

	On May 24, 2016, a
	convertible note payable was issued to Ilan Malka. The note included a beneficial conversion
	feature which resulted in a $35,000 discount recorded as a reduction of debt
	and an increase to additional paid in capital.

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	The Company recorded an amortization expense of $3,548 related to this note.
	</font>
	</P>
	</font>
	<P>
	<b>Note 6. Payable - Not Convertible</b></P>
	On July 8, 2014 the company issued a convertible promissory note to Axel
	Springer Plug &amp; Play Accelerator GmbH (the &quot;Holder&quot;), in the amounts of
	$29,719. The Convertible Notes are convertible at the lessor of a market
	based discounted and a fixed rate derived from a fixed market cap. The
	Holders have the right following the Date of Issuance, and until any time
	until the convertible Promissory Note is fully paid, to convert any
	outstanding and unpaid principal portion of the Convertible Promissory Note,
	and accrued interest, into fully paid and non-assessable shares of Common
	Stock. Holder was not issued warrants with the Convertible Promissory Note.
	<p>As of December 31, 2015 this note is no longer convertible since
	pursuant to the loan agreement the in the event that prior to December
	31,2015 (the &quot;Maturity Date&quot;), the Company shall consummate a financing
	round led by unaffiliated investors in the amount of at least Euro 200,000, at a
	Company pre-money valuation on a fully diluted basis of at least Euro 750,000 (a
	&quot;Qualified Round&quot;), the Holder shall be entitled (but not obligated) to
	convert the entire loan amount into the most senior class of shares of the
	Company issued in such Qualified Round, based on a price per share equal to
	the lower of the price per share reflected by a Company pre-money valuation
	on a fully diluted basis calculated at the time of conversion equal to
	Euro 1,500,000; or - price per share which reflects a 20% discount on the lowest
	price per share issued pursuant to such Qualified Round. If upon the
	occurrence of such event the note holder elects not to convert upon
	receiving notice of such event, then the loan becomes non-convertible. </p>
	<P>
	On January 14 and 16, 2015, we issued two promissory notes in the amount of
	$15,000 each to two different unaffiliated party in consideration for cash
	transferred to the Company (the &quot;January 2015 Notes&quot;). The January 2015
	Notes bears interest at the rate of 1% per annum, are due and payable on
	January 14 and 16, 2016 and are not convertible to common stock. </P>
	<P>
	One of the notes was repaid in full on March 3, 2015 with interest due
	waived the by the debtor, and the second note was repaid on April 22, 2015
	with interest due waived the by the debtor.</P>
	<P>
	During the second quarter of 2015, an agreement was reached with the holder of
	$120,979 advance payable note to settle the full amount due for $30,000 and
	interest due. The settlement with all note holders resulted in $528 loss on
	debt settlement due to the payment being higher than principal and accrued
	interest as of that date as well as a charge of $90,979 considered a
	contribution of capital due to the fact that note holder, IMWT, was a
	related party. </P>
	<P>
	We concluded that these notes have a stated rate of interest that is
	different from the rate of interest that is appropriate for this type of
	debt at the date of the transaction. Accordingly, the company imputed
	interest at an appropriate rate estimated at 8% as prescribed under FASB ASC
	835. The resultant charge of $6,280 for the period ending December 31, 2014
	and $4,113 for the period ending March 31, 2015 to interest expense was
	considered a contribution of capital and was recorded in additional paid in
	capital. </P>
	<P>
	On November 16, 2014 four individuals loaned amount to company, totaling
	$87,910 with maturity dates of November 16, 2015 and bearing an interest
	rate of 8% per annum, these notes were fully converted on July 16, 2015 to
	Company shares of commons stock and warrants as described in Note 3. </P>
	<P>
	On March 9, 2016 four individuals lent the company a total of $34,547 with
	maturity dates of November 16, 2015 and bearing an interest rate of 8% per
	annum. As of June 30, 2016, the loan was fully repaid.</P>
	<P>
	For the periods ended June 30, 2016 and December 31, 2015, the Company has
	recognized $21,420 and $19,285, respectively, in accrued interest expense
	related to the stated interest rate on the notes. Interest expense for the
	periods ended June 30, 2016 and June 30, 2015, respectively, were $21,887
	and $11,829, as well as $43,372 and $0 from the amortization of debt
	discount. </P>
	<P>
	<b>Note 7. Commitments and Contingencies</b></P>
	<P>
	The Company received research and development grants from the State of
	Israel according to guidelines and procedures of the Office of the Chief
	Scientist of the Ministry of Industry and Trade. According to the agreement,
	the Company is obliged to pay royalties on the sale of products developed
	with the participation of the Chief Scientist. The royalty rate is 3.5% and
	the total royalties will not exceed the amount of the grants. As of June 30,
	2016, the Company had an outstanding contingent liability to pay royalties
	in the amount of $186,335, with $15,795 in accrued interest. </P>
	<P>
	<b>Note 8. Derivative Liabilities</b></P>
	<P>
	On July 8, 2014 the company issued a convertible promissory note to Axel
	Springer Plug &amp; Play Accelerator GmbH (the "Holder"), in the amounts of
	$29,719.</P>
	<P>
	The Convertible note is convertible at the lessor of a market based
	discounted and a fixed rate derived from a fixed market cap. The Holder has
	the right following the Date of Issuance, and until any time until the
	convertible Promissory Note is fully paid, to convert any outstanding and
	unpaid principal portion of the Convertible Promissory Note, and accrued
	interest, into fully paid and non-assessable shares of Common Stock. The
	Holder was not issued warrants with the Convertible Promissory Note.</P>
	<P>
	The following shows the changes in the derivative liability measured on a
	recurring basis for the six months ended June 30, 2016 and year
	ended December 31, 2015.</P>
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; text-align: center; height: 0%;">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; height: 1px;"></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; height: 1px;">Level 3</TD>
	</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; height: 1px;">Derivative Liability at December 31, 2014</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">$</TD>
	<TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">20,532</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 71%; text-align: left; padding-bottom: 1.5pt; height: 1px;">
	Extinguishment of Derivative Liability</TD>
    <TD STYLE="width: 1%; text-align: right; border-bottom: Black 1.5pt solid; height: 1px;"></TD>
	<TD STYLE="width: 25%; text-align: right; border-bottom: Black 1.5pt solid; height: 1px;">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">(20,532)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD style="text-align: left; height: 1px;">Derivative Liability at December 31, 2015</TD>
    <TD STYLE="text-align: right; height: 1px;">$</TD>
	<TD STYLE="text-align: right; height: 1px;">-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left; height: 1px;">Derivative Liability at
	June 30, 2016</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">$</TD>
	<TD STYLE="text-align: right; border-bottom: Black 2.5pt double; height: 1px;">
	-</TD></TR>
</TABLE>

	</font>

	<P>
	For the periods ended June 30, 2016 and December 31, 2015 the Company has
	recognized $0 and $2,013, respectively, in accrued interest expense related
	to the stated interest rate on the notes. Interest expense for the periods
	ended June 30, 2016 and December 31, 2015, respectively, were $21,887 and
	$30,604, of which $0 and $0 is from the amortization of debt discount related
	to this note The note is no longer considered convertible since the lender
	elected not to convert, and as such the derivative was written off. </P>
	<P>
	As of December 31, 2015 the company has a $0 derivative liability and a
	$29,719 convertible note payable, net of discount of $0. As of June 30,
	2016, the Company has $0 derivative liability and $222,377 of convertible notes
	payable, net of discount of $412,628. </P>
	<P>
	In accordance to ASC #815, Accounting for Derivative Instruments and Hedging
	Activities, we evaluated the holder's non-detachable conversion right
	provision and liquidated damages clause, contained in the terms governing
	the Note to determine whether the features qualify as an embedded derivative
	instruments at issuance. Such non-detachable conversion right provision and
	liquidated damages clause did not need to be accounted for as derivative
	financial instruments. Additionally, since the conversion price of the two
	notes represented the fair market value of the Company's common stock at the
	time of issuance, no beneficial conversion feature exists. We believe that
	the Company's shares of common stock is and have been very thinly traded
	during the last 3 years and that the fair value of the stock price was
	deemed not to be a fair value. Management decided that because the Company's
	ability to continue as a going concern was in question and that it has no
	revenue sources that the conversion price was a better measure of fair
	market value. Based on that decision, no beneficial conversion feature was
	reflected in the financial statements and the $20,165 extinguishment of debt
	was reflected in the current period earnings and $0 extinguishment of debt
	was reflected in the current period earnings. </P>
	<P>
	<b>Note 9. Other Receivables</b></P>
	<P>
	As of June 30, 2016 and December 31, 2015 the Company had other receivables
	of $8,212 and $25,797, respectively, which represent VAT refunds claimed
	resulting from excess VAT paid over VAT received. </P>
	<P>
	<b>Note 10. Accounts Payable and Accrued Liabilities</b></P>
	<P>
	As of June 30, 2016 and December 31, 2015, the Company had Accounts payable
	and accrued liabilities of $48,204 and $90,705, respectively.</P>
	<P>
	<b>Note 11. Subsequent Events</b></P>
	<P>
	On August 4, 2016, 31,250 shares were issued to one service provider as per
	the terms of the service agreement. </P>
	<P>
	On July 7, 2016, Emerald entered in a Securities Purchase Agreement and a
	Registration Rights Agreement with Firstfire Global Opportunities Fund LLC,
	a New York limited liability company (hereinafter &quot;Firstfire&quot;), pursuant to
	which the Registrant has issued and sold to Firstfire a secured convertible
	note bearing interest at 8% per annum in the principal amount of $100,000
	with a maturity date on June 19, 2017 (the &quot;Note&quot;). In connection with the
	Securities Purchase Agreement, the Registrant also granted Firstfire 250,000
	Class A and 250,000 Class B Warrants. </P>
	</font>
	</font>
<p Style='page-break-before:always'>

<font size="2">
<a name="ITEM_2._MANAGEMENTS_DISCUSSION_AND_ANALYSIS_AND_PLAN_OF_OPERATION">ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATION</a>S <font size="1">
<a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font></font></p>

<p><i>Overview</i></p>
	<p>The following plan of operation provides information which management
	believes is relevant to an assessment and understanding of our results of
	operations and financial condition. The discussion should be read along with
	our financial statements and notes thereto. This section includes a number
	of forward-looking statements that reflect our current views with respect to
	future events and financial performance. Forward-looking statements are
	often identified by words like believe, expect, estimate, anticipate,
	intend, project and similar expressions, or words which refer to future
	events. These forward-looking statements are subject to certain risks and
	uncertainties that could cause actual results to differ materially from our
	predictions.</p>
	<p><i>Plan of Operations</i></p>
	<p>We are a digital health startup company engaged in the development, sale
	and service of imaging solutions utilizing our proprietary DermaCompare
	software that we developed for use in derma imaging and analytics (our &quot;DermaCompare&quot;
	or &quot;Product&quot;). In our development of the DermaCompare technology, we
	utilized the knowledge learned from advanced military image processing and
	data analytics to improve the analysis of medical images for the benefit of
	patients and the medical community. We believe that our proprietary
	DermaCompare software represents an advancement in skin cancer screening
	that should enable physicians to more readily identify and monitor changes
	in their patients' skin characteristics.</p>
	<p>DermaCompare is Emerald's first application of its technology, which we
	believe represents an advance in the early detection of skin cancer.
	DermaCompare is based on automated image analytics software using advanced
	algorithms for alignment, anchoring, identifying and detecting changes in
	the shapes, colors and sizes of skin lesions, which could potentially become
	Melanoma. We apply our DermaCompare technology in image capture, correction
	and intelligent data extraction in the market for derma imaging products.</p>
	<p>Our DermaCompare solution allows dermatologists and other medical care
	professionals, using a set of 25 total body photography (&quot;TBP&quot;), to capture
	sets of skin lesion images with, among other devices, digital cameras,
	camera-equipped smart phones or tablets. These images are then transmitted
	online and are remotely analyzed by professionals using our DermaCompare
	software.</p>
	<p>Our DermaCompare imaging software has 2 main modules:</p>

<font size="2" face="Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
    SaaS cloud-based Dr. Module that can be launched on any desktop computer connected to the Internet; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mobile
    APP for mass population uses can be installed on smart phones or tablets with iOS or Android operating systems. </FONT></TD></TR>
</TABLE>

</font>


	</font>

	<p>Our future plans also contemplate the use of wearable computing and
	imaging devices such as Google glasses or other comparable devices.</p>
	<p>Our sales and marketing plan, which has already commenced, is to sell
	licenses for our DermaCompare imaging software to: NHSs, HMOs, health
	insurance companies, hospitals and medical clinics through distributers,
	health care channel partners or directly through independent salespersons
	and/or web purchase to dermatologists and other physicians (GPs) that we
	expect to purchase licenses based on the number of potential numbers of
	patients.</p>
	<p>In furtherance of our business plan, which has resulted in us becoming an
	operating company, we have entered into a series of agreements with
	unaffiliated third parties for the distribution of its DermaCompare
	Technology, as follows:</p>
	<p>1. On August 12, 2013, Emerald entered into an exclusive distribution
	with Derma Italy Sri, organized under the laws of the Italy (&quot;Derma Italy&quot;),
	pursuant to which Derma Italy was granted exclusive distribution rights in
	Italy;<br>2. On December 1, 2013, Emerald entered into a distribution
	agreement with S. Bokhorst - Creatiekracht, organized under the laws of the
	Netherlands, pursuant to which S. Bokhorst was granted exclusive
	distribution in the Netherlands; <br>3. On February 6, 2014, Emerald entered
	into a distribution agreement with Medical Edge Pty Ltd, organized under the
	laws of Australia (&quot;Medical Edge&quot;), pursuant to which Medical Edge was
	granted exclusive distribution rights in the markets of Australia, New
	Zealand and Oceania;<br>4. On January 14, 2015, Emerald entered into a
	Project Agreement with Realize S.A. and Ubitech, entities engaged in IT
	related to medical technology in Greece, and MEDISP and MPUoP, academic and
	research institutes in Greece (collectively, the &quot;Greek Partners&quot;). Emerald
	and the Greek Partners anticipate imminent grants from the Office of Chief
	Scientist of the State of Israel and the General Secretariat for Research
	and Technology of Greece, respectively, the proceeds of which will be used
	for development of enhanced smartphone applications for diagnosis of early
	stage Melanoma.&nbsp;</p>
	<p>During the six months ended June 30, 2016, we raised $735,913 through the issuance of equity and debt and
	we may be expected to require up to an additional $1.5 million in capital
	during the next 12 months to fully implement our business plan and fund our
	operations.&nbsp;</p>
	<p><i>Results of Operations during the three months ended June 30, 2016 as
	compared to the three months ended June 30, 2015</i></p>
	<p>We have not generated any revenues during the three months ended June 30,
	2016 and 2015. </p>
	<p>Our general and administrative expenses increased to $969,216 for the
	three months ended June 30, 2016 as compared to $5,570 during the same
	period in the prior year. The significant increase was due to increased
	expenses relating to our new business activities as well as share-based compensation. </p>
	<p>Our research and development expenses increased to $192,002 for the three
	months ended June 30, 2016 as compared to $237,095 during the same period in the
	prior year. The decrease was due to more focused research and development
	expenses related to our DermaCare product.</p>
	<p>
	<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	During the three-month period ended June 30, 2016 and
	2015, we incurred a loss from operations of $1,161,218 and $242,665, respectively.
	</font></p>
	<p>Interest expense increased to $14,128 for the three months ended June 30,
	2016 as compared to $4,346 during the same period in the prior year due to
	increased loans. </p>
	<p>Depreciation and amortization expense increased to $47,718 for the three months ended
	June 30, 2016 as compared to $0 during the same period in the prior year due to
	expenses related to beneficial conversion features of notes issued during
	the three months ended June 30, 2016. </p>
	<p>We incurred other income of $28,587 during the three-month period ended
	June 30, 2016 as compared to $0 in the same period in the prior year.</p>
	<p>We recorded a gain of $6,503 from currency adjustments during the three
	months ended June 30, 2016 as compared to a loss of $4,110 in the same
	period in the prior year.</p>
	<p>
	<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	During the three-month period ended June 30, 2016 and
	2015 we incurred $1,187,974 and $251,121 in net loss, respectively.</font></p>
	<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<p><i>Results of Operations during the six months ended June 30, 2016 as
	compared to the six months ended June 30, 2015</i></p>
	<p>We have not generated any revenues during the six months ended June 30,
	2016 and 2015. </p>
	<p>Our general and administrative expenses increased to $2,768,736 for the
	six months ended June 30, 2016 as compared to $174,391 during the same
	period in the prior year. The significant increase was due to increased
	expenses relating to our new business activities as well as share-based compensation. </p>
	<p>Our research and development expenses increased to $295,350 for the six
	months ended June 30, 2016 as compared to $247,400 during the same period in the
	prior year. The increase during the six-month period was due to additional research and development
	expenses related to our DermaCare product.</p>
	<p>During the six-month period ended June 30, 2016 and
	2015, we incurred a loss from operations of $3,064,086 and $421,791, respectively. </p>
	<p>Interest expense increased to $21,887 for the six months ended June 30,
	2016 as compared to $11,829 during the same period in the prior year due to
	increased loans. We recorded $0 and $367 in expense related to a change in
	fair value of derivative during the six month period ended June 30, 2016 and
	2015, respectively.</p>
	<p>Depreciation and amortization expense increased to $51,665 for the six months ended
	June 30, 2016 as compared to $0 during the same period in the prior year due to
	expenses related to beneficial conversion features of notes issued during
	the six months ended June 30, 2016. </p>
	<p>We incurred other income of $28,587 during the six-month period ended
	June 30, 2016 as compared to $0 in the same period in the prior year.</p>
	<p>We recorded a gain of $20,847 from currency adjustments during the six
	months ended June 30, 2016 as compared to a gain of $1,808 in the same
	period in the prior year.</p>
	<p>During the six-month period ended June 30, 2016 and
	2015 we incurred $3,088,204 and $431,445 in net loss, respectively.</p>
	</font>
	<p><i>Liquidity and Capital Resources</i></p>
	<p>Our balance sheet as of June 30, 2016 reflects current assets of $282,971
	consisting of $274,759 in cash and $8,212 in other receivables. As of December 31, 2015, we had
	current assets of $141,246 consisting of cash of $115,449 and $25,797 in other
	receivables. We had fixed assets, net of $17,735, as of June 30, 2016 and $21,120 as of December 31, 2015.</p>
	<p>As of June 30, 2016, we had total assets of $300,706 and total assets of
	$162,366 as of December 31, 2015.</p>
	<p>As of June 30, 2016, we had total current liabilities of $534,390
	consisting of $48,204 in accounts payable and accrued liabilities, $22,786
	in
	employee payable, $3,081in employee payable to related party, $21,887 accrued
	interest payable, $216,055 in convertible notes payable and $222,377 in short
	term notes payable. </p>
	<p>As of <font size="2" face="Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">

	<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	December 31, 2015, we have had total current liabilities of $288,775 consisting of $90,705 in accounts
	payable and accrued liabilities, $3,480 in accounts payable to related
	party, $25,612 employee payable, $19,285 in accrued interest, short-term
	note payable of $119,974 and $29,719 in convertible note payable.</font></font></font></p>
	<p>We had negative working capital of $251,419 as of June 30, 2016
	and a negative working capital $147,529 at December 31, 2015. Our
	total liabilities as of June 30, 2016 were $534,390 as compared to $288,775 at
	December 31, 2015.</p>
	<p>During the period ended June 30, 2016, we had negative cash flow from
	operations of $536,741, which was the result of a net loss of $3,088,204,
	a decrease in accounts payable of $1,777 and a decrease in accrued expenses of $45,779 offset by
	<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	$8,293 in depreciation expense, $43,373 in amortization expense, <font size="2">
	$2,074,736 in non-cash compensation related to the issuance of services,
	<font size="2" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	$455,032 related to options issued for services and </font></font></font>$17,585
	decrease in
	other receivables.</p>
	<p>During the six months ended June 30, 2016, we acquired assets valued at
	$474 as compared to disposing assets valued at $25,317 in the same period in the prior year.</p>
	<p>During the period ended June 30, 2016, we had cash flow from
	financing activities of $701,366, which was the result of $735,913 proceeds
	from borrowings offset by debt payments of $34,547.</p>
	<p>During the period ended June 30, 2015, we had negative cash flow from
	operations of $431,725, which was the result of a net loss of $431,445
	offset by depreciation expenses of $1,878, amortization of debt expenses of $4,399, a
	loss of a change in fair value of derivatives of $367, an amount due from
	related party of $6,443, an increase in other
	receivables of $25,689, a decrease in accounts payable of $2,577, an
	increase in accounts payable from related party of $1,087, employee payable
	of $23,800, an increase in other current liabilities of $14,202 and an increase in
	accrued expenses of $7,430. </p>
	<p>During the period ended June 30, 2015, we had cash flow from financing activities
	of $531,798 consisting of debt issuance.</p>
	<p>There are no limitations in the Company's certificate of incorporation on
	the Company's ability to borrow funds or raise funds through the issuance of
	restricted common stock to effect a business combination. The Company's
	limited resources and lack of having cash-generating business operations may
	make it difficult to borrow funds or raise capital. The Company's
	limitations to borrow funds or raise funds through the issuance of
	restricted capital stock required to effect or facilitate a business
	combination may have a material adverse effect on the Company's financial
	condition and future prospects, including the ability to complete a business
	combination. To the extent that debt financing ultimately proves to be
	available, any borrowing will subject us to various risks traditionally
	associated with indebtedness, including the risks of interest rate
	fluctuations and insufficiency of cash flow to pay principal and interest,
	including debt of an acquired business.</p>
	<p>The Company has only limited capital. Additional financing is necessary
	for the Company to continue as a going concern. Our independent auditors
	have unqualified audit opinion for the period ended December 31, 2015 with an
	explanatory paragraph on going concern.</p>
	<p>In view of these matters, realization of a major portion of the assets in
	the accompanying balance sheet is dependent upon continued operations of the
	Company. Management believes that actions presently being taken to obtain
	additional equity financing will provide the opportunity to continue as a
	going concern.</p>

<font size="2">
<a name="ITEM_3._QUANTITATIVE_AND_QUALITATIVE_DISCLOSURES_ABOUT_MARKET_RISK">
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK <font size="1">
<a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font></font></p>

<font
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have not entered
into, and do not expect to enter into, financial instruments for trading or hedging
purposes.</font><p><a name="ITEM_4._CONTROLS_AND_PROCEDURES">ITEM 4.
CONTROLS AND PROCEDURES</a> <font size="1"><a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font></p>

<font size="2" face="Times New Roman">
<I><P ALIGN="JUSTIFY">Evaluation of disclosure controls and procedures.</I> As of June 30, 2016, the Company's chief executive officer and chief financial officer conducted an evaluation regarding the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act).</P>
<P>Management has assessed the effectiveness of our internal control over financial reporting as of June 30, 2016. Management's assessment was based on criteria set forth in Internal Control - Integrated Framework (1992), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based upon this assessment, management concluded that, as of June 30, 2016, our internal control over financial reporting was not effective, based upon those criteria, as a result of the identification of the material weaknesses described below.</P>

<P>A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.</P>

<P>Specifically, management identified the following control weaknesses: (i) the Company has not implemented measures that would prevent one individual from overriding the internal control system. (ii) The Company utilizes accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and/or can be adjusted so as not to provide an adequate audit trail of entries made in the accounting software.</P>

<P>Accordingly, while the Company has identified certain material weaknesses in its system of internal control over financial reporting, it believes that it has taken reasonable steps to ascertain that the financial information contained in this report is in accordance with generally accepted accounting principles. The Company does not believe that this control weakness has resulted in deficient financial reporting because the Chief Financial Officer and Chief Executive Officers are aware of their responsibilities under the SEC's reporting requirements and personally certify the financial reports. </P>

<P>Management has determined that current resources would be appropriately applied elsewhere and when resources permit, they will alleviate material weaknesses through various steps.</P>
<I><P ALIGN="JUSTIFY">Changes in internal controls.</I> During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</P>

</font>

	<div style="text-align: center">
		<b>PART II - OTHER INFORMATION</b></div>

	<a name="ITEM_1._LEGAL_PROCEEDINGS">ITEM 1. LEGAL
PROCEEDINGS</a><b> </b><font size="2" color="#000000"><font size="1">
	<a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font><p>None.</font></p>

<font size="2" color="#000000"><a name="ITEM_1A._RISK_FACTORS">ITEM 1A.
RISK FACTORS</a> <font size="1"><a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font></font><p><font face="Times New Roman" size="2">See risk factors discussed
in Part I, &quot;Item&nbsp;1. Description of Business, subheading Risk Factors&quot; in
our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2015.</font></p>

	<a name="ITEM_2._UNREGISTERED_SALES_OF_EQUITY_SECURITIES_AND_USE_OF_PROCEEDS">
	ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS <font size="1">
	</font> <font size="1">
	<a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font><p>During the three-month period ended June 30, 2016, the
	Company issued the following unregistered equity securities:</p>

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">
	<P>

	On April 5, 2016, the Company issued 150,000 shares to one service provider
	for services valued at $105,000 based on the Company's stock price of $0.70
	per share on the date of issuance.</P>
	<P>

	On May 10, 2016, the Company issued 41,667 shares to one service provider
	for services valued at $172,911 based on the Company's stock price of $1.75
	per share on the date of issuance.</P>
	<P>

	On May 18, 2016, the Company issued 150,000 shares to one service provider
	for services valued at $102,000 based on the Company's stock price of $0.68
	per share on the date of issuance.</P>
	<P>

	On June 28, 2016, the Company issued 175,000 shares to one service provider
	for services valued at $122,500 based on the Company's stock price of $0.70
	per share on the date of issuance.</P>
	<P>

	On June 30, 2016, the Company issued 333,333 shares to one service provider
	for services valued at $226,666 based on the Company's stock price of $0.68
	per share on the date of issuance.</P>
	<font size="2" face="Times New Roman">
	<p>Share based payment transactions were accounted for in accordance with the
	requirements of ASC 505-50 Equity Based Payments to Non Employees. Paragraph
	505-50-30-6 establishes that share-based payment transactions with
	non-employees shall be measured at the fair value of the consideration
	received or the fair value of the equity instruments issued, whichever is
	more reliably measurable. The Company measured share-based payment
	transactions at the fair value of the shares issued at date of grant, the
	Company believes that the value of the shares is more reliably measurable.</p>
	<p>The Company believes
that the issuances and sale of the restricted shares were exempt from
registration pursuant to Section 4(2) of the Act as privately negotiated,
isolated, non-recurring transactions not involving any public solicitation. The
recipients in each case represented their intention to acquire the securities
for investment only and not with a view to the distribution thereof. Appropriate
restrictive legends are affixed to the stock certificates issued in such
transactions. All recipients of restricted shares either received adequate
information about the Company or had access, through employment, relation and/or
business relationships with the Company to such information. </p>

	</font>
	</font>

	<a name="ITEM_3.&nbsp;DEFAULTS_UPON_SENIOR_SECURITIES">ITEM
3.&nbsp;DEFAULTS UPON SENIOR SECURITIES</a><b> </b><font size="1">
	<a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font><p><font size="2">None.</font></p>

	<a name="ITEM_4.&nbsp;MINE_SAFETY_DISCLOSURE_">ITEM
4.&nbsp;MINE SAFETY DISCLOSURE</a><font size="1"> <a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font><p><font size="2">None.</font></p>

	<a name="ITEM_5.&nbsp;OTHER_INFORMATION">ITEM
5.&nbsp;OTHER INFORMATION</a><b> </b><font size="1">
	<a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font><p><font size="2">None.</font></p>

	<a name="ITEM_6.&nbsp;EXHIBITS">ITEM 6.&nbsp;EXHIBITS</a> <font size="1">
	<a href="#TABLE_OF_CONTENTS">Back to Table of
Contents</a></font><p ALIGN="JUSTIFY" style="text-align: justify"><font size="2">(a) The following documents
are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. </font></p>
	<font size="2" face="Times New Roman">

<table border="0" cellpadding="0" cellspacing="0" width="100%" height="0%">
  <tr>
    <td width="8%" bgcolor="#fffff" height="0%"><font size="1"><strong>Exhibit No.</strong></font></td>
    <td width="92%" bgcolor="#fffff" height="0%"><font size="1"><strong>Description</strong></font></td>
  </tr>
  <tr>
    <td width="8%" bgcolor="#FFFFFF" height="0%"><font size="2">31.1<td width="92%" bgcolor="#FFFFFF" style="height: 1px"><font size="2">Certification of CEO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section
    302 of the Sarbanes-Oxley Act of 2002.</td>
  </tr>
    <tr>

    <td width="8%" bgcolor="#FFFFFF" height="0%"><font size="2">31.2</td>
    <td width="92%" bgcolor="#FFFFFF" style="height: 1px"><font size="2">Certification of CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section
    302 of the Sarbanes-Oxley Act of 2002.</td>
	</tr>
	<tr>

    <td width="8%" bgcolor="#FFFFFF" height="0%"><font size="2">32.1</td>
    <td width="92%" bgcolor="#FFFFFF" style="height: 1px"><font size="2">Certification of CEO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the
    Sarbanes-Oxley Act of 2002.</font></td>
	</tr>
  <tr>
    <td width="8%" bgcolor="#FFFFFF" height="0%"><font size="2">32.2</td>
    <td width="92%" bgcolor="#FFFFFF" style="height: 1px"><font size="2">Certification of CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the
    Sarbanes-Oxley Act of 2002.</font></td>
  </tr>
</table>

	</font>

	<p Style='page-break-before:always'>		<font
size="2"><p ALIGN="CENTER">SIGNATURES</p>

	<p ALIGN="JUSTIFY">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned.</font></p>
	<p style="text-align: center">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">EMERALD MEDICAL APPLICATIONS CORP.</font></p>
	<p ALIGN="JUSTIFY">
	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">By:
	<i>/s/
<font size="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">Lior Wayn</font></font></i><br>
<font size="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">Lior Wayn</font></font><br>
Chief Executive Officer<br>
(Principal Executive Officer)<br>
Date: August 22, 2016<br>
<br>
By:<i> /s/ David Ben Naim</i><br>
	David Ben Naim<br>
Chief Financial Officer<br>
(Principal Financial and Principal Accounting Officer)<br>
Date: August 22, 2016<br>
<br>
Pursuant to the requirements of the Securities Act of 1934, this report has been signed by
the following persons on behalf of the registrant and in the capacities and on the dates
indicated.<br>
<br>
By: <i>/s/
<font size="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">Yair Fudim</font></font></i><br>
<font size="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">Yair Fudim</font></font><br>
	Chairman<br>Date: August 22, 2016</font></p>
	<p ALIGN="JUSTIFY">
	<font size="2" face="Times New Roman">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">By:
	<i>/s/
<font size="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">Lior Wayn</font></font></i><br>
<font size="2">

	<font size="2" face="Times New Roman" style="display: inline; font-size: 10pt; font-family: 'Times New Roman'">Lior Wayn</font></font><br>
	Director<br>
Date: August 22, 2016</font></font></p>
</div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>exh31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>

<head>
<title>Exhibit 31</title>
</head>

<body>
<b><u><font SIZE="1">

<p align="center"></font><font size="2">CERTIFICATION</font></p>
</u>

<p></b><font size="2">I, Lior Wayn, certify that:</font> </p>

<p><font size="2">1. I have reviewed this quarterly report of Emerald Medical
Applications Corp.;</font>
</p>

<p><font size="2">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</font></p>

<p><font size="2">3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the&nbsp; issuer as of, and for, the
periods presented in this report;</font></p>

<p><font size="2">4. The&nbsp; issuer's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as 4efined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the&nbsp; issuer and have:</font>
</p>

<p><font size="2">(a) Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the&nbsp; issuer, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</font></p>

<p><font size="2">(b) Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</font></p>

<p><font size="2">(c) Evaluated the effectiveness of the&nbsp; issuer's disclosure
controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and</font></p>

<p><font size="2">(d) Disclosed in this report any change in the&nbsp; issuer's internal
control over financial reporting that occurred during the&nbsp; issuer's most recent
fiscal quarter (the&nbsp; issuer's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
issuer's internal control over financial reporting; and</font></p>

<p><font size="2">5. The&nbsp; issuer's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the
&nbsp; issuer's auditors and the audit committee of the&nbsp; issuer's board of directors
(or persons performing the equivalent functions):</font> </p>

<p><font size="2">(a) All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably likely to
adversely affect the&nbsp; issuer's ability to record, process, summarize and report
financial information; and</font></p>

<p><font size="2">(b) Any fraud, whether r not material, that involves management or other
employees who have a significant role in the&nbsp; issuer's internal control over
financial reporting.</font></p>

<p><font size="2">Date: August 22, 2016</font></p>

<p><font size="2">/s/ Lior Wayn<br>
CEO </font></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>exh31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>

<head>
<title>Exhibit 31</title>
</head>

<body>
<b><u><font SIZE="1">

<p align="center"></font><font size="2">CERTIFICATION</font></p>
</u>

<p></b><font size="2">I,
<font size="2" style="font-family: 'Times New Roman'; font-size: 10pt; display: inline">
<font face="Times New Roman" size="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; display: inline;">
David Ben Naim</font></font>, certify that:</font> </p>

<p><font size="2">1. I have reviewed this quarterly report of Emerald Medical
Applications Corp.;</font>
</p>

<p><font size="2">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</font></p>

<p><font size="2">3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the&nbsp; issuer as of, and for, the
periods presented in this report;</font></p>

<p><font size="2">4. The&nbsp; issuer's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as 4efined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the&nbsp; issuer and have:</font>
</p>

<p><font size="2">(a) Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the&nbsp; issuer, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</font></p>

<p><font size="2">(b) Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</font></p>

<p><font size="2">(c) Evaluated the effectiveness of the&nbsp; issuer's disclosure
controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and</font></p>

<p><font size="2">(d) Disclosed in this report any change in the&nbsp; issuer's internal
control over financial reporting that occurred during the&nbsp; issuer's most recent
fiscal quarter (the&nbsp; issuer's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
issuer's internal control over financial reporting; and</font></p>

<p><font size="2">5. The&nbsp; issuer's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the
&nbsp; issuer's auditors and the audit committee of the&nbsp; issuer's board of directors
(or persons performing the equivalent functions):</font> </p>

<p><font size="2">(a) All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably likely to
adversely affect the&nbsp; issuer's ability to record, process, summarize and report
financial information; and</font></p>

<p><font size="2">(b) Any fraud, whether r not material, that involves management or other
employees who have a significant role in the&nbsp; issuer's internal control over
financial reporting.</font></p>

<p><font size="2">Date: August 22, 2016</font></p>

<p><font size="2">/s/
<font size="2" style="font-family: 'Times New Roman'; font-size: 10pt; display: inline">
<font face="Times New Roman" size="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; display: inline;">
David Ben Naim</font></font><br>
CFO </font></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>exh32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>

<body>

<p align="left"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">Exhibit 32.1</font></p>

<p align="center"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">CERTIFICATION
PURSUANT TO<br>
18 U.S.C. SECTION 1350,<br>
AS ADOPTED PURSUANT TO SECTION 906<br>
OF THE SARBANES-OXLEY ACT OF 2002</font></p>

<p style="text-align: justify"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">In
connection with the quarterly report of Emerald Medical Applications Corp. (the
&quot;Company&quot;)
on Form 10-Q for the period ended June 30, 2016 (the &quot;Report&quot;), as filed with
the Securities and Exchange Commission on the date hereof, I, Lior Wayn, CEO of
the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</font></p>

<p style="text-align: justify"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">1. The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended; and<br>
2. The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.</font></p>

<p><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">/s/ Lior Wayn</font></p>

<p><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">Lior Wayn<br>
CEO<br>
Dated: August 22, 2016</font></p>

<p><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">A signed original of this written
statement required by Section 906 has been provided to Emerald Medical
Applications Corp. and will
be retained by the Company and furnished to the Securities and Exchange Commission or its
staff upon request.</font></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>exh32_2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>

<head>
<title>Exhibit 32</title>
</head>

<body>

<p align="left"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">Exhibit 32.2</font></p>

<p align="center"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">CERTIFICATION
PURSUANT TO<br>
18 U.S.C. SECTION 1350,<br>
AS ADOPTED PURSUANT TO SECTION 906<br>
OF THE SARBANES-OXLEY ACT OF 2002</font></p>

<p style="text-align: justify"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">In
connection with the quarterly report of Emerald Medical Applications Corp. (the
&quot;Company&quot;)
on Form 10-Q for the period ended June 30, 2016 (the &quot;Report&quot;), as filed with
the Securities and Exchange Commission on the date hereof, I,
<font size="2" style="font-family: 'Times New Roman'; font-size: 10pt; display: inline">
<font face="Times New Roman" size="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; display: inline;">
David Ben Naim</font></font>, CFO of
the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</font></p>

<p style="text-align: justify"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">1. The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended; and<br>
2. The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.</font></p>

<p><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">/s/
<font size="2" style="font-family: 'Times New Roman'; font-size: 10pt; display: inline">
<font face="Times New Roman" size="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; display: inline;">
David Ben Naim</font></font></font></p>

<p><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">
<font size="2" style="font-family: 'Times New Roman'; font-size: 10pt; display: inline">
<font face="Times New Roman" size="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; display: inline;">
David Ben Naim</font></font><br>
CFO<br>
Dated: August 22, 2016</font></p>

<p><font face="TIMES NEW ROMAN, TIMES, SERIF" size="2">A signed original of this written
statement required by Section 906 has been provided to Emerald Medical
Applications Corp. and will
be retained by the Company and furnished to the Securities and Exchange Commission or its
staff upon request.</font></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>mrla-20160630.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2015 [PPXM8K19K1334NYCARL5]. www.edgarsuite.com -->
<xbrl xmlns='http://www.xbrl.org/2003/instance' xmlns:us-gaap='http://fasb.org/us-gaap/2015-01-31' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:dei='http://xbrl.sec.gov/dei/2014-01-31' xmlns:fil='http://dermacompare.com/20160630' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrli='http://www.xbrl.org/2003/instance'>
	<link:schemaRef xlink:type='simple' xlink:href='mrla-20160630.xsd' />
	<us-gaap:Revenues decimals='INF' contextRef='Y16Q2' unitRef='USD'>0</us-gaap:Revenues>
	<us-gaap:Revenues decimals='INF' contextRef='Y15Q2' unitRef='USD'>0</us-gaap:Revenues>
	<us-gaap:Revenues decimals='INF' contextRef='D160101_160630' unitRef='USD'>0</us-gaap:Revenues>
	<us-gaap:Revenues decimals='INF' contextRef='D150101_150630' unitRef='USD'>0</us-gaap:Revenues>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='Y16Q2' unitRef='USD'>-192002</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='Y15Q2' unitRef='USD'>-237095</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='D160101_160630' unitRef='USD'>-295350</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='D150101_150630' unitRef='USD'>-247400</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='Y16Q2' unitRef='USD'>-969216</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='Y15Q2' unitRef='USD'>-5570</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='D160101_160630' unitRef='USD'>-2768736</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='D150101_150630' unitRef='USD'>-174391</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='Y16Q2' unitRef='USD'>-1161218</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='Y15Q2' unitRef='USD'>-242665</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='D160101_160630' unitRef='USD'>-3064086</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='D150101_150630' unitRef='USD'>-421791</us-gaap:OperatingExpenses>
	<fil:LossFromOperations decimals='INF' contextRef='Y16Q2' unitRef='Pure'>-1161218</fil:LossFromOperations>
	<fil:LossFromOperations decimals='INF' contextRef='Y15Q2' unitRef='Pure'>-242665</fil:LossFromOperations>
	<fil:LossFromOperations decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-3064086</fil:LossFromOperations>
	<fil:LossFromOperations decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-421791</fil:LossFromOperations>
	<us-gaap:InterestExpense decimals='INF' contextRef='Y16Q2' unitRef='USD'>-14128</us-gaap:InterestExpense>
	<us-gaap:InterestExpense decimals='INF' contextRef='Y15Q2' unitRef='USD'>-4346</us-gaap:InterestExpense>
	<us-gaap:InterestExpense decimals='INF' contextRef='D160101_160630' unitRef='USD'>-21887</us-gaap:InterestExpense>
	<us-gaap:InterestExpense decimals='INF' contextRef='D150101_150630' unitRef='USD'>-11829</us-gaap:InterestExpense>
	<us-gaap:UnrealizedGainLossOnDerivatives decimals='INF' contextRef='Y16Q2' unitRef='USD'>0</us-gaap:UnrealizedGainLossOnDerivatives>
	<us-gaap:UnrealizedGainLossOnDerivatives decimals='INF' contextRef='Y15Q2' unitRef='USD'>0</us-gaap:UnrealizedGainLossOnDerivatives>
	<us-gaap:UnrealizedGainLossOnDerivatives decimals='INF' contextRef='D160101_160630' unitRef='USD'>0</us-gaap:UnrealizedGainLossOnDerivatives>
	<us-gaap:UnrealizedGainLossOnDerivatives decimals='INF' contextRef='D150101_150630' unitRef='USD'>367</us-gaap:UnrealizedGainLossOnDerivatives>
	<us-gaap:Depreciation decimals='INF' contextRef='Y16Q2' unitRef='USD'>-47718</us-gaap:Depreciation>
	<us-gaap:Depreciation decimals='INF' contextRef='Y15Q2' unitRef='USD'>0</us-gaap:Depreciation>
	<us-gaap:Depreciation decimals='INF' contextRef='D160101_160630' unitRef='USD'>-51665</us-gaap:Depreciation>
	<us-gaap:Depreciation decimals='INF' contextRef='D150101_150630' unitRef='USD'>0</us-gaap:Depreciation>
	<us-gaap:AmortizationOfDebtDiscountPremium decimals='INF' contextRef='Y16Q2' unitRef='USD'>28587</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium decimals='INF' contextRef='Y15Q2' unitRef='USD'>0</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium decimals='INF' contextRef='D160101_160630' unitRef='USD'>28587</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium decimals='INF' contextRef='D150101_150630' unitRef='USD'>0</us-gaap:AmortizationOfDebtDiscountPremium>
	<fil:GainLossFromForeignCurrency decimals='INF' contextRef='Y16Q2' unitRef='Pure'>6503</fil:GainLossFromForeignCurrency>
	<fil:GainLossFromForeignCurrency decimals='INF' contextRef='Y15Q2' unitRef='Pure'>-4110</fil:GainLossFromForeignCurrency>
	<fil:GainLossFromForeignCurrency decimals='INF' contextRef='D160101_160630' unitRef='Pure'>20847</fil:GainLossFromForeignCurrency>
	<fil:GainLossFromForeignCurrency decimals='INF' contextRef='D150101_150630' unitRef='Pure'>1808</fil:GainLossFromForeignCurrency>
	<fil:FinancialIncomeExpense decimals='INF' contextRef='Y16Q2' unitRef='Pure'>-26756</fil:FinancialIncomeExpense>
	<fil:FinancialIncomeExpense decimals='INF' contextRef='Y15Q2' unitRef='Pure'>-8456</fil:FinancialIncomeExpense>
	<fil:FinancialIncomeExpense decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-24118</fil:FinancialIncomeExpense>
	<fil:FinancialIncomeExpense decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-9654</fil:FinancialIncomeExpense>
	<fil:TotalIncomeExpense decimals='INF' contextRef='Y16Q2' unitRef='Pure'>-1187974</fil:TotalIncomeExpense>
	<fil:TotalIncomeExpense decimals='INF' contextRef='Y15Q2' unitRef='Pure'>-251121</fil:TotalIncomeExpense>
	<fil:TotalIncomeExpense decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-3088204</fil:TotalIncomeExpense>
	<fil:TotalIncomeExpense decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-431445</fil:TotalIncomeExpense>
	<fil:ProvisionForIncomeTaxes decimals='INF' contextRef='Y16Q2' unitRef='Pure'>0</fil:ProvisionForIncomeTaxes>
	<fil:ProvisionForIncomeTaxes decimals='INF' contextRef='Y15Q2' unitRef='Pure'>0</fil:ProvisionForIncomeTaxes>
	<fil:ProvisionForIncomeTaxes decimals='INF' contextRef='D160101_160630' unitRef='Pure'>0</fil:ProvisionForIncomeTaxes>
	<fil:ProvisionForIncomeTaxes decimals='INF' contextRef='D150101_150630' unitRef='Pure'>0</fil:ProvisionForIncomeTaxes>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='Y16Q2' unitRef='USD'>-1187974</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='Y15Q2' unitRef='USD'>-251121</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='D160101_160630' unitRef='USD'>-3088204</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='D150101_150630' unitRef='USD'>-431445</us-gaap:NetIncomeLoss>
	<us-gaap:EarningsPerShareBasicAndDiluted decimals='INF' contextRef='Y16Q2' unitRef='UsdPerShare'>-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted decimals='INF' contextRef='Y15Q2' unitRef='UsdPerShare'>-1.18</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted decimals='INF' contextRef='D160101_160630' unitRef='UsdPerShare'>-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted decimals='INF' contextRef='D150101_150630' unitRef='UsdPerShare'>-2.03</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted decimals='INF' contextRef='Y16Q2' unitRef='Shares'>18890670</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted decimals='INF' contextRef='Y15Q2' unitRef='Shares'>213001</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted decimals='INF' contextRef='D160101_160630' unitRef='Shares'>18121314</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted decimals='INF' contextRef='D150101_150630' unitRef='Shares'>213001</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<fil:NetLoss decimals='INF' contextRef='Y16Q2' unitRef='Pure'>-1187974</fil:NetLoss>
	<fil:NetLoss decimals='INF' contextRef='D150104_150630' unitRef='Pure'>-251121</fil:NetLoss>
	<fil:NetLoss decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-3088204</fil:NetLoss>
	<fil:NetLoss decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-431445</fil:NetLoss>
	<fil:ChangeInUnrealizedForeignCurrencyTranslationGainLoss decimals='INF' contextRef='Y16Q2' unitRef='Pure'>-3</fil:ChangeInUnrealizedForeignCurrencyTranslationGainLoss>
	<fil:ChangeInUnrealizedForeignCurrencyTranslationGainLoss decimals='INF' contextRef='D150104_150630' unitRef='Pure'>-15771</fil:ChangeInUnrealizedForeignCurrencyTranslationGainLoss>
	<fil:ChangeInUnrealizedForeignCurrencyTranslationGainLoss decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-4841</fil:ChangeInUnrealizedForeignCurrencyTranslationGainLoss>
	<fil:ChangeInUnrealizedForeignCurrencyTranslationGainLoss decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-25550</fil:ChangeInUnrealizedForeignCurrencyTranslationGainLoss>
	<us-gaap:ComprehensiveIncomeNetOfTax decimals='INF' contextRef='Y16Q2' unitRef='USD'>-1187977</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax decimals='INF' contextRef='D150104_150630' unitRef='USD'>-266892</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax decimals='INF' contextRef='D160101_160630' unitRef='USD'>-3093045</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax decimals='INF' contextRef='D150101_150630' unitRef='USD'>-456995</us-gaap:ComprehensiveIncomeNetOfTax>
	<fil:NetLoss1 decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-3088204</fil:NetLoss1>
	<fil:NetLoss1 decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-431445</fil:NetLoss1>
	<fil:DepreciationExpense decimals='INF' contextRef='D160101_160630' unitRef='Pure'>8293</fil:DepreciationExpense>
	<fil:DepreciationExpense decimals='INF' contextRef='D150101_150630' unitRef='Pure'>1878</fil:DepreciationExpense>
	<fil:AmortizationOfDebtDiscount decimals='INF' contextRef='D160101_160630' unitRef='Pure'>43373</fil:AmortizationOfDebtDiscount>
	<fil:AmortizationOfDebtDiscount decimals='INF' contextRef='D150101_150630' unitRef='Pure'>4399</fil:AmortizationOfDebtDiscount>
	<fil:ChangeInFairValueOfDerivative decimals='INF' contextRef='D160101_160630' unitRef='Pure'>0</fil:ChangeInFairValueOfDerivative>
	<fil:ChangeInFairValueOfDerivative decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-367</fil:ChangeInFairValueOfDerivative>
	<fil:SharesIssuedForServices decimals='INF' contextRef='D160101_160630' unitRef='Pure'>2074736</fil:SharesIssuedForServices>
	<fil:SharesIssuedForServices decimals='INF' contextRef='D150101_150630' unitRef='Pure'>0</fil:SharesIssuedForServices>
	<fil:OptionsIssuedForServices decimals='INF' contextRef='D160101_160630' unitRef='Pure'>455032</fil:OptionsIssuedForServices>
	<fil:OptionsIssuedForServices decimals='INF' contextRef='D150101_150630' unitRef='Pure'>0</fil:OptionsIssuedForServices>
	<fil:DueFromRelatedParty decimals='INF' contextRef='D160101_160630' unitRef='Pure'>0</fil:DueFromRelatedParty>
	<fil:DueFromRelatedParty decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-6443</fil:DueFromRelatedParty>
	<fil:DecreaseIncreaseInOtherReceivable decimals='INF' contextRef='D160101_160630' unitRef='Pure'>17585</fil:DecreaseIncreaseInOtherReceivable>
	<fil:DecreaseIncreaseInOtherReceivable decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-25689</fil:DecreaseIncreaseInOtherReceivable>
	<us-gaap:IncreaseDecreaseInPayablesToCustomers decimals='INF' contextRef='D160101_160630' unitRef='USD'>-1777</us-gaap:IncreaseDecreaseInPayablesToCustomers>
	<us-gaap:IncreaseDecreaseInPayablesToCustomers decimals='INF' contextRef='D150101_150630' unitRef='USD'>-2577</us-gaap:IncreaseDecreaseInPayablesToCustomers>
	<fil:DecreaseIncreaseInAccountsPayableRelatedParty decimals='INF' contextRef='D160101_160630' unitRef='Pure'>0</fil:DecreaseIncreaseInAccountsPayableRelatedParty>
	<fil:DecreaseIncreaseInAccountsPayableRelatedParty decimals='INF' contextRef='D150101_150630' unitRef='Pure'>1087</fil:DecreaseIncreaseInAccountsPayableRelatedParty>
	<fil:DecreaseIncreaseInEmployeePayable decimals='INF' contextRef='D160101_160630' unitRef='Pure'>0</fil:DecreaseIncreaseInEmployeePayable>
	<fil:DecreaseIncreaseInEmployeePayable decimals='INF' contextRef='D150101_150630' unitRef='Pure'>23800</fil:DecreaseIncreaseInEmployeePayable>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities decimals='INF' contextRef='D160101_160630' unitRef='USD'>0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities decimals='INF' contextRef='D150101_150630' unitRef='USD'>14202</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<fil:DecreaseIncreaseInAccruedEpenses decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-45779</fil:DecreaseIncreaseInAccruedEpenses>
	<fil:DecreaseIncreaseInAccruedEpenses decimals='INF' contextRef='D150101_150630' unitRef='Pure'>7430</fil:DecreaseIncreaseInAccruedEpenses>
	<fil:CashFlowsUsedByOperatingActivities decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-536741</fil:CashFlowsUsedByOperatingActivities>
	<fil:CashFlowsUsedByOperatingActivities decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-413725</fil:CashFlowsUsedByOperatingActivities>
	<fil:CashPaidForFixedAssets decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-474</fil:CashPaidForFixedAssets>
	<fil:CashPaidForFixedAssets decimals='INF' contextRef='D150101_150630' unitRef='Pure'>25317</fil:CashPaidForFixedAssets>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities decimals='INF' contextRef='D160101_160630' unitRef='USD'>-474</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities decimals='INF' contextRef='D150101_150630' unitRef='USD'>25317</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<fil:BorrowingsOnDebt decimals='INF' contextRef='D160101_160630' unitRef='Pure'>735913</fil:BorrowingsOnDebt>
	<fil:BorrowingsOnDebt decimals='INF' contextRef='D150101_150630' unitRef='Pure'>531798</fil:BorrowingsOnDebt>
	<fil:PrincipalPaymentsOnDebt decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-34547</fil:PrincipalPaymentsOnDebt>
	<fil:PrincipalPaymentsOnDebt decimals='INF' contextRef='D150101_150630' unitRef='Pure'>0</fil:PrincipalPaymentsOnDebt>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities decimals='INF' contextRef='D160101_160630' unitRef='USD'>701366</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities decimals='INF' contextRef='D150101_150630' unitRef='USD'>531798</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<fil:ForeignCurrencyAdjustments decimals='INF' contextRef='D160101_160630' unitRef='Pure'>-4841</fil:ForeignCurrencyAdjustments>
	<fil:ForeignCurrencyAdjustments decimals='INF' contextRef='D150101_150630' unitRef='Pure'>-25550</fil:ForeignCurrencyAdjustments>
	<fil:NetIncreaseDecreaseInCash decimals='INF' contextRef='D160101_160630' unitRef='Pure'>159310</fil:NetIncreaseDecreaseInCash>
	<fil:NetIncreaseDecreaseInCash decimals='INF' contextRef='D150101_150630' unitRef='Pure'>67206</fil:NetIncreaseDecreaseInCash>
	<fil:CashAndCashEquivalentsBeginningOfPeriod decimals='INF' contextRef='E15' unitRef='Pure'>115449</fil:CashAndCashEquivalentsBeginningOfPeriod>
	<fil:CashAndCashEquivalentsBeginningOfPeriod decimals='INF' contextRef='E14' unitRef='Pure'>14411</fil:CashAndCashEquivalentsBeginningOfPeriod>
	<fil:CashAndCashEquivalentsEndOfPeriod decimals='INF' contextRef='E16Q2' unitRef='Pure'>274759</fil:CashAndCashEquivalentsEndOfPeriod>
	<fil:CashAndCashEquivalentsEndOfPeriod decimals='INF' contextRef='E15Q2' unitRef='Pure'>56067</fil:CashAndCashEquivalentsEndOfPeriod>
	<fil:BcfDueToConvertibleNotePayable decimals='INF' contextRef='D160101_160630' unitRef='Pure'>456000</fil:BcfDueToConvertibleNotePayable>
	<fil:BcfDueToConvertibleNotePayable decimals='INF' contextRef='D150101_150630' unitRef='Pure'>0</fil:BcfDueToConvertibleNotePayable>
	<fil:CashlessConversionOfClassBWarrants decimals='INF' contextRef='D160101_160630' unitRef='Pure'>193</fil:CashlessConversionOfClassBWarrants>
	<fil:CashlessConversionOfClassBWarrants decimals='INF' contextRef='D150101_150630' unitRef='Pure'>0</fil:CashlessConversionOfClassBWarrants>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue decimals='INF' contextRef='E16Q2' unitRef='USD'>274759</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue decimals='INF' contextRef='I151230' unitRef='USD'>115449</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:OtherReceivables decimals='INF' contextRef='E16Q2' unitRef='USD'>8212</us-gaap:OtherReceivables>
	<us-gaap:OtherReceivables decimals='INF' contextRef='I151230' unitRef='USD'>25797</us-gaap:OtherReceivables>
	<us-gaap:AssetsCurrent decimals='INF' contextRef='E16Q2' unitRef='USD'>282971</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent decimals='INF' contextRef='I151230' unitRef='USD'>141246</us-gaap:AssetsCurrent>
	<us-gaap:PropertyPlantAndEquipmentOtherNet decimals='INF' contextRef='E16Q2' unitRef='USD'>17735</us-gaap:PropertyPlantAndEquipmentOtherNet>
	<us-gaap:PropertyPlantAndEquipmentOtherNet decimals='INF' contextRef='I151230' unitRef='USD'>21120</us-gaap:PropertyPlantAndEquipmentOtherNet>
	<us-gaap:Assets decimals='INF' contextRef='E16Q2' unitRef='USD'>300706</us-gaap:Assets>
	<us-gaap:Assets decimals='INF' contextRef='I151230' unitRef='USD'>162366</us-gaap:Assets>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent decimals='INF' contextRef='E16Q2' unitRef='USD'>48204</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent decimals='INF' contextRef='I151230' unitRef='USD'>90705</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
	<fil:EmployeePayable decimals='INF' contextRef='E16Q2' unitRef='Pure'>22786</fil:EmployeePayable>
	<fil:EmployeePayable decimals='INF' contextRef='I151230' unitRef='Pure'>25612</fil:EmployeePayable>
	<fil:EmployeePayableRelatedParty decimals='INF' contextRef='E16Q2' unitRef='Pure'>3081</fil:EmployeePayableRelatedParty>
	<fil:EmployeePayableRelatedParty decimals='INF' contextRef='I151230' unitRef='Pure'>3480</fil:EmployeePayableRelatedParty>
	<us-gaap:InterestPayableCurrent decimals='INF' contextRef='E16Q2' unitRef='USD'>21887</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent decimals='INF' contextRef='I151230' unitRef='USD'>19285</us-gaap:InterestPayableCurrent>
	<fil:ShortTermNotesPayable decimals='INF' contextRef='E16Q2' unitRef='Pure'>186336</fil:ShortTermNotesPayable>
	<fil:ShortTermNotesPayable decimals='INF' contextRef='I151230' unitRef='Pure'>119974</fil:ShortTermNotesPayable>
	<fil:ConvertibleNotePayableDefault decimals='INF' contextRef='E16Q2' unitRef='Pure'>29719</fil:ConvertibleNotePayableDefault>
	<fil:ConvertibleNotePayableDefault decimals='INF' contextRef='I151230' unitRef='Pure'>0</fil:ConvertibleNotePayableDefault>
	<fil:ConvertibleNotePayableNetOfDiscountOf73562And0Respectively decimals='INF' contextRef='E16Q2' unitRef='Pure'>222377</fil:ConvertibleNotePayableNetOfDiscountOf73562And0Respectively>
	<fil:ConvertibleNotePayableNetOfDiscountOf73562And0Respectively decimals='INF' contextRef='I151230' unitRef='Pure'>29719</fil:ConvertibleNotePayableNetOfDiscountOf73562And0Respectively>
	<fil:TotalCurrentLiabilities decimals='INF' contextRef='E16Q2' unitRef='Pure'>534390</fil:TotalCurrentLiabilities>
	<fil:TotalCurrentLiabilities decimals='INF' contextRef='I151230' unitRef='Pure'>288775</fil:TotalCurrentLiabilities>
	<us-gaap:Liabilities decimals='INF' contextRef='E16Q2' unitRef='USD'>534390</us-gaap:Liabilities>
	<us-gaap:Liabilities decimals='INF' contextRef='I151230' unitRef='USD'>288775</us-gaap:Liabilities>
	<us-gaap:PreferredStockValue id='us-gaap_PreferredStockValue_E16Q2_id' decimals='INF' contextRef='E16Q2' unitRef='USD'>0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue id='us-gaap_PreferredStockValue_I151230_id' decimals='INF' contextRef='I151230' unitRef='USD'>0</us-gaap:PreferredStockValue>
	<us-gaap:CommonStockValue id='us-gaap_CommonStockValue_E16Q2_id' decimals='INF' contextRef='E16Q2' unitRef='USD'>1948</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue id='us-gaap_CommonStockValue_I151230_id' decimals='INF' contextRef='I151230' unitRef='USD'>1533</us-gaap:CommonStockValue>
	<fil:AccumulatedOtherComprehensiveIncomeLoss decimals='INF' contextRef='E16Q2' unitRef='Pure'>-24178</fil:AccumulatedOtherComprehensiveIncomeLoss>
	<fil:AccumulatedOtherComprehensiveIncomeLoss decimals='INF' contextRef='I151230' unitRef='Pure'>-19337</fil:AccumulatedOtherComprehensiveIncomeLoss>
	<us-gaap:AdditionalPaidInCapital decimals='INF' contextRef='E16Q2' unitRef='USD'>11738066</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital decimals='INF' contextRef='I151230' unitRef='USD'>8752711</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit decimals='INF' contextRef='E16Q2' unitRef='USD'>-11949520</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit decimals='INF' contextRef='I151230' unitRef='USD'>-8861316</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:StockholdersEquity decimals='INF' contextRef='E16Q2' unitRef='USD'>-233684</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity decimals='INF' contextRef='I151230' unitRef='USD'>-126409</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity decimals='INF' contextRef='E16Q2' unitRef='USD'>300706</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity decimals='INF' contextRef='I151230' unitRef='USD'>162366</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:NatureOfOperations contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p&gt;&lt;b&gt;Note 1. The Company&lt;/b&gt;&lt;/p&gt; &lt;p&gt;&lt;i&gt;Organizational Background&lt;/i&gt;&lt;/p&gt; &lt;p&gt;Emerald Medical Applications Corp. (&amp;quot;the Company&amp;quot;) (f/k/a Zaxis International Inc.) was incorporated in Ohio in 1989, it&apos;s fiscal year end is December 31st. On August 25, 1995, The Company merged with a subsidiary of The InFerGene Company (&amp;quot;InFerGene&amp;quot;) and InFerGene changed its name to The Company International Inc. InFerGene was incorporated in California in 1984 and subsequently changed its domicile in connection with the merger into The Company to Delaware in 1985. Operations ceased operations in 2002. In November 2002, the Company and its subsidiaries filed a petition for bankruptcy in the U.S. Bankruptcy Court Northern District of Ohio. On October 13, 2004, the Company emerged from bankruptcy. &lt;/p&gt; &lt;p&gt;On July 14, 2015 the closing of the Share Exchange Agreement was held (the &amp;quot;Closing&amp;quot;) and as a result, Emerald Medical Applications Ltd. became a wholly-owned subsidiary of the Registrant. Pursuant to the Closing of the Share Exchange Agreement, the Company issued 5,474,545 shares of its common stock, par value $0.0001 (the &amp;quot;Shares&amp;quot; or &amp;quot;Common Stock&amp;quot;) to Lior Wayn, Emerald&apos;s CEO and the sole holder of Emerald Medical Applications Ltd.&apos;s ordinary Shares, representing 40.58% of the company&apos;s 13,489,905 outstanding Shares, in exchange for 100% of Emerald Medical Applications Ltd.&apos;s ordinary Shares. &lt;/p&gt; &lt;p&gt;Subsequently to the Closing Mr. Lior Wayn has been appointed as the Company&apos;s CEO, and has been granted considerable influence on the appointment of new directors thereby creating a new management structure for the company replacing the old management. Additionally Mr. Wayn is to receive additional shares in the future contingent on the Company achieving commercial milestone. Thus the new management, headed by Mr. Wayn, is considered to be in control of more than 50% of the company and with the ability to make all management decisions.&lt;/p&gt; &lt;p&gt;Emerald is a company organized under the laws of the State of Israel on February 17, 2010. Emerald is digital health Startup Company engaged in the development, sale and service of imaging solutions utilizing its proprietary DermaCompare software that it developed for use in derma imaging and analytics (&amp;quot;DermaCompare&amp;quot;). Emerald believes that its proprietary DermaCompare software represents an advancement in skin cancer screening that should enable physicians to more readily identify and monitor changes in their patients&apos; skin characteristics. &lt;/p&gt; &lt;p&gt;Emerald&apos;s DermaCompare solution allows dermatologists and other medical care professionals, using a set of 25 total body photography (&amp;quot;TBP&amp;quot;), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smartphones or tablets. These images are then transmitted online and are remotely analyzed by professionals using our DermaCompare software.&lt;/p&gt; &lt;p&gt;Emerald&apos;s sales and marketing plan is to sell licenses for our imaging software to: NHSs, HMOs, health insurance companies, hospitals and medical clinics through distributers, health care channel partners or directly through independent salespersons and/or web purchase to dermatologists and other physicians (GPs) that we expect to purchase licenses based on the number of potential numbers of patients.&lt;/p&gt; &lt;p&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt; &lt;p&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred operating losses since inception. Further, as of June 30, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company&apos;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.&lt;/p&gt; &lt;p&gt;The Company elected December 31 as its fiscal year end.&lt;/p&gt; &lt;p&gt;&lt;i&gt;Significant Accounting Policies&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt; &lt;p&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt; &lt;p&gt;For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of June 30, 2016 and December 31, 2015.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Other Receivables&lt;/i&gt;&lt;/p&gt; &lt;p&gt;The company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of June 30, 2016 was $8,212.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Currency Translation and other Comprehensive Income&lt;/i&gt;&lt;/p&gt; &lt;p&gt;Balance sheet items are translated using all current translation method for self-contained foreign operations (where functional currency = foreign currency) whereby assets and liabilities are translated using the exchange rate on the date of the balance sheet. It translates revenues, expenses, and net income using the average exchange rate during the period. The foreign exchange adjustment that results from applying the all-current method appears in other comprehensive income, a separate shareholders&apos; equity account, and does not affect net income each period.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 5 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes pla&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;ce.&lt;/p&gt; &lt;p&gt;&lt;i&gt;Valuation of Long-Lived Assets&lt;/i&gt;&lt;/p&gt; &lt;p&gt;We review the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Stock Based Compensation&lt;/i&gt;&lt;/p&gt; &lt;p&gt;Stock-based awards are accounted for using the fair value method in accordance with ASC 718,&amp;nbsp;Share-Based Payments. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company&apos;s common stock, the estimated volatility of the Company&apos;s common stock, the exercise price of the warrants and the risk free interest rate.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Accounting For Obligations And Instruments Potentially To Be Settled In The Company&apos;s Own Stock: &lt;/i&gt;&lt;/p&gt; &lt;p&gt;We account for obligations and instruments potentially to be settled in the Company&apos;s stock in accordance with FASB ASC 815,&amp;nbsp;Accounting for Derivative Financial Instruments.&amp;nbsp;This issue addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company&apos;s own stock.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/p&gt; &lt;p&gt;The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/p&gt; &lt;p&gt;As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows.&lt;/p&gt; &lt;p&gt;Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt; &lt;p&gt;The Company values its derivative instruments related to embedded conversion features and warrants from the issuance of convertible debentures in accordance with the Level 3 guidelines. For the six-month period ended June 30, 2016 and the twelve month period ending December 31, 2015, the following table reconciles the beginning and ending balances for financial instruments that are recognized at fair value in these consolidated financial statements. The fair value of embedded conversion features that have floating conversion features and tainted common stock equivalents (warrants and convertible debt) are estimated using a Binomial Lattice model. The key inputs to this valuation model as of December 31, 2015, were: Volatility of 143.9% for the six-month period ended June 30, 2016 and 132.4% for the twelve months period ending December 31, 2015, inherent term of instruments equal to the remaining contractual term, quoted closing stock prices on valuation dates, and various settlement scenarios and probability percentages summing to 100%.&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at June 30, 2016&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100.0%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Level 3 - Derivative liabilities from:&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Balance at June 30, 2016&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;New Issuances&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Settlements&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Change in Fair Value&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;27%&quot; valign=&quot;bottom&quot; style=&apos;width:27.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Convertible Note&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;2%&quot; valign=&quot;bottom&quot; style=&apos;width:2.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;16%&quot; valign=&quot;bottom&quot; style=&apos;width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;9%&quot; valign=&quot;bottom&quot; style=&apos;width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;276&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;20&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;163&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;10&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;60&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;70&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;91&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at December 31, 2015&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100.0%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Level 3 - Derivative liabilities from:&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Balance at December 31, 2015&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;New Issuances&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Extinguishment&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Change in Fair Value&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;27%&quot; valign=&quot;bottom&quot; style=&apos;width:27.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Convertible Note&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;2%&quot; valign=&quot;bottom&quot; style=&apos;width:2.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;16%&quot; valign=&quot;bottom&quot; style=&apos;width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;(20,532)&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;9%&quot; valign=&quot;bottom&quot; style=&apos;width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;273&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;17&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;158&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;10&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;58&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;4&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;95&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;6&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;89&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Changes in the unobservable input values would likely cause material changes in the fair value of the Company&apos;s Level 3 financial instruments. The significant unobservable input used in the fair value measurement is the estimation for probability percentages assigned to future expected settlement possibilities. A significant increase (decrease) in this distribution of percentages would result in a higher (lower) fair value measurement.&lt;/p&gt; &lt;p&gt;The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2016 and December 31, 2015:&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at June 30, 2016&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;80%&quot; style=&apos;width:80.0%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Level 3&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Assets&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Assets&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;78%&quot; valign=&quot;bottom&quot; style=&apos;width:78.0%;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative liability&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;18%&quot; valign=&quot;bottom&quot; style=&apos;width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 2.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt;text-indent:.5in&apos;&gt;&lt;b&gt;&amp;nbsp; &lt;/b&gt;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at December 31, 2015&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp; &lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;80%&quot; style=&apos;width:80.0%;border-collapse:collapse&apos;&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Level 3&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Assets&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;78%&quot; valign=&quot;bottom&quot; style=&apos;width:78.0%;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Assets&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;18%&quot; valign=&quot;bottom&quot; style=&apos;width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative liability&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 2.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;The fair values of our debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.&lt;/p&gt; &lt;p&gt;There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the year ended December 31, 2015.&lt;/p&gt; &lt;p&gt;The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of June 30, 2016 or December 31, 2015.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Earnings per Common Share&lt;/i&gt;&lt;/p&gt; &lt;p&gt;We compute net income (loss) per share in accordance with ASC 260,&amp;nbsp;Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2012.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt; &lt;p&gt;We have adopted FASB ASC 740,&amp;nbsp;Accounting for Income Taxes.&amp;nbsp;Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.&lt;/p&gt; &lt;p&gt;We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.&lt;/p&gt; &lt;p&gt;Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate.&lt;/p&gt; &lt;p&gt;In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be.&lt;/p&gt; &lt;p&gt;ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current period and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Uncertain Tax Positions&lt;/i&gt;&lt;/p&gt; &lt;p&gt;When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.&lt;/p&gt; &lt;p&gt;Our federal and state income tax returns are open for fiscal years ending on or after December 31, 2011. We are not under examination by any jurisdiction for any tax year. At June 30, 2016 we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under FIN&amp;nbsp;48.&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt; &lt;p&gt;In September, 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805) (&amp;quot;ASU 2015-16&amp;quot;). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period&apos;s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company&apos;s consolidated financial statements.&lt;/p&gt; &lt;p&gt;In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (&amp;quot;ASU 2015-14&amp;quot;). The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods with that reporting period.&lt;/p&gt; &lt;p&gt;In April 2015, the Financial Accounting Standards Board (&amp;quot;FASB&amp;quot;) issued Accounting Standards Update (&amp;quot;ASU&amp;quot;) No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (&amp;quot;ASU 2015-03&amp;quot;), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/p&gt; &lt;p&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. Further, as of June 30, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company&apos;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.&lt;/p&gt;</us-gaap:NatureOfOperations>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;Note 2. Stockholders&apos; Equity.&lt;/b&gt;&lt;/p&gt; &lt;p&gt;On January 8, 2015 the shareholders approved a resolution to increase the authorized common shares from 100,000,000 to 490,000,000 shares. All other provisions of the common shares remain unchanged. Also on that date, the Company declared a reverse split of common stock at the ration of 1:4. The stock split was effective January 8, 2015 for holders of record as of that date. Except as otherwise noted, all share, option and warrant numbers have been restated to give retroactive effect to this split. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred at January 1, 2012.&lt;/p&gt; &lt;p&gt;&lt;i&gt;Recent Issuances of Common Stock&lt;/i&gt;&lt;/p&gt; &lt;p&gt;Between January 15, 2015 and March 15, 2015, the Company sold a total of 2,052,000 units for cash consideration of $780,000 at a price of $0.40 (the &amp;quot;Units&amp;quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $351,433 for the common stock and $428,567 for the class A warrants. The warrants were valued using the Black-Scholes model with 153% volatility and discount rates ranging between 0.44% to 0.7%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. &lt;/p&gt; &lt;p&gt;Between April 1, 2015 and June 29, 2015, the Company sold a total of 1,012,500 units for cash consideration of $405,000 at a price of $0.40 (the &amp;quot;Units&amp;quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $158,123 for the common stock and $246,877 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between163% - 177% and discount rates ranging between 0.54% to 0.71%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. &lt;/p&gt; &lt;p&gt;Between July 1, 2015 and September 30, 2015, the Company sold a total of 140,000 units for cash consideration of $15,000 at price of $0.107 (the &amp;quot;Units&amp;quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $4,294 for the common stock and $10,706 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility of 153% and discount rates of 0.61%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. &lt;/p&gt; &lt;p&gt;Between July 1, 2015 and September 30, 2015, the Company sold a total of 862,500 units for cash consideration of $345,000 at price of $0.40 (the &amp;quot;Units&amp;quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $118,415 for the common stock and $226,585 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between 153% - 182% and discount rates ranging between 0.54% to 0.71%. Of these units $65,000 were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger and $280,000 cash was received subsequent to Closing of the reverse merger. &lt;/p&gt; &lt;p&gt;On July 16, 2015 and August 6, 2015, the company issue 517,900 shares to one service provider and 100,000 shares to two service providers, respectively, for services valued at a total value of $617,900, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. &lt;/p&gt; &lt;p&gt;On July 16, 2015, 5 Emerald debt holders in amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The Loss on Settlement of Debt recorded was $678,027. &lt;/p&gt; &lt;p&gt;On July 14, 2015 the Company issued Emerald&apos;s CEO and founder, Lior Wayn, 5,474,545 shares as per the share purchase agreement valued at $877,380, valued on the date of grant for the price of common stock. &lt;/p&gt; &lt;p&gt;On July 16, 2015 consultants were issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share The fair value of these warrants is $2,199,507. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class B warrants are fully vested and were accordingly included in expenses as stock based compensation. &lt;/p&gt; &lt;p&gt;On July 16, 2015 consultants were issued 2,536,247 Class C Warrants exercisable for a 90 day period, commencing 90 days after the effective date of this Registration Statement, at an exercise price of $0.40 to acquire one (1) share of Common Stock and one (1) Class A Warrant at an exercise price of $0.80. The fair value of these warrants is $3,143,581. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class C warrants are fully vested and were accordingly included in expenses as stock based compensation.&lt;/p&gt; &lt;p&gt;On November 17, 2015 the Company sold 250,000 units for cash consideration of $100,000 at price of $0.40 (the &amp;quot;Units&amp;quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $41,304 for the common stock and $58,696 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between 149% and discount rate of 0.50%. These warrants are fully vested and the fair value and included as stock based compensation on the prior year retained earnings. &lt;/p&gt; &lt;p&gt;Between November 5, 2015 and November 16, 2015 the company issue 268,084 shares to three service provider and for services valued at a total value of $268,084, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. &lt;/p&gt; &lt;p&gt;On October 1, 2015, the Company granted a total of 534,400 stock options (the &amp;quot;Options&amp;quot;) to three company employees. The options vest over 5 quarters and are exercisable at prices ranging from $0.01 to $0.40 per Share. The options were valued using the Black-Scholes model with 149% volatility and 0.67% discount rate for a total value of $528,857. Of this amount, $397,547 was expensed as of December 31, 2015 and $42,394 as of March 31, 2016. An additional $42,394 was expensed during the three-month period ended June 30, 2016.&lt;/p&gt; &lt;p&gt;On January 26, 2016 and March 17, 2016, the Company issued 125,000 shares to one service provider and 50,000 shares to two service providers, respectively, for services valued at a total value of $251,250, arrived at using the stock price on date of grant of $1.75 and $0.65, respectively, per Nasdaq.com. &lt;/p&gt; &lt;p&gt;On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. &lt;/p&gt; &lt;p&gt;On January 26, 2016, consultants that were previously issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share, exercised the warrants on a cashless basis resulting in 1,928,572 shares issued with no additional related expense booked. &lt;/p&gt; &lt;p&gt;On February 11 and 18, 2016, the Company granted a total of 403,333 stock options (the &amp;quot;Options&amp;quot;) to three company employees. The options vest over periods of between 1 and 8 quarters and are exercisable at prices ranging from $0.01 to $0.40 per Share. The options were valued using the Black-Scholes model with 157% volatility and 0.56% discount rate for a total value of $400,914. Of this amount, $231,920 was expensed during the three-months ended March 31, 2016 and $48,711 during the three-months ended June 30, 2016.&lt;/p&gt; &lt;p&gt;On March 24, 2016, a convertible note payable was issued to GoldMed Ltd. The warrants were valued at a fair value of $56,030. The note included a beneficial conversion feature which resulted in a $75,000 discount recorded as a reduction of debt and an increase to additional paid in capital.&lt;/p&gt; &lt;p&gt;On April 5, 2016, the Company issued 150,000 shares to one service provider for services valued at $105,000 based on the Company&apos;s stock price of $0.70 per share on the date of issuance.&lt;/p&gt; &lt;p&gt;On May 10, 2016, the Company issued 41,667 shares to one service provider for services valued at $72,911 based on the Company&apos;s stock price of $1.75 per share on the date of issuance.&lt;/p&gt; &lt;p&gt;On May 18, 2016, the Company issued 150,000 shares to one service provider for services valued at $102,000 based on the Company&apos;s stock price of $0.68 per share on the date of issuance.&lt;/p&gt; &lt;p&gt;On June 28, 2016, the Company issued 175,000 shares to one service provider for services valued at $122,500 based on the Company&apos;s stock price of $0.70 per share on the date of issuance.&lt;/p&gt; &lt;p&gt;On June 30, 2016, the Company issued 333,333 shares to one service provider for services valued at $226,666 based on the Company&apos;s stock price of $0.68 per share on the date of issuance.&lt;/p&gt; &lt;p&gt;On June 6, 2016, a convertible note payable was issued to Alpha Capital. The attached warrants were valued at a fair value of $440,000. The note included a beneficial conversion feature which resulted in a $300,000 discount recorded as a reduction of debt and an increase to additional paid in capital.&lt;/p&gt; &lt;p&gt;On April 11, 2016, a convertible note payable was issued to Maz Partner. The attached warrants were valued at a fair value of $80,000. The note included a beneficial conversion feature which resulted in a $46,000 discount recorded as a reduction of debt and an increase to additional paid in capital.&lt;/p&gt; &lt;p&gt;On June 30, 2016, a convertible note payable was issued to Ilan Malka. The attached warrants were valued at a fair value of $40,000. The note included a beneficial conversion feature which resulted in a $35,000 discount recorded as a reduction of debt and an increase to additional paid in capital.&lt;/p&gt; &lt;p&gt;On April 14, 2016, the Company granted a total of 450,000 stock options (the &amp;quot;Options&amp;quot;) to one Company director. The options vest over periods of between 1 and 3 quarters and are exercisable at $0.60 per share. The options were valued using the Black-Scholes model with 233% volatility and 0.56% discount rate for a total value of $268,839. The Company expensed $89,613 during the three-months ended June 30, 2016 related to these options.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;Note 3. Related Party Transactions &lt;/b&gt;&lt;/p&gt; &lt;p&gt;On July 16, 2015 5 Emerald debt holders in amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The Loss on Settlement of Debt recorded was $678,027. &lt;/p&gt; &lt;p&gt;On July 14, 2015 the Company issued Emerald&apos;s CEO and founder, Lior Wayn, 5,474,545 shares as per the share purchase agreement valued at $877,380, valued on the date of grant for the price of common stock. &lt;/p&gt; &lt;p&gt;The company&apos;s CEO, Lior Wayn was owed $3,310 and $3,480 payable as of June 30, 2016 and December 31, 2015, respectively. &lt;/p&gt; &lt;p&gt;Following Closing of the reverse merger, $490,000 loan from Zaxis International Inc. to Emerald Medical Applications Ltd. was rendered an intercompany loan and as such was written off.&lt;/p&gt; &lt;p&gt;On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;Note 10. Accounts Payable and Accrued Liabilities&lt;/b&gt;&lt;/p&gt; &lt;p&gt;As of June 30, 2016 and December 31, 2015, the Company had Accounts payable and accrued liabilities of $48,204 and $90,705, respectively.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
	<us-gaap:ShortTermDebtTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;FR&quot;&gt;Note 5. Notes Payable.&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p&gt;&lt;i&gt;&lt;font lang=&quot;FR&quot;&gt;Convertible Notes Payable&lt;/font&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;On March 24, 2016, the Company issued a convertible promissory note to GoldMed Ltd. in the amount of $75,000. The Convertible Note is convertible to 187,500 units at $0.40 (the &amp;quot;Units&amp;quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 months. Since the market price on the date of issuance was higher than the conversion price, a beneficial conversion feature was calculated at $78,750, but only $75,000 was recorded. $20,137 was recorded as amortization expense of for the period ending June 30, 2016, compared to amortization expense of $0 as of December 31, 2015. &lt;/p&gt; &lt;p&gt;On June 20, 2016, a $400,000 convertible note payable and 200,000 warrants exercisable at $0.80 per share with a term of 24 months was issued to Alpha Capital. The note included a beneficial conversion feature which resulted in a $300,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $8,219 related to this note. &lt;/p&gt; &lt;p&gt;On March 31, 2016, a $80,000 convertible note payable and 200,000 warrants exercisable at $0.80 per share with a term of 24 months was issued to Maz Partner. The note included a beneficial conversion feature which resulted in a $46,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $11,468 related to this note. &lt;/p&gt; &lt;p&gt;On May 24, 2016, a convertible note payable was issued to Ilan Malka. The note included a beneficial conversion feature which resulted in a $35,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $3,548 related to this note. &lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;Note 6. Payable - Not Convertible&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;On July 8, 2014 the company issued a convertible promissory note to Axel Springer Plug &amp;amp; Play Accelerator GmbH (the &amp;quot;Holder&amp;quot;), in the amounts of $29,719. The Convertible Notes are convertible at the lessor of a market based discounted and a fixed rate derived from a fixed market cap. The Holders have the right following the Date of Issuance, and until any time until the convertible Promissory Note is fully paid, to convert any outstanding and unpaid principal portion of the Convertible Promissory Note, and accrued interest, into fully paid and non-assessable shares of Common Stock. Holder was not issued warrants with the Convertible Promissory Note. &lt;/p&gt; &lt;p&gt;As of December 31, 2015 this note is no longer convertible since pursuant to the loan agreement the in the event that prior to December 31,2015 (the &amp;quot;Maturity Date&amp;quot;), the Company shall consummate a financing round led by unaffiliated investors in the amount of at least Euro 200,000, at a Company pre-money valuation on a fully diluted basis of at least Euro 750,000 (a &amp;quot;Qualified Round&amp;quot;), the Holder shall be entitled (but not obligated) to convert the entire loan amount into the most senior class of shares of the Company issued in such Qualified Round, based on a price per share equal to the lower of the price per share reflected by a Company pre-money valuation on a fully diluted basis calculated at the time of conversion equal to Euro 1,500,000; or - price per share which reflects a 20% discount on the lowest price per share issued pursuant to such Qualified Round. If upon the occurrence of such event the note holder elects not to convert upon receiving notice of such event, then the loan becomes non-convertible. &lt;/p&gt; &lt;p&gt;On January 14 and 16, 2015, we issued two promissory notes in the amount of $15,000 each to two different unaffiliated party in consideration for cash transferred to the Company (the &amp;quot;January 2015 Notes&amp;quot;). The January 2015 Notes bears interest at the rate of 1% per annum, are due and payable on January 14 and 16, 2016 and are not convertible to common stock. &lt;/p&gt; &lt;p&gt;One of the notes was repaid in full on March 3, 2015 with interest due waived the by the debtor, and the second note was repaid on April 22, 2015 with interest due waived the by the debtor.&lt;/p&gt; &lt;p&gt;During the second quarter of 2015, an agreement was reached with the holder of $120,979 advance payable note to settle the full amount due for $30,000 and interest due. The settlement with all note holders resulted in $528 loss on debt settlement due to the payment being higher than principal and accrued interest as of that date as well as a charge of $90,979 considered a contribution of capital due to the fact that note holder, IMWT, was a related party. &lt;/p&gt; &lt;p&gt;We concluded that these notes have a stated rate of interest that is different from the rate of interest that is appropriate for this type of debt at the date of the transaction. Accordingly, the company imputed interest at an appropriate rate estimated at 8% as prescribed under FASB ASC 835. The resultant charge of $6,280 for the period ending December 31, 2014 and $4,113 for the period ending March 31, 2015 to interest expense was considered a contribution of capital and was recorded in additional paid in capital. &lt;/p&gt; &lt;p&gt;On November 16, 2014 four individuals loaned amount to company, totaling $87,910 with maturity dates of November 16, 2015 and bearing an interest rate of 8% per annum, these notes were fully converted on July 16, 2015 to Company shares of commons stock and warrants as described in Note 3. &lt;/p&gt; &lt;p&gt;On March 9, 2016 four individuals lent the company a total of $34,547 with maturity dates of November 16, 2015 and bearing an interest rate of 8% per annum. As of June 30, 2016, the loan was fully repaid.&lt;/p&gt; &lt;p&gt;For the periods ended June 30, 2016 and December 31, 2015, the Company has recognized $21,420 and $19,285, respectively, in accrued interest expense related to the stated interest rate on the notes. Interest expense for the periods ended June 30, 2016 and June 30, 2015, respectively, were $21,887 and $11,829, as well as $43,372 and $0 from the amortization of debt discount. &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;Note 7. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt; &lt;p&gt;The Company received research and development grants from the State of Israel according to guidelines and procedures of the Office of the Chief Scientist of the Ministry of Industry and Trade. According to the agreement, the Company is obliged to pay royalties on the sale of products developed with the participation of the Chief Scientist. The royalty rate is 3.5% and the total royalties will not exceed the amount of the grants. As of June 30, 2016, the Company had an outstanding contingent liability to pay royalties in the amount of $186,335, with $15,795 in accrued interest. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;80%&quot; style=&apos;width:80.0%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Level 3&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Assets&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Assets&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;78%&quot; valign=&quot;bottom&quot; style=&apos;width:78.0%;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative liability&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;18%&quot; valign=&quot;bottom&quot; style=&apos;width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 2.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt;text-indent:.5in&apos;&gt;&lt;b&gt;&amp;nbsp; &lt;/b&gt;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at December 31, 2015&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp; &lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;80%&quot; style=&apos;width:80.0%;border-collapse:collapse&apos;&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Level 3&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Assets&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;78%&quot; valign=&quot;bottom&quot; style=&apos;width:78.0%;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Assets&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;18%&quot; valign=&quot;bottom&quot; style=&apos;width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative liability&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 2.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;Note 9. Other Receivables&lt;/b&gt;&lt;/p&gt; &lt;p&gt;As of June 30, 2016 and December 31, 2015 the Company had other receivables of $8,212 and $25,797, respectively, which represent VAT refunds claimed resulting from excess VAT paid over VAT received. &lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
	<us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;Note 4. Employee Payable.&lt;/b&gt;&lt;/p&gt; &lt;p&gt;For the periods ended June 30, 2016 and December 31, 2015 the Company had $25,867 and $25,612, respectively, in employee payable related to the monthly wages payable to the company&apos;s employees. &lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
	<us-gaap:UseOfEstimates contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt; &lt;p&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt; &lt;p&gt;For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of June 30, 2016 and December 31, 2015.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Other Receivables&lt;/i&gt;&lt;/p&gt; &lt;p&gt;The company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of June 30, 2016 was $8,212.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Currency Translation and other Comprehensive Income&lt;/i&gt;&lt;/p&gt; &lt;p&gt;Balance sheet items are translated using all current translation method for self-contained foreign operations (where functional currency = foreign currency) whereby assets and liabilities are translated using the exchange rate on the date of the balance sheet. It translates revenues, expenses, and net income using the average exchange rate during the period. The foreign exchange adjustment that results from applying the all-current method appears in other comprehensive income, a separate shareholders&apos; equity account, and does not affect net income each period.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 5 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes pla&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p&gt;&lt;i&gt;Valuation of Long-Lived Assets&lt;/i&gt;&lt;/p&gt; &lt;p&gt;We review the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Stock Based Compensation&lt;/i&gt;&lt;/p&gt; &lt;p&gt;Stock-based awards are accounted for using the fair value method in accordance with ASC 718,&amp;nbsp;Share-Based Payments. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company&apos;s common stock, the estimated volatility of the Company&apos;s common stock, the exercise price of the warrants and the risk free interest rate.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:DerivativesEmbeddedDerivatives contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Accounting For Obligations And Instruments Potentially To Be Settled In The Company&apos;s Own Stock: &lt;/i&gt;&lt;/p&gt; &lt;p&gt;We account for obligations and instruments potentially to be settled in the Company&apos;s stock in accordance with FASB ASC 815,&amp;nbsp;Accounting for Derivative Financial Instruments.&amp;nbsp;This issue addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company&apos;s own stock.&lt;/p&gt;</us-gaap:DerivativesEmbeddedDerivatives>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/p&gt; &lt;p&gt;The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/p&gt; &lt;p&gt;As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows.&lt;/p&gt; &lt;p&gt;Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt; &lt;p&gt;The Company values its derivative instruments related to embedded conversion features and warrants from the issuance of convertible debentures in accordance with the Level 3 guidelines. For the six-month period ended June 30, 2016 and the twelve month period ending December 31, 2015, the following table reconciles the beginning and ending balances for financial instruments that are recognized at fair value in these consolidated financial statements. The fair value of embedded conversion features that have floating conversion features and tainted common stock equivalents (warrants and convertible debt) are estimated using a Binomial Lattice model. The key inputs to this valuation model as of December 31, 2015, were: Volatility of 143.9% for the six-month period ended June 30, 2016 and 132.4% for the twelve months period ending December 31, 2015, inherent term of instruments equal to the remaining contractual term, quoted closing stock prices on valuation dates, and various settlement scenarios and probability percentages summing to 100%.&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at June 30, 2016&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100.0%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Level 3 - Derivative liabilities from:&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Balance at June 30, 2016&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;New Issuances&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Settlements&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Change in Fair Value&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;27%&quot; valign=&quot;bottom&quot; style=&apos;width:27.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Convertible Note&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;2%&quot; valign=&quot;bottom&quot; style=&apos;width:2.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;16%&quot; valign=&quot;bottom&quot; style=&apos;width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;9%&quot; valign=&quot;bottom&quot; style=&apos;width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;276&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;20&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;163&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;10&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;60&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;70&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;91&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at December 31, 2015&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100.0%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Level 3 - Derivative liabilities from:&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Balance at December 31, 2015&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;New Issuances&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Extinguishment&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Change in Fair Value&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;27%&quot; valign=&quot;bottom&quot; style=&apos;width:27.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Convertible Note&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;2%&quot; valign=&quot;bottom&quot; style=&apos;width:2.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;16%&quot; valign=&quot;bottom&quot; style=&apos;width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;(20,532)&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;9%&quot; valign=&quot;bottom&quot; style=&apos;width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;273&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;17&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;158&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;10&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;58&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;4&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;95&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;6&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;89&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Changes in the unobservable input values would likely cause material changes in the fair value of the Company&apos;s Level 3 financial instruments. The significant unobservable input used in the fair value measurement is the estimation for probability percentages assigned to future expected settlement possibilities. A significant increase (decrease) in this distribution of percentages would result in a higher (lower) fair value measurement.&lt;/p&gt; &lt;p&gt;The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2016 and December 31, 2015:&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at June 30, 2016&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;80%&quot; style=&apos;width:80.0%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Level 3&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Assets&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Assets&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;78%&quot; valign=&quot;bottom&quot; style=&apos;width:78.0%;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative liability&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;18%&quot; valign=&quot;bottom&quot; style=&apos;width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 2.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt;text-indent:.5in&apos;&gt;&lt;b&gt;&amp;nbsp; &lt;/b&gt;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at December 31, 2015&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp; &lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;80%&quot; style=&apos;width:80.0%;border-collapse:collapse&apos;&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Level 3&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Assets&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;78%&quot; valign=&quot;bottom&quot; style=&apos;width:78.0%;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Assets&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;18%&quot; valign=&quot;bottom&quot; style=&apos;width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative liability&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 2.5pt 0in&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Total Liabilities&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;The fair values of our debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.&lt;/p&gt; &lt;p&gt;There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the year ended December 31, 2015.&lt;/p&gt; &lt;p&gt;The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of June 30, 2016 or December 31, 2015.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Earnings per Common Share&lt;/i&gt;&lt;/p&gt; &lt;p&gt;We compute net income (loss) per share in accordance with ASC 260,&amp;nbsp;Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2012.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt; &lt;p&gt;We have adopted FASB ASC 740,&amp;nbsp;Accounting for Income Taxes.&amp;nbsp;Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.&lt;/p&gt; &lt;p&gt;We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.&lt;/p&gt; &lt;p&gt;Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate.&lt;/p&gt; &lt;p&gt;In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be.&lt;/p&gt; &lt;p&gt;ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current period and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:IncomeTaxUncertaintiesPolicy contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Uncertain Tax Positions&lt;/i&gt;&lt;/p&gt; &lt;p&gt;When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.&lt;/p&gt; &lt;p&gt;Our federal and state income tax returns are open for fiscal years ending on or after December 31, 2011. We are not under examination by any jurisdiction for any tax year. At June 30, 2016 we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under FIN&amp;nbsp;48.&lt;/p&gt;</us-gaap:IncomeTaxUncertaintiesPolicy>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt; &lt;p&gt;In September, 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805) (&amp;quot;ASU 2015-16&amp;quot;). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period&apos;s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company&apos;s consolidated financial statements.&lt;/p&gt; &lt;p&gt;In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (&amp;quot;ASU 2015-14&amp;quot;). The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods with that reporting period.&lt;/p&gt; &lt;p&gt;In April 2015, the Financial Accounting Standards Board (&amp;quot;FASB&amp;quot;) issued Accounting Standards Update (&amp;quot;ASU&amp;quot;) No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (&amp;quot;ASU 2015-03&amp;quot;), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at June 30, 2016&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100.0%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Level 3 - Derivative liabilities from:&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Balance at June 30, 2016&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;New Issuances&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Settlements&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Change in Fair Value&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;27%&quot; valign=&quot;bottom&quot; style=&apos;width:27.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Convertible Note&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;2%&quot; valign=&quot;bottom&quot; style=&apos;width:2.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;16%&quot; valign=&quot;bottom&quot; style=&apos;width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;9%&quot; valign=&quot;bottom&quot; style=&apos;width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;276&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;20&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;163&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;10&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;60&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;70&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;91&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Fair Value Measurements at December 31, 2015&lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100.0%;border-collapse:collapse&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Level 3 - Derivative liabilities from:&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Balance at December 31, 2015&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;New Issuances&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Extinguishment&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Change in Fair Value&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;27%&quot; valign=&quot;bottom&quot; style=&apos;width:27.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Convertible Note&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;2%&quot; valign=&quot;bottom&quot; style=&apos;width:2.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;16%&quot; valign=&quot;bottom&quot; style=&apos;width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;6%&quot; valign=&quot;bottom&quot; style=&apos;width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;(20,532)&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;9%&quot; valign=&quot;bottom&quot; style=&apos;width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td width=&quot;273&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;17&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;9&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;158&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;10&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;58&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;4&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;95&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;6&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;td width=&quot;89&quot; style=&apos;border:none&apos;&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:OtherLiabilitiesTableTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;Note 8. Derivative Liabilities&lt;/b&gt;&lt;/p&gt; &lt;p&gt;On July 8, 2014 the company issued a convertible promissory note to Axel Springer Plug &amp;amp; Play Accelerator GmbH (the &amp;quot;Holder&amp;quot;), in the amounts of $29,719.&lt;/p&gt; &lt;p&gt;The Convertible note is convertible at the lessor of a market based discounted and a fixed rate derived from a fixed market cap. The Holder has the right following the Date of Issuance, and until any time until the convertible Promissory Note is fully paid, to convert any outstanding and unpaid principal portion of the Convertible Promissory Note, and accrued interest, into fully paid and non-assessable shares of Common Stock. The Holder was not issued warrants with the Convertible Promissory Note.&lt;/p&gt; &lt;p&gt;The following shows the changes in the derivative liability measured on a recurring basis for the six months ended June 30, 2016 and year ended December 31, 2015.&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100.0%;border-collapse:collapse&apos;&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Level 3&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative Liability at December 31, 2014&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;20,532&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td width=&quot;71%&quot; valign=&quot;bottom&quot; style=&apos;width:71.0%;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Extinguishment of Derivative Liability&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td width=&quot;25%&quot; valign=&quot;bottom&quot; style=&apos;width:25.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;(20,532)&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0;height:.6pt&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative Liability at December 31, 2015&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 2.5pt 0in;height:.6pt&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative Liability at June 30, 2016&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;For the periods ended June 30, 2016 and December 31, 2015 the Company has recognized $0 and $2,013, respectively, in accrued interest expense related to the stated interest rate on the notes. Interest expense for the periods ended June 30, 2016 and December 31, 2015, respectively, were $21,887 and $30,604, of which $0 and $0 is from the amortization of debt discount related to this note The note is no longer considered convertible since the lender elected not to convert, and as such the derivative was written off. &lt;/p&gt; &lt;p&gt;As of December 31, 2015 the company has a $0 derivative liability and a $29,719 convertible note payable, net of discount of $0. As of June 30, 2016, the Company has $0 derivative liability and $222,377 of convertible notes payable, net of discount of $412,628. &lt;/p&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;In accordance to ASC #815, Accounting for Derivative Instruments and Hedging Activities, we evaluated the holder&apos;s non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the Note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted for as derivative financial instruments. Additionally, since the conversion price of the two notes represented the fair market value of the Company&apos;s common stock at the time of issuance, no beneficial conversion feature exists. We believe that the Company&apos;s shares of common stock is and have been very thinly traded during the last 3 years and that the fair value of the stock price was deemed not to be a fair value. Management decided that because the Company&apos;s ability to continue as a going concern was in question and that it has no revenue sources that the conversion price was a better measure of fair market value. Based on that decision, no beneficial conversion feature was reflected in the financial statements and the $20,165 extinguishment of debt was reflected in the current period earnings and $0 extinguishment of debt was reflected in the current period earnings.&lt;/p&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100.0%;border-collapse:collapse&apos;&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:center&apos;&gt;Level 3&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative Liability at December 31, 2014&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;20,532&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td width=&quot;71%&quot; valign=&quot;bottom&quot; style=&apos;width:71.0%;background:white;padding:0in 0in 1.5pt 0in;height:.6pt&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Extinguishment of Derivative Liability&lt;/p&gt; &lt;/td&gt; &lt;td width=&quot;1%&quot; valign=&quot;bottom&quot; style=&apos;width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt;&lt;/td&gt; &lt;td width=&quot;25%&quot; valign=&quot;bottom&quot; style=&apos;width:25.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;(20,532)&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0;height:.6pt&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative Liability at December 31, 2015&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style=&apos;height:.6pt&apos;&gt; &lt;td valign=&quot;bottom&quot; style=&apos;background:white;padding:0in 0in 2.5pt 0in;height:.6pt&apos;&gt; &lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;Derivative Liability at June 30, 2016&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;margin:0in;margin-bottom:.0001pt;text-align:right&apos;&gt;-&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
	<dei:DocumentType contextRef='D160101_160630'>10-Q</dei:DocumentType>
	<dei:DocumentPeriodEndDate contextRef='D160101_160630'>2016-06-30</dei:DocumentPeriodEndDate>
	<dei:AmendmentFlag contextRef='D160101_160630'>false</dei:AmendmentFlag>
	<dei:EntityRegistrantName contextRef='D160101_160630'>Emerald Medical Applications Corp.</dei:EntityRegistrantName>
	<dei:EntityCentralIndexKey contextRef='D160101_160630'>0000797542</dei:EntityCentralIndexKey>
	<dei:TradingSymbol contextRef='D160101_160630'>mrla</dei:TradingSymbol>
	<dei:CurrentFiscalYearEndDate contextRef='D160101_160630'>--12-31</dei:CurrentFiscalYearEndDate>
	<dei:EntityCommonStockSharesOutstanding decimals='INF' contextRef='E16Q2' unitRef='Shares'>19474461</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityPublicFloat decimals='INF' contextRef='E01Q2' unitRef='USD'>14673348</dei:EntityPublicFloat>
	<dei:EntityFilerCategory contextRef='D160101_160630'>Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityCurrentReportingStatus contextRef='D160101_160630'>Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityVoluntaryFilers contextRef='D160101_160630'>No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef='D160101_160630'>No</dei:EntityWellKnownSeasonedIssuer>
	<dei:DocumentFiscalYearFocus contextRef='D160101_160630'>2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentFiscalPeriodFocus contextRef='D160101_160630'>Q2</dei:DocumentFiscalPeriodFocus>
	<us-gaap:SubsequentEventsTextBlock contextRef='D160101_160630'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0in;margin-bottom:.0001pt&apos;&gt;&lt;b&gt;Note 11. Subsequent Events&lt;/b&gt;&lt;/p&gt; &lt;p&gt;On August 4, 2016, 31,250 shares were issued to one service provider as per the terms of the service agreement. &lt;/p&gt; &lt;p&gt;On July 7, 2016, Emerald entered in a Securities Purchase Agreement and a Registration Rights Agreement with Firstfire Global Opportunities Fund LLC, a New York limited liability company (hereinafter &amp;quot;Firstfire&amp;quot;), pursuant to which the Registrant has issued and sold to Firstfire a secured convertible note bearing interest at 8% per annum in the principal amount of $100,000 with a maturity date on June 19, 2017 (the &amp;quot;Note&amp;quot;). In connection with the Securities Purchase Agreement, the Registrant also granted Firstfire 250,000 Class A and 250,000 Class B Warrants. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
	<context id='E16Q2'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<instant>2016-06-30</instant>
		</period>
	</context>
	<context id='E01Q2'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<instant>2201-06-30</instant>
		</period>
	</context>
	<context id='D160101_160630'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<startDate>2016-01-01</startDate>
			<endDate>2016-06-30</endDate>
		</period>
	</context>
	<context id='I151230'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<instant>2015-12-30</instant>
		</period>
	</context>
	<context id='Y16Q2'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<startDate>2016-04-01</startDate>
			<endDate>2016-06-30</endDate>
		</period>
	</context>
	<context id='Y15Q2'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<startDate>2015-04-01</startDate>
			<endDate>2015-06-30</endDate>
		</period>
	</context>
	<context id='D150101_150630'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<startDate>2015-01-01</startDate>
			<endDate>2015-06-30</endDate>
		</period>
	</context>
	<context id='D150104_150630'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<startDate>2015-01-04</startDate>
			<endDate>2015-06-30</endDate>
		</period>
	</context>
	<context id='E15'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<instant>2015-12-31</instant>
		</period>
	</context>
	<context id='E14'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<instant>2014-12-31</instant>
		</period>
	</context>
	<context id='E15Q2'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0000797542</identifier>
		</entity>
		<period>
			<instant>2015-06-30</instant>
		</period>
	</context>
	<unit id='Pure'>
		<measure>pure</measure>
	</unit>
	<unit id='USD'>
		<measure>iso4217:USD</measure>
	</unit>
	<unit id='Shares'>
		<measure>shares</measure>
	</unit>
	<unit id='UsdPerShare'>
		<divide>
			<unitNumerator>
				<measure>iso4217:USD</measure>
			</unitNumerator>
			<unitDenominator>
				<measure>shares</measure>
			</unitDenominator>
		</divide>
	</unit>
	<link:footnoteLink xlink:type='extended' xlink:role='http://www.xbrl.org/2003/role/link'>
		<link:loc xlink:type='locator' xlink:label='us-gaap_PreferredStockValue_E16Q2_lab' xlink:href='#us-gaap_PreferredStockValue_E16Q2_id' />
		<link:loc xlink:type='locator' xlink:label='us-gaap_PreferredStockValue_I151230_lab' xlink:href='#us-gaap_PreferredStockValue_I151230_id' />
		<link:loc xlink:type='locator' xlink:label='us-gaap_CommonStockValue_E16Q2_lab' xlink:href='#us-gaap_CommonStockValue_E16Q2_id' />
		<link:loc xlink:type='locator' xlink:label='us-gaap_CommonStockValue_I151230_lab' xlink:href='#us-gaap_CommonStockValue_I151230_id' />
		<link:footnoteArc xlink:type='arc' order='1.0' xlink:from='us-gaap_PreferredStockValue_E16Q2_lab' xlink:to='footnote_57BB053F0' xlink:arcrole='http://www.xbrl.org/2003/arcrole/fact-footnote' />
		<link:footnoteArc xlink:type='arc' order='1.0' xlink:from='us-gaap_PreferredStockValue_I151230_lab' xlink:to='footnote_57BB053F0' xlink:arcrole='http://www.xbrl.org/2003/arcrole/fact-footnote' />
		<link:footnoteArc xlink:type='arc' order='1.0' xlink:from='us-gaap_CommonStockValue_E16Q2_lab' xlink:to='footnote_57BB053F1' xlink:arcrole='http://www.xbrl.org/2003/arcrole/fact-footnote' />
		<link:footnoteArc xlink:type='arc' order='1.0' xlink:from='us-gaap_CommonStockValue_I151230_lab' xlink:to='footnote_57BB053F1' xlink:arcrole='http://www.xbrl.org/2003/arcrole/fact-footnote' />
		<link:footnote xlink:type='resource' xlink:label='footnote_57BB053F0' xlink:role='http://www.xbrl.org/2003/role/footnote' xml:lang='en-US'>$0.0001 par value; 10,000,000 shares authorized; none issued.</link:footnote>
		<link:footnote xlink:type='resource' xlink:label='footnote_57BB053F1' xlink:role='http://www.xbrl.org/2003/role/footnote' xml:lang='en-US'>$0.0001 par value; 490,000,000 shares authorized; 19,474,461 and 15,325,889 issued and outstanding at June 30, 2016 and December 31, 2015, respectively.</link:footnote>
	</link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mrla-20160630.xsd
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2015 [PPXM8K19K1334NYCARL5]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2015-01-31' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:dei='http://xbrl.sec.gov/dei/2014-01-31' xmlns:fil='http://dermacompare.com/20160630' targetNamespace='http://dermacompare.com/20160630' xmlns:link='http://www.xbrl.org/2003/linkbase' attributeFormDefault='unqualified' elementFormDefault='qualified' xmlns:xbrli='http://www.xbrl.org/2003/instance'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="mrla-20160630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="mrla-20160630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="mrla-20160630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="mrla-20160630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyOtherReceivablesPolicies" id="idr_DisclosureNote1TheCompanyOtherReceivablesPolicies">
				<link:definition>000190 - Disclosure - Note 1. The Company: Other Receivables (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote2StockholdersEquity" id="idr_DisclosureNote2StockholdersEquity">
				<link:definition>000070 - Disclosure - Note 2. Stockholders&apos; Equity.</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies" id="idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies">
				<link:definition>000200 - Disclosure - Note 1. The Company: Currency Translation and Other Comprehensive Income (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss" id="idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss">
				<link:definition>000040 - Statement - Emerald Medical Applications Corp. - Statement of Comprehensive Income (Loss)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote6PayableNotConvertible" id="idr_DisclosureNote6PayableNotConvertible">
				<link:definition>000110 - Disclosure - Note 6. Payable - Not Convertible</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies" id="idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies">
				<link:definition>000210 - Disclosure - Note 1. The Company: Property and Equipment (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies" id="idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies">
				<link:definition>000170 - Disclosure - Note 1. The Company: Use of Estimates (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables" id="idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables">
				<link:definition>000300 - Disclosure - Note 1. The Company: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote11SubsequentEvents" id="idr_DisclosureNote11SubsequentEvents">
				<link:definition>000160 - Disclosure - Note 11. Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote4EmployeePayable" id="idr_DisclosureNote4EmployeePayable">
				<link:definition>000090 - Disclosure - Note 4. Employee Payable.</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote3RelatedPartyTransactions" id="idr_DisclosureNote3RelatedPartyTransactions">
				<link:definition>000080 - Disclosure - Note 3. Related Party Transactions</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies" id="idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies">
				<link:definition>000230 - Disclosure - Note 1. The Company: Stock Based Compensation (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompany" id="idr_DisclosureNote1TheCompany">
				<link:definition>000060 - Disclosure - Note 1. The Company</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpBalanceSheets" id="idr_EmeraldMedicalApplicationsCorpBalanceSheets">
				<link:definition>000020 - Statement - Emerald Medical Applications Corp. - Balance Sheets</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyIncomeTaxesPolicies" id="idr_DisclosureNote1TheCompanyIncomeTaxesPolicies">
				<link:definition>000270 - Disclosure - Note 1. The Company: Income Taxes (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies" id="idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies">
				<link:definition>000240 - Disclosure - Note 1. The Company: Accounting For Obligations and Instruments Potentially To Be Settled in The Company&apos;s Own Stock (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables" id="idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables">
				<link:definition>000320 - Disclosure - Note 8. Derivative Liabilities: Schedule of Derivative Instruments (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfOperations" id="idr_EmeraldMedicalApplicationsCorpStatementsOfOperations">
				<link:definition>000030 - Statement - Emerald Medical Applications Corp. - Statements of Operations</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote10AccountsPayableAndAccruedLiabilities" id="idr_DisclosureNote10AccountsPayableAndAccruedLiabilities">
				<link:definition>000150 - Disclosure - Note 10. Accounts Payable and Accrued Liabilities</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilities" id="idr_DisclosureNote8DerivativeLiabilities">
				<link:definition>000130 - Disclosure - Note 8. Derivative Liabilities</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies" id="idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies">
				<link:definition>000280 - Disclosure - Note 1. The Company: Uncertain Tax Positions (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows" id="idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows">
				<link:definition>000050 - Statement - Emerald Medical Applications Corp. - Statements of Cash Flows</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote9OtherReceivables" id="idr_DisclosureNote9OtherReceivables">
				<link:definition>000140 - Disclosure - Note 9. Other Receivables</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies" id="idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies">
				<link:definition>000180 - Disclosure - Note 1. The Company: Cash and Cash Equivalents (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote5NotesPayable" id="idr_DisclosureNote5NotesPayable">
				<link:definition>000100 - Disclosure - Note 5. Notes Payable.</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote7CommitmentsAndContingencies" id="idr_DisclosureNote7CommitmentsAndContingencies">
				<link:definition>000120 - Disclosure - Note 7. Commitments and Contingencies</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies" id="idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies">
				<link:definition>000290 - Disclosure - Note 1. The Company: Recent Accounting Pronouncements (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies" id="idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies">
				<link:definition>000260 - Disclosure - Note 1. The Company: Earnings Per Common Share (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables" id="idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables">
				<link:definition>000310 - Disclosure - Note 1. The Company: Fair Value Measurements: Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies" id="idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies">
				<link:definition>000250 - Disclosure - Note 1. The Company: Fair Value Measurements (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies" id="idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies">
				<link:definition>000220 - Disclosure - Note 1. The Company: Valuation of Long-lived Assets (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/numeric'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/non-numeric'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import namespace='http://fasb.org/us-gaap/2015-01-31' schemaLocation='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd' />
	<import namespace='http://xbrl.sec.gov/dei/2014-01-31' schemaLocation='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BalanceSheetsAbstract' name='BalanceSheetsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CurrentAssetsAbstract' name='CurrentAssetsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FixedAssetsNetAbstract' name='FixedAssetsNetAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_LiabilitiesAndStockholdersEquityDeficitAbstract' name='LiabilitiesAndStockholdersEquityDeficitAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CurrentLiabilitiesAbstract' name='CurrentLiabilitiesAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EmployeePayable' name='EmployeePayable' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EmployeePayableRelatedParty' name='EmployeePayableRelatedParty' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_ShortTermNotesPayable' name='ShortTermNotesPayable' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_ConvertibleNotePayableDefault' name='ConvertibleNotePayableDefault' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively' name='ConvertibleNotePayableNetOfDiscountOf73562And0Respectively' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_TotalCurrentLiabilities' name='TotalCurrentLiabilities' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_StockholdersDeficitAbstract' name='StockholdersDeficitAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_AccumulatedOtherComprehensiveIncomeLoss' name='AccumulatedOtherComprehensiveIncomeLoss' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DocumentAndEntityInformationAbstract' name='DocumentAndEntityInformationAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_StatementsOfOperationsAbstract' name='StatementsOfOperationsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ExpensesAbstract' name='ExpensesAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_LossFromOperations' name='LossFromOperations' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GainLossFromForeignCurrency' name='GainLossFromForeignCurrency' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FinancialIncomeExpense' name='FinancialIncomeExpense' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_TotalIncomeExpense' name='TotalIncomeExpense' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ProvisionForIncomeTaxes' name='ProvisionForIncomeTaxes' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_WeightedAverageSharesOutstandingAbstract' name='WeightedAverageSharesOutstandingAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NetLoss' name='NetLoss' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss' name='ChangeInUnrealizedForeignCurrencyTranslationGainLoss' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CashFlowsFromOperatingActivitiesAbstract' name='CashFlowsFromOperatingActivitiesAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NetLoss1' name='NetLoss1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract' name='AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DepreciationExpense' name='DepreciationExpense' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AmortizationOfDebtDiscount' name='AmortizationOfDebtDiscount' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ChangeInFairValueOfDerivative' name='ChangeInFairValueOfDerivative' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SharesIssuedForServices' name='SharesIssuedForServices' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OptionsIssuedForServices' name='OptionsIssuedForServices' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IncreaseDecreaseInCashResultingFromChangesInAbstract' name='IncreaseDecreaseInCashResultingFromChangesInAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DueFromRelatedParty' name='DueFromRelatedParty' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DecreaseIncreaseInOtherReceivable' name='DecreaseIncreaseInOtherReceivable' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DecreaseIncreaseInAccountsPayableRelatedParty' name='DecreaseIncreaseInAccountsPayableRelatedParty' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DecreaseIncreaseInEmployeePayable' name='DecreaseIncreaseInEmployeePayable' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DecreaseIncreaseInAccruedEpenses' name='DecreaseIncreaseInAccruedEpenses' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CashFlowsUsedByOperatingActivities' name='CashFlowsUsedByOperatingActivities' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CashFlowsFromInvestingActivitiesAbstract' name='CashFlowsFromInvestingActivitiesAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CashPaidForFixedAssets' name='CashPaidForFixedAssets' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CashFlowsFromFinancingActivitiesAbstract' name='CashFlowsFromFinancingActivitiesAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BorrowingsOnDebt' name='BorrowingsOnDebt' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PrincipalPaymentsOnDebt' name='PrincipalPaymentsOnDebt' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ForeignCurrencyAdjustments' name='ForeignCurrencyAdjustments' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NetIncreaseDecreaseInCash' name='NetIncreaseDecreaseInCash' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_CashAndCashEquivalentsBeginningOfPeriod' name='CashAndCashEquivalentsBeginningOfPeriod' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_CashAndCashEquivalentsEndOfPeriod' name='CashAndCashEquivalentsEndOfPeriod' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NonCashTransactionAbstract' name='NonCashTransactionAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BcfDueToConvertibleNotePayable' name='BcfDueToConvertibleNotePayable' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CashlessConversionOfClassBWarrants' name='CashlessConversionOfClassBWarrants' />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mrla-20160630_cal.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2015 [PPXM8K19K1334NYCARL5]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://dermacompare.com/20160630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpBalanceSheets" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_EmeraldMedicalApplicationsCorpBalanceSheets"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpBalanceSheets">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mrla-20160630_def.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2015 [PPXM8K19K1334NYCARL5]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://dermacompare.com/20160630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpBalanceSheets" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_EmeraldMedicalApplicationsCorpBalanceSheets"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpBalanceSheets"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfOperations" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_EmeraldMedicalApplicationsCorpStatementsOfOperations"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfOperations"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompany" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompany"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompany"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote2StockholdersEquity" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote2StockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote2StockholdersEquity"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote3RelatedPartyTransactions" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote3RelatedPartyTransactions"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote3RelatedPartyTransactions"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote4EmployeePayable" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote4EmployeePayable"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote4EmployeePayable"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote5NotesPayable" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote5NotesPayable"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote5NotesPayable"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote6PayableNotConvertible" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote6PayableNotConvertible"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote6PayableNotConvertible"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote7CommitmentsAndContingencies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote7CommitmentsAndContingencies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote7CommitmentsAndContingencies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilities" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote8DerivativeLiabilities"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilities"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote9OtherReceivables" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote9OtherReceivables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote9OtherReceivables"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote10AccountsPayableAndAccruedLiabilities" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote10AccountsPayableAndAccruedLiabilities"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote10AccountsPayableAndAccruedLiabilities"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote11SubsequentEvents" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote11SubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote11SubsequentEvents"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyOtherReceivablesPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyOtherReceivablesPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyOtherReceivablesPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyIncomeTaxesPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyIncomeTaxesPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyIncomeTaxesPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables"/>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mrla-20160630_lab.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2015 [PPXM8K19K1334NYCARL5]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://dermacompare.com/20160630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation of Long-lived Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:to='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock' xlink:label='us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Currency Translation and Other Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock' xlink:to='lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock' xlink:label='us-gaap_OtherLiabilitiesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLiabilitiesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 8. Derivative Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLiabilitiesTableTextBlock' xlink:to='lab_us-gaap_OtherLiabilitiesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_WeightedAverageSharesOutstandingAbstract' xlink:label='fil_WeightedAverageSharesOutstandingAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WeightedAverageSharesOutstandingAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted average shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WeightedAverageSharesOutstandingAbstract' xlink:to='lab_fil_WeightedAverageSharesOutstandingAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted' xlink:label='us-gaap_EarningsPerShareBasicAndDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasicAndDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic and diluted net loss per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasicAndDiluted' xlink:to='lab_us-gaap_EarningsPerShareBasicAndDiluted'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ConvertibleNotePayableDefault' xlink:label='fil_ConvertibleNotePayableDefault'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConvertibleNotePayableDefault' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Convertible note payable - default</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConvertibleNotePayableDefault' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Convertible note payable - default, as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ConvertibleNotePayableDefault' xlink:to='lab_fil_ConvertibleNotePayableDefault'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock' xlink:label='us-gaap_FairValueMeasurementPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fair Value Measurements</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FairValueMeasurementPolicyPolicyTextBlock' xlink:to='lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 11. Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_OptionsIssuedForServices' xlink:label='fil_OptionsIssuedForServices'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsIssuedForServices' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options issued for services</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsIssuedForServices' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Options issued for services, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsIssuedForServices' xlink:to='lab_fil_OptionsIssuedForServices'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_SharesIssuedForServices' xlink:label='fil_SharesIssuedForServices'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesIssuedForServices' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares issued for services</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesIssuedForServices' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Shares issued for services, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SharesIssuedForServices' xlink:to='lab_fil_SharesIssuedForServices'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_LiabilitiesAndStockholdersEquityDeficitAbstract' xlink:label='fil_LiabilitiesAndStockholdersEquityDeficitAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LiabilitiesAndStockholdersEquityDeficitAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Liabilities and Stockholders&apos; Equity (Deficit)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LiabilitiesAndStockholdersEquityDeficitAbstract' xlink:to='lab_fil_LiabilitiesAndStockholdersEquityDeficitAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet' xlink:label='us-gaap_PropertyPlantAndEquipmentOtherNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentOtherNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fixed assets, net of accumulated depreciation of $10,751 and $6,536, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentOtherNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentOtherNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DocumentAndEntityInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document and Entity Information:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='lab_fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerSharePolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings Per Common Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerSharePolicyTextBlock' xlink:to='lab_us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DecreaseIncreaseInAccountsPayableRelatedParty' xlink:label='fil_DecreaseIncreaseInAccountsPayableRelatedParty'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DecreaseIncreaseInAccountsPayableRelatedParty' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(Decrease) increase in accounts payable - related party</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DecreaseIncreaseInAccountsPayableRelatedParty' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the (Decrease) increase in accounts payable - related party, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DecreaseIncreaseInAccountsPayableRelatedParty' xlink:to='lab_fil_DecreaseIncreaseInAccountsPayableRelatedParty'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DepreciationExpense' xlink:label='fil_DepreciationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DepreciationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation expense {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DepreciationExpense' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Depreciation expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DepreciationExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Depreciation expense, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DepreciationExpense' xlink:to='lab_fil_DepreciationExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapital' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapital' xlink:to='lab_us-gaap_AdditionalPaidInCapital'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherReceivables' xlink:label='us-gaap_OtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherReceivables' xlink:to='lab_us-gaap_OtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_BalanceSheetsAbstract' xlink:label='fil_BalanceSheetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BalanceSheetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Balance Sheets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BalanceSheetsAbstract' xlink:to='lab_fil_BalanceSheetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Voluntary Filers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock' xlink:label='us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock' xlink:to='lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_AmortizationOfDebtDiscount' xlink:label='fil_AmortizationOfDebtDiscount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationOfDebtDiscount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization of debt discount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationOfDebtDiscount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Amortization of debt discount, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AmortizationOfDebtDiscount' xlink:to='lab_fil_AmortizationOfDebtDiscount'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_LossFromOperations' xlink:label='fil_LossFromOperations'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LossFromOperations' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(Loss) from operations</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LossFromOperations' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the (Loss) from operations, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LossFromOperations' xlink:to='lab_fil_LossFromOperations'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_StockholdersDeficitAbstract' xlink:label='fil_StockholdersDeficitAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_StockholdersDeficitAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; deficit:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_StockholdersDeficitAbstract' xlink:to='lab_fil_StockholdersDeficitAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy' xlink:label='us-gaap_TradeAndOtherAccountsReceivablePolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TradeAndOtherAccountsReceivablePolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Receivables {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TradeAndOtherAccountsReceivablePolicy' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Other Receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TradeAndOtherAccountsReceivablePolicy' xlink:to='lab_us-gaap_TradeAndOtherAccountsReceivablePolicy'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashAndCashEquivalentsBeginningOfPeriod' xlink:label='fil_CashAndCashEquivalentsBeginningOfPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsBeginningOfPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and cash equivalents - beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsBeginningOfPeriod' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash and cash equivalents - beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsBeginningOfPeriod' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Cash and cash equivalents - beginning of period, as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashAndCashEquivalentsBeginningOfPeriod' xlink:to='lab_fil_CashAndCashEquivalentsBeginningOfPeriod'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities' xlink:label='us-gaap_IncreaseDecreaseInOtherCurrentLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(Decrease) increase in in other current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOtherCurrentLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_IncreaseDecreaseInCashResultingFromChangesInAbstract' xlink:label='fil_IncreaseDecreaseInCashResultingFromChangesInAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncreaseDecreaseInCashResultingFromChangesInAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Increase (decrease) in cash resulting from changes in:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncreaseDecreaseInCashResultingFromChangesInAbstract' xlink:to='lab_fil_IncreaseDecreaseInCashResultingFromChangesInAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive gain (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract' xlink:label='us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement of Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract' xlink:to='lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestExpense' xlink:to='lab_us-gaap_InterestExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_EmployeePayableRelatedParty' xlink:label='fil_EmployeePayableRelatedParty'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EmployeePayableRelatedParty' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Employee payable - related party</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EmployeePayableRelatedParty' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Employee payable - related party, as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EmployeePayableRelatedParty' xlink:to='lab_fil_EmployeePayableRelatedParty'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Recent Accounting Pronouncements</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and Equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PolicyTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Policies</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='lab_us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_BcfDueToConvertibleNotePayable' xlink:label='fil_BcfDueToConvertibleNotePayable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BcfDueToConvertibleNotePayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BCF due to convertible note payable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BcfDueToConvertibleNotePayable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the BCF due to convertible note payable, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BcfDueToConvertibleNotePayable' xlink:to='lab_fil_BcfDueToConvertibleNotePayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash provided by financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DecreaseIncreaseInOtherReceivable' xlink:label='fil_DecreaseIncreaseInOtherReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DecreaseIncreaseInOtherReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Decrease (increase) in other receivable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DecreaseIncreaseInOtherReceivable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Decrease (increase) in other receivable, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DecreaseIncreaseInOtherReceivable' xlink:to='lab_fil_DecreaseIncreaseInOtherReceivable'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ExpensesAbstract' xlink:label='fil_ExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Expenses:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExpensesAbstract' xlink:to='lab_fil_ExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 7. Commitments and Contingencies</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:to='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashlessConversionOfClassBWarrants' xlink:label='fil_CashlessConversionOfClassBWarrants'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashlessConversionOfClassBWarrants' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cashless conversion of class B warrants</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashlessConversionOfClassBWarrants' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Cashless conversion of class B warrants, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashlessConversionOfClassBWarrants' xlink:to='lab_fil_CashlessConversionOfClassBWarrants'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DecreaseIncreaseInAccruedEpenses' xlink:label='fil_DecreaseIncreaseInAccruedEpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DecreaseIncreaseInAccruedEpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(Decrease) increase in accrued epenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DecreaseIncreaseInAccruedEpenses' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the (Decrease) increase in accrued epenses, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DecreaseIncreaseInAccruedEpenses' xlink:to='lab_fil_DecreaseIncreaseInAccruedEpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPayablesToCustomers' xlink:label='us-gaap_IncreaseDecreaseInPayablesToCustomers'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPayablesToCustomers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(Decrease) increase in accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPayablesToCustomers' xlink:to='lab_us-gaap_IncreaseDecreaseInPayablesToCustomers'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ShortTermNotesPayable' xlink:label='fil_ShortTermNotesPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ShortTermNotesPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Short term notes payable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ShortTermNotesPayable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Short term notes payable, as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ShortTermNotesPayable' xlink:to='lab_fil_ShortTermNotesPayable'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CurrentLiabilitiesAbstract' xlink:label='fil_CurrentLiabilitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CurrentLiabilitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CurrentLiabilitiesAbstract' xlink:to='lab_fil_CurrentLiabilitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxUncertaintiesPolicy' xlink:label='us-gaap_IncomeTaxUncertaintiesPolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxUncertaintiesPolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Uncertain Tax Positions</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxUncertaintiesPolicy' xlink:to='lab_us-gaap_IncomeTaxUncertaintiesPolicy'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_UseOfEstimates' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Use of Estimates</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_UseOfEstimates' xlink:to='lab_us-gaap_UseOfEstimates'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_NetIncreaseDecreaseInCash' xlink:label='fil_NetIncreaseDecreaseInCash'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetIncreaseDecreaseInCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net increase (decrease) in cash</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetIncreaseDecreaseInCash' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Net increase (decrease) in cash, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetIncreaseDecreaseInCash' xlink:to='lab_fil_NetIncreaseDecreaseInCash'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_GainLossFromForeignCurrency' xlink:label='fil_GainLossFromForeignCurrency'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GainLossFromForeignCurrency' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gain/loss from foreign currency</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GainLossFromForeignCurrency' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gain/loss from foreign currency, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GainLossFromForeignCurrency' xlink:to='lab_fil_GainLossFromForeignCurrency'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CurrentAssetsAbstract' xlink:label='fil_CurrentAssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CurrentAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CurrentAssetsAbstract' xlink:to='lab_fil_CurrentAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy' xlink:label='us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy' xlink:to='lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ChangeInFairValueOfDerivative' xlink:label='fil_ChangeInFairValueOfDerivative'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangeInFairValueOfDerivative' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Change in fair value of derivative {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangeInFairValueOfDerivative' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Change in fair value of derivative</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangeInFairValueOfDerivative' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Change in fair value of derivative, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ChangeInFairValueOfDerivative' xlink:to='lab_fil_ChangeInFairValueOfDerivative'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss' xlink:label='fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Change in unrealized foreign currency translation gain (loss)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Change in unrealized foreign currency translation gain (loss), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss' xlink:to='lab_fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:label='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic and diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:to='lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetIncomeLoss' xlink:to='lab_us-gaap_NetIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_TotalIncomeExpense' xlink:label='fil_TotalIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total income (expense)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Total income (expense), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalIncomeExpense' xlink:to='lab_fil_TotalIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract' xlink:label='us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherIncomeAndExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income (expense):</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='lab_us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock' xlink:label='us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 10. Accounts Payable and Accrued Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock' xlink:to='lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_PrincipalPaymentsOnDebt' xlink:label='fil_PrincipalPaymentsOnDebt'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPaymentsOnDebt' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal payments on debt</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPaymentsOnDebt' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Principal payments on debt, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPaymentsOnDebt' xlink:to='lab_fil_PrincipalPaymentsOnDebt'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashFlowsFromInvestingActivitiesAbstract' xlink:label='fil_CashFlowsFromInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashFlowsFromInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash flows from investing activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashFlowsFromInvestingActivitiesAbstract' xlink:to='lab_fil_CashFlowsFromInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium' xlink:label='us-gaap_AmortizationOfDebtDiscountPremium'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfDebtDiscountPremium' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortizatio expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AmortizationOfDebtDiscountPremium' xlink:to='lab_us-gaap_AmortizationOfDebtDiscountPremium'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives' xlink:label='us-gaap_UnrealizedGainLossOnDerivatives'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_UnrealizedGainLossOnDerivatives' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Change in fair value of derivative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_UnrealizedGainLossOnDerivatives' xlink:to='lab_us-gaap_UnrealizedGainLossOnDerivatives'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated deficit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively' xlink:label='fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Convertible note payable - net of discount of $73,562 and $0, respectively</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Convertible note payable - net of discount of $73,562 and $0, respectively, as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively' xlink:to='lab_fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock' xlink:label='us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 9. Other Receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock' xlink:to='lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock' xlink:label='us-gaap_DebtDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DebtDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 6. Payable - Not Convertible</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DebtDisclosureTextBlock' xlink:to='lab_us-gaap_DebtDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ForeignCurrencyAdjustments' xlink:label='fil_ForeignCurrencyAdjustments'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyAdjustments' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyAdjustments' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Foreign currency adjustments, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ForeignCurrencyAdjustments' xlink:to='lab_fil_ForeignCurrencyAdjustments'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ProvisionForIncomeTaxes' xlink:label='fil_ProvisionForIncomeTaxes'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ProvisionForIncomeTaxes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ProvisionForIncomeTaxes' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Provision for income taxes, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ProvisionForIncomeTaxes' xlink:to='lab_fil_ProvisionForIncomeTaxes'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research and development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Revenues' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Revenues' xlink:to='lab_us-gaap_Revenues'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Stockholders&apos; equity (deficit)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockValue' xlink:to='lab_us-gaap_PreferredStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTextBlock' xlink:label='us-gaap_ShortTermDebtTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShortTermDebtTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 5. Notes Payable.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShortTermDebtTextBlock' xlink:to='lab_us-gaap_ShortTermDebtTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 3. Related Party Transactions</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:to='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashFlowsFromFinancingActivitiesAbstract' xlink:label='fil_CashFlowsFromFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashFlowsFromFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash flows from financing activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashFlowsFromFinancingActivitiesAbstract' xlink:to='lab_fil_CashFlowsFromFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_NetLoss1' xlink:label='fil_NetLoss1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLoss1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLoss1' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Net loss</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLoss1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Net loss, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetLoss1' xlink:to='lab_fil_NetLoss1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statements of Cash Flows</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='lab_us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent' xlink:label='us-gaap_InterestPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued interest payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPayableCurrent' xlink:to='lab_us-gaap_InterestPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_EmployeePayable' xlink:label='fil_EmployeePayable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EmployeePayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Employee payable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EmployeePayable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Employee payable, as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EmployeePayable' xlink:to='lab_fil_EmployeePayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock' xlink:label='us-gaap_IncomeTaxPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income Taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxPolicyTextBlock' xlink:to='lab_us-gaap_IncomeTaxPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock' xlink:label='us-gaap_OtherLiabilitiesDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLiabilitiesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 4. Employee Payable.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLiabilitiesDisclosureTextBlock' xlink:to='lab_us-gaap_OtherLiabilitiesDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DecreaseIncreaseInEmployeePayable' xlink:label='fil_DecreaseIncreaseInEmployeePayable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DecreaseIncreaseInEmployeePayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(Decrease) increase in employee payable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DecreaseIncreaseInEmployeePayable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the (Decrease) increase in employee payable, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DecreaseIncreaseInEmployeePayable' xlink:to='lab_fil_DecreaseIncreaseInEmployeePayable'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_FinancialIncomeExpense' xlink:label='fil_FinancialIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FinancialIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Financial income (expense)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_FinancialIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Financial income (expense), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FinancialIncomeExpense' xlink:to='lab_fil_FinancialIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>General and administrative expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_GeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent' xlink:label='us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable and accrued liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent' xlink:to='lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 2. Stockholders&apos; Equity.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:to='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashPaidForFixedAssets' xlink:label='fil_CashPaidForFixedAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashPaidForFixedAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid for fixed assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashPaidForFixedAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Cash paid for fixed assets, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashPaidForFixedAssets' xlink:to='lab_fil_CashPaidForFixedAssets'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_NetLoss' xlink:label='fil_NetLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLoss' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Net loss, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetLoss' xlink:to='lab_fil_NetLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock' xlink:label='us-gaap_ScheduleOfDerivativeInstrumentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Derivative Instruments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfDerivativeInstrumentsTextBlock' xlink:to='lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashFlowsUsedByOperatingActivities' xlink:label='fil_CashFlowsUsedByOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashFlowsUsedByOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash flows used by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashFlowsUsedByOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Cash flows used by operating activities, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashFlowsUsedByOperatingActivities' xlink:to='lab_fil_CashFlowsUsedByOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DueFromRelatedParty' xlink:label='fil_DueFromRelatedParty'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DueFromRelatedParty' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Due from related party</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DueFromRelatedParty' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Due from related party, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DueFromRelatedParty' xlink:to='lab_fil_DueFromRelatedParty'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashFlowsFromOperatingActivitiesAbstract' xlink:label='fil_CashFlowsFromOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashFlowsFromOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash flows from operating activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashFlowsFromOperatingActivitiesAbstract' xlink:to='lab_fil_CashFlowsFromOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_StatementsOfOperationsAbstract' xlink:label='fil_StatementsOfOperationsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_StatementsOfOperationsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statements of Operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='lab_fil_StatementsOfOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Liabilities and Stockholders&apos; Equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total Liabilities and Stockholders&apos; Equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock' xlink:label='us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:to='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_NonCashTransactionAbstract' xlink:label='fil_NonCashTransactionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NonCashTransactionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Non-cash transaction:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NonCashTransactionAbstract' xlink:to='lab_fil_NonCashTransactionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashAndCashEquivalentsEndOfPeriod' xlink:label='fil_CashAndCashEquivalentsEndOfPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsEndOfPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and cash equivalents - end of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsEndOfPeriod' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash and cash equivalents - end of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsEndOfPeriod' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Cash and cash equivalents - end of period, as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashAndCashEquivalentsEndOfPeriod' xlink:to='lab_fil_CashAndCashEquivalentsEndOfPeriod'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_AccumulatedOtherComprehensiveIncomeLoss' xlink:label='fil_AccumulatedOtherComprehensiveIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedOtherComprehensiveIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive income (loss)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedOtherComprehensiveIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Accumulated other comprehensive income (loss), as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccumulatedOtherComprehensiveIncomeLoss' xlink:to='lab_fil_AccumulatedOtherComprehensiveIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_TotalCurrentLiabilities' xlink:label='fil_TotalCurrentLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalCurrentLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalCurrentLiabilities' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Total current liabilities, as of the indicated date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalCurrentLiabilities' xlink:to='lab_fil_TotalCurrentLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives' xlink:label='us-gaap_DerivativesEmbeddedDerivatives'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DerivativesEmbeddedDerivatives' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounting For Obligations and Instruments Potentially To Be Settled in The Company&apos;s Own Stock:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DerivativesEmbeddedDerivatives' xlink:to='lab_us-gaap_DerivativesEmbeddedDerivatives'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NatureOfOperations' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Note 1. The Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NatureOfOperations' xlink:to='lab_us-gaap_NatureOfOperations'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_BorrowingsOnDebt' xlink:label='fil_BorrowingsOnDebt'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BorrowingsOnDebt' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Borrowings on debt</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BorrowingsOnDebt' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Borrowings on debt, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BorrowingsOnDebt' xlink:to='lab_fil_BorrowingsOnDebt'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract' xlink:label='fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract' xlink:to='lab_fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_FixedAssetsNetAbstract' xlink:label='fil_FixedAssetsNetAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FixedAssetsNetAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fixed assets, net:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FixedAssetsNetAbstract' xlink:to='lab_fil_FixedAssetsNetAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Assets {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mrla-20160630_pre.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2015 [PPXM8K19K1334NYCARL5]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://dermacompare.com/20160630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentType' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_TradingSymbol' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='15.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpBalanceSheets" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_EmeraldMedicalApplicationsCorpBalanceSheets"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpBalanceSheets">
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_BalanceSheetsAbstract' xlink:label='fil_BalanceSheetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CurrentAssetsAbstract' xlink:label='fil_CurrentAssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_CurrentAssetsAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherReceivables' xlink:label='us-gaap_OtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_OtherReceivables' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_AssetsCurrent' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_FixedAssetsNetAbstract' xlink:label='fil_FixedAssetsNetAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_FixedAssetsNetAbstract' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet' xlink:label='us-gaap_PropertyPlantAndEquipmentOtherNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentOtherNet' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_Assets' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_LiabilitiesAndStockholdersEquityDeficitAbstract' xlink:label='fil_LiabilitiesAndStockholdersEquityDeficitAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_LiabilitiesAndStockholdersEquityDeficitAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CurrentLiabilitiesAbstract' xlink:label='fil_CurrentLiabilitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_CurrentLiabilitiesAbstract' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent' xlink:label='us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_EmployeePayable' xlink:label='fil_EmployeePayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_EmployeePayable' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_EmployeePayableRelatedParty' xlink:label='fil_EmployeePayableRelatedParty'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_EmployeePayableRelatedParty' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent' xlink:label='us-gaap_InterestPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_InterestPayableCurrent' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ShortTermNotesPayable' xlink:label='fil_ShortTermNotesPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_ShortTermNotesPayable' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ConvertibleNotePayableDefault' xlink:label='fil_ConvertibleNotePayableDefault'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_ConvertibleNotePayableDefault' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively' xlink:label='fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_TotalCurrentLiabilities' xlink:label='fil_TotalCurrentLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_TotalCurrentLiabilities' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_StockholdersDeficitAbstract' xlink:label='fil_StockholdersDeficitAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_StockholdersDeficitAbstract' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_PreferredStockValue' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_AccumulatedOtherComprehensiveIncomeLoss' xlink:label='fil_AccumulatedOtherComprehensiveIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='fil_AccumulatedOtherComprehensiveIncomeLoss' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_AdditionalPaidInCapital' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BalanceSheetsAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='27.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfOperations" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_EmeraldMedicalApplicationsCorpStatementsOfOperations"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfOperations">
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_StatementsOfOperationsAbstract' xlink:label='fil_StatementsOfOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_Revenues' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ExpensesAbstract' xlink:label='fil_ExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='fil_ExpensesAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_GeneralAndAdministrativeExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_LossFromOperations' xlink:label='fil_LossFromOperations'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='fil_LossFromOperations' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract' xlink:label='us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_OtherIncomeAndExpensesAbstract' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_InterestExpense' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives' xlink:label='us-gaap_UnrealizedGainLossOnDerivatives'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_UnrealizedGainLossOnDerivatives' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium' xlink:label='us-gaap_AmortizationOfDebtDiscountPremium'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_AmortizationOfDebtDiscountPremium' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_GainLossFromForeignCurrency' xlink:label='fil_GainLossFromForeignCurrency'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='fil_GainLossFromForeignCurrency' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_FinancialIncomeExpense' xlink:label='fil_FinancialIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='fil_FinancialIncomeExpense' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_TotalIncomeExpense' xlink:label='fil_TotalIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='fil_TotalIncomeExpense' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ProvisionForIncomeTaxes' xlink:label='fil_ProvisionForIncomeTaxes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='fil_ProvisionForIncomeTaxes' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_NetIncomeLoss' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted' xlink:label='us-gaap_EarningsPerShareBasicAndDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_EarningsPerShareBasicAndDiluted' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_WeightedAverageSharesOutstandingAbstract' xlink:label='fil_WeightedAverageSharesOutstandingAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='fil_WeightedAverageSharesOutstandingAbstract' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:label='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StatementsOfOperationsAbstract' xlink:to='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' use='optional' order='19.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract' xlink:label='us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_NetLoss' xlink:label='fil_NetLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract' xlink:to='fil_NetLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss' xlink:label='fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract' xlink:to='fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashFlowsFromOperatingActivitiesAbstract' xlink:label='fil_CashFlowsFromOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_CashFlowsFromOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_NetLoss1' xlink:label='fil_NetLoss1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_NetLoss1' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract' xlink:label='fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DepreciationExpense' xlink:label='fil_DepreciationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_DepreciationExpense' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_AmortizationOfDebtDiscount' xlink:label='fil_AmortizationOfDebtDiscount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_AmortizationOfDebtDiscount' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ChangeInFairValueOfDerivative' xlink:label='fil_ChangeInFairValueOfDerivative'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_ChangeInFairValueOfDerivative' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_SharesIssuedForServices' xlink:label='fil_SharesIssuedForServices'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_SharesIssuedForServices' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_OptionsIssuedForServices' xlink:label='fil_OptionsIssuedForServices'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_OptionsIssuedForServices' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_IncreaseDecreaseInCashResultingFromChangesInAbstract' xlink:label='fil_IncreaseDecreaseInCashResultingFromChangesInAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_IncreaseDecreaseInCashResultingFromChangesInAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DueFromRelatedParty' xlink:label='fil_DueFromRelatedParty'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_DueFromRelatedParty' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DecreaseIncreaseInOtherReceivable' xlink:label='fil_DecreaseIncreaseInOtherReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_DecreaseIncreaseInOtherReceivable' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPayablesToCustomers' xlink:label='us-gaap_IncreaseDecreaseInPayablesToCustomers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInPayablesToCustomers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DecreaseIncreaseInAccountsPayableRelatedParty' xlink:label='fil_DecreaseIncreaseInAccountsPayableRelatedParty'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_DecreaseIncreaseInAccountsPayableRelatedParty' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DecreaseIncreaseInEmployeePayable' xlink:label='fil_DecreaseIncreaseInEmployeePayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_DecreaseIncreaseInEmployeePayable' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities' xlink:label='us-gaap_IncreaseDecreaseInOtherCurrentLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInOtherCurrentLiabilities' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_DecreaseIncreaseInAccruedEpenses' xlink:label='fil_DecreaseIncreaseInAccruedEpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_DecreaseIncreaseInAccruedEpenses' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashFlowsUsedByOperatingActivities' xlink:label='fil_CashFlowsUsedByOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_CashFlowsUsedByOperatingActivities' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashFlowsFromInvestingActivitiesAbstract' xlink:label='fil_CashFlowsFromInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_CashFlowsFromInvestingActivitiesAbstract' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashPaidForFixedAssets' xlink:label='fil_CashPaidForFixedAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_CashPaidForFixedAssets' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashFlowsFromFinancingActivitiesAbstract' xlink:label='fil_CashFlowsFromFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_CashFlowsFromFinancingActivitiesAbstract' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_BorrowingsOnDebt' xlink:label='fil_BorrowingsOnDebt'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_BorrowingsOnDebt' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_PrincipalPaymentsOnDebt' xlink:label='fil_PrincipalPaymentsOnDebt'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_PrincipalPaymentsOnDebt' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_ForeignCurrencyAdjustments' xlink:label='fil_ForeignCurrencyAdjustments'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_ForeignCurrencyAdjustments' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_NetIncreaseDecreaseInCash' xlink:label='fil_NetIncreaseDecreaseInCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_NetIncreaseDecreaseInCash' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashAndCashEquivalentsBeginningOfPeriod' xlink:label='fil_CashAndCashEquivalentsBeginningOfPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_CashAndCashEquivalentsBeginningOfPeriod' use='optional' order='27.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashAndCashEquivalentsEndOfPeriod' xlink:label='fil_CashAndCashEquivalentsEndOfPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_CashAndCashEquivalentsEndOfPeriod' use='optional' order='28.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_NonCashTransactionAbstract' xlink:label='fil_NonCashTransactionAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_NonCashTransactionAbstract' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_BcfDueToConvertibleNotePayable' xlink:label='fil_BcfDueToConvertibleNotePayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_BcfDueToConvertibleNotePayable' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='mrla-20160630.xsd#fil_CashlessConversionOfClassBWarrants' xlink:label='fil_CashlessConversionOfClassBWarrants'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='fil_CashlessConversionOfClassBWarrants' use='optional' order='31.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompany" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompany"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompany">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NatureOfOperations' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote2StockholdersEquity" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote2StockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote2StockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_StockholdersEquityNoteDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote3RelatedPartyTransactions" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote3RelatedPartyTransactions"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote3RelatedPartyTransactions">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote4EmployeePayable" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote4EmployeePayable"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote4EmployeePayable">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock' xlink:label='us-gaap_OtherLiabilitiesDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OtherLiabilitiesDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote5NotesPayable" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote5NotesPayable"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote5NotesPayable">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTextBlock' xlink:label='us-gaap_ShortTermDebtTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ShortTermDebtTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote6PayableNotConvertible" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote6PayableNotConvertible"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote6PayableNotConvertible">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock' xlink:label='us-gaap_DebtDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DebtDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote7CommitmentsAndContingencies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote7CommitmentsAndContingencies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote7CommitmentsAndContingencies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilities" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote8DerivativeLiabilities"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilities">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock' xlink:label='us-gaap_OtherLiabilitiesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OtherLiabilitiesTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote9OtherReceivables" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote9OtherReceivables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote9OtherReceivables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock' xlink:label='us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote10AccountsPayableAndAccruedLiabilities" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote10AccountsPayableAndAccruedLiabilities"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote10AccountsPayableAndAccruedLiabilities">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock' xlink:label='us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote11SubsequentEvents" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote11SubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote11SubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_UseOfEstimates' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_CashAndCashEquivalentsPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyOtherReceivablesPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyOtherReceivablesPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyOtherReceivablesPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy' xlink:label='us-gaap_TradeAndOtherAccountsReceivablePolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_TradeAndOtherAccountsReceivablePolicy' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock' xlink:label='us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy' xlink:label='us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives' xlink:label='us-gaap_DerivativesEmbeddedDerivatives'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_DerivativesEmbeddedDerivatives' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock' xlink:label='us-gaap_FairValueMeasurementPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_FairValueMeasurementPolicyPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_EarningsPerSharePolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyIncomeTaxesPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyIncomeTaxesPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyIncomeTaxesPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock' xlink:label='us-gaap_IncomeTaxPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_IncomeTaxPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxUncertaintiesPolicy' xlink:label='us-gaap_IncomeTaxUncertaintiesPolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_IncomeTaxUncertaintiesPolicy' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock' xlink:label='us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock' xlink:label='us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables" xlink:type="simple" xlink:href="mrla-20160630.xsd#idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock' xlink:label='us-gaap_ScheduleOfDerivativeInstrumentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfDerivativeInstrumentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6779267200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2201</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Emerald Medical Applications Corp.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">mrla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000797542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">19,474,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,673,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6779241216">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Emerald Medical Applications Corp. - Balance Sheets<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 274,759<span></span>
</td>
<td class="nump">$ 115,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,212<span></span>
</td>
<td class="nump">25,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">282,971<span></span>
</td>
<td class="nump">141,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FixedAssetsNetAbstract', window );"><strong>Fixed assets, net:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Fixed assets, net of accumulated depreciation of $10,751 and $6,536, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,735<span></span>
</td>
<td class="nump">21,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">300,706<span></span>
</td>
<td class="nump">162,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 48,204<span></span>
</td>
<td class="nump">$ 90,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EmployeePayable', window );">Employee payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,786<span></span>
</td>
<td class="nump">25,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EmployeePayableRelatedParty', window );">Employee payable - related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">3,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,887<span></span>
</td>
<td class="nump">$ 19,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ShortTermNotesPayable', window );">Short term notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">186,336<span></span>
</td>
<td class="nump">119,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConvertibleNotePayableDefault', window );">Convertible note payable - default</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,719<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively', window );">Convertible note payable - net of discount of $73,562 and $0, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222,377<span></span>
</td>
<td class="nump">29,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalCurrentLiabilities', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">534,390<span></span>
</td>
<td class="nump">288,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 534,390<span></span>
</td>
<td class="nump">$ 288,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockholdersDeficitAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1,948<span></span>
</td>
<td class="nump">$ 1,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccumulatedOtherComprehensiveIncomeLoss', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,178)<span></span>
</td>
<td class="num">(19,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,738,066<span></span>
</td>
<td class="nump">$ 8,752,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,949,520)<span></span>
</td>
<td class="num">(8,861,316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' equity (deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(233,684)<span></span>
</td>
<td class="num">(126,409)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300,706<span></span>
</td>
<td class="nump">$ 162,366<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">$0.0001 par value; 10,000,000 shares authorized; none issued.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">$0.0001 par value; 490,000,000 shares authorized; 19,474,461 and 15,325,889 issued and outstanding at June 30, 2016 and December 31, 2015, respectively.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccumulatedOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Accumulated other comprehensive income (loss), as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccumulatedOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConvertibleNotePayableDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Convertible note payable - default, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ConvertibleNotePayableDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Convertible note payable - net of discount of $73,562 and $0, respectively, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ConvertibleNotePayableNetOfDiscountOf73562And0Respectively</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EmployeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Employee payable, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EmployeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EmployeePayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Employee payable - related party, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EmployeePayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FixedAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FixedAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ShortTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Short term notes payable, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ShortTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockholdersDeficitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_StockholdersDeficitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Total current liabilities, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amounts due as of the balance sheet date from parties or arising from transactions not otherwise specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of capitalized assets classified as property, plant and equipment not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6780024864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Emerald Medical Applications Corp. - Statements of Operations<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StatementsOfOperationsAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(192,002)<span></span>
</td>
<td class="num">(237,095)<span></span>
</td>
<td class="num">(295,350)<span></span>
</td>
<td class="num">(247,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(969,216)<span></span>
</td>
<td class="num">(5,570)<span></span>
</td>
<td class="num">(2,768,736)<span></span>
</td>
<td class="num">(174,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">$ (1,161,218)<span></span>
</td>
<td class="num">$ (242,665)<span></span>
</td>
<td class="num">$ (3,064,086)<span></span>
</td>
<td class="num">$ (421,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LossFromOperations', window );">(Loss) from operations</a></td>
<td class="num">(1,161,218)<span></span>
</td>
<td class="num">(242,665)<span></span>
</td>
<td class="num">(3,064,086)<span></span>
</td>
<td class="num">(421,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">$ (14,128)<span></span>
</td>
<td class="num">$ (4,346)<span></span>
</td>
<td class="num">$ (21,887)<span></span>
</td>
<td class="num">$ (11,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="num">(47,718)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(51,665)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortizatio expense</a></td>
<td class="nump">$ 28,587<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 28,587<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GainLossFromForeignCurrency', window );">Gain/loss from foreign currency</a></td>
<td class="nump">6,503<span></span>
</td>
<td class="num">(4,110)<span></span>
</td>
<td class="nump">20,847<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FinancialIncomeExpense', window );">Financial income (expense)</a></td>
<td class="num">(26,756)<span></span>
</td>
<td class="num">(8,456)<span></span>
</td>
<td class="num">(24,118)<span></span>
</td>
<td class="num">(9,654)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalIncomeExpense', window );">Total income (expense)</a></td>
<td class="num">(1,187,974)<span></span>
</td>
<td class="num">(251,121)<span></span>
</td>
<td class="num">(3,088,204)<span></span>
</td>
<td class="num">(431,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProvisionForIncomeTaxes', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss)</a></td>
<td class="num">$ (1,187,974)<span></span>
</td>
<td class="num">$ (251,121)<span></span>
</td>
<td class="num">$ (3,088,204)<span></span>
</td>
<td class="num">$ (431,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share | $ / shares</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (2.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WeightedAverageSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted | shares</a></td>
<td class="nump">18,890,670<span></span>
</td>
<td class="nump">213,001<span></span>
</td>
<td class="nump">18,121,314<span></span>
</td>
<td class="nump">213,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FinancialIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Financial income (expense), during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FinancialIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GainLossFromForeignCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Gain/loss from foreign currency, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_GainLossFromForeignCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LossFromOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the (Loss) from operations, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LossFromOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProvisionForIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Provision for income taxes, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ProvisionForIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StatementsOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_StatementsOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Total income (expense), during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WeightedAverageSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_WeightedAverageSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771343584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Emerald Medical Applications Corp. - Statement of Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetLoss', window );">Net loss</a></td>
<td class="num">(1,187,974)<span></span>
</td>
<td class="num">(3,088,204)<span></span>
</td>
<td class="num">(251,121)<span></span>
</td>
<td class="num">(431,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss', window );">Change in unrealized foreign currency translation gain (loss)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4,841)<span></span>
</td>
<td class="num">(15,771)<span></span>
</td>
<td class="num">(25,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive gain (loss)</a></td>
<td class="num">$ (1,187,977)<span></span>
</td>
<td class="num">$ (3,093,045)<span></span>
</td>
<td class="num">$ (266,892)<span></span>
</td>
<td class="num">$ (456,995)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Change in unrealized foreign currency translation gain (loss), during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ChangeInUnrealizedForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Net loss, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6785104128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Emerald Medical Applications Corp. - Statements of Cash Flows<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashFlowsFromOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetLoss1', window );">Net loss</a></td>
<td class="num">(3,088,204)<span></span>
</td>
<td class="num">(431,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="nump">8,293<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">43,373<span></span>
</td>
<td class="nump">4,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ChangeInFairValueOfDerivative', window );">Change in fair value of derivative</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">2,074,736<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsIssuedForServices', window );">Options issued for services</a></td>
<td class="nump">455,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncreaseDecreaseInCashResultingFromChangesInAbstract', window );"><strong>Increase (decrease) in cash resulting from changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DueFromRelatedParty', window );">Due from related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DecreaseIncreaseInOtherReceivable', window );">Decrease (increase) in other receivable</a></td>
<td class="nump">17,585<span></span>
</td>
<td class="num">(25,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPayablesToCustomers', window );">(Decrease) increase in accounts payable</a></td>
<td class="num">$ (1,777)<span></span>
</td>
<td class="num">$ (2,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DecreaseIncreaseInAccountsPayableRelatedParty', window );">(Decrease) increase in accounts payable - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DecreaseIncreaseInEmployeePayable', window );">(Decrease) increase in employee payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">(Decrease) increase in in other current liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DecreaseIncreaseInAccruedEpenses', window );">(Decrease) increase in accrued epenses</a></td>
<td class="num">(45,779)<span></span>
</td>
<td class="nump">7,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashFlowsUsedByOperatingActivities', window );">Cash flows used by operating activities</a></td>
<td class="num">(536,741)<span></span>
</td>
<td class="num">(413,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashFlowsFromInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashPaidForFixedAssets', window );">Cash paid for fixed assets</a></td>
<td class="num">(474)<span></span>
</td>
<td class="nump">25,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="num">$ (474)<span></span>
</td>
<td class="nump">$ 25,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BorrowingsOnDebt', window );">Borrowings on debt</a></td>
<td class="nump">735,913<span></span>
</td>
<td class="nump">531,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPaymentsOnDebt', window );">Principal payments on debt</a></td>
<td class="num">(34,547)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">$ 701,366<span></span>
</td>
<td class="nump">$ 531,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ForeignCurrencyAdjustments', window );">Foreign currency adjustments</a></td>
<td class="num">(4,841)<span></span>
</td>
<td class="num">(25,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetIncreaseDecreaseInCash', window );">Net increase (decrease) in cash</a></td>
<td class="nump">159,310<span></span>
</td>
<td class="nump">67,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashAndCashEquivalentsBeginningOfPeriod', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">115,449<span></span>
</td>
<td class="nump">14,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashAndCashEquivalentsEndOfPeriod', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">274,759<span></span>
</td>
<td class="nump">56,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NonCashTransactionAbstract', window );"><strong>Non-cash transaction:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BcfDueToConvertibleNotePayable', window );">BCF due to convertible note payable</a></td>
<td class="nump">456,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashlessConversionOfClassBWarrants', window );">Cashless conversion of class B warrants</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Amortization of debt discount, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BcfDueToConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the BCF due to convertible note payable, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BcfDueToConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BorrowingsOnDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Borrowings on debt, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BorrowingsOnDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashAndCashEquivalentsBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Cash and cash equivalents - beginning of period, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashAndCashEquivalentsBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashAndCashEquivalentsEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Cash and cash equivalents - end of period, as of the indicated date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashAndCashEquivalentsEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashFlowsFromFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashFlowsFromFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashFlowsFromInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashFlowsFromInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashFlowsFromOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashFlowsFromOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashFlowsUsedByOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Cash flows used by operating activities, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashFlowsUsedByOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashPaidForFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Cash paid for fixed assets, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashPaidForFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashlessConversionOfClassBWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Cashless conversion of class B warrants, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashlessConversionOfClassBWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ChangeInFairValueOfDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Change in fair value of derivative, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ChangeInFairValueOfDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DecreaseIncreaseInAccountsPayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the (Decrease) increase in accounts payable - related party, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DecreaseIncreaseInAccountsPayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DecreaseIncreaseInAccruedEpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the (Decrease) increase in accrued epenses, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DecreaseIncreaseInAccruedEpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DecreaseIncreaseInEmployeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the (Decrease) increase in employee payable, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DecreaseIncreaseInEmployeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DecreaseIncreaseInOtherReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Decrease (increase) in other receivable, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DecreaseIncreaseInOtherReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Depreciation expense, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Due from related party, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ForeignCurrencyAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Foreign currency adjustments, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ForeignCurrencyAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncreaseDecreaseInCashResultingFromChangesInAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncreaseDecreaseInCashResultingFromChangesInAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetIncreaseDecreaseInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Net increase (decrease) in cash, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetIncreaseDecreaseInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Net loss, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NonCashTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NonCashTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Options issued for services, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OptionsIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPaymentsOnDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Principal payments on debt, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPaymentsOnDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Shares issued for services, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPayablesToCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change during the period, either increase or decrease, in amounts payable to customers. The term customers generally excludes other broker-dealers; persons who are principal officers, directors, and stockholders; and persons whose securities or funds are part of the regulatory net capital of the broker-dealer. Another broker-dealer's account can be classified as a customer if the account is carried as an omnibus account in compliance with certain regulations. The accounts of principal officers, directors and stockholders may be combined in the customer captions if they are not material and the combination is disclosed in the oath that is required to accompany the annual audited FOCUS Report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Rule 15c3<br> -Number 240<br> -Section 1<br> -Paragraph 1<br> -Article 15c3<br> -Subsection c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPayablesToCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774913344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Note 1. The Company</a></td>
<td class="text"><!--egx--><p><b>Note 1. The Company</b></p> <p><i>Organizational Background</i></p> <p>Emerald Medical Applications Corp. (&quot;the Company&quot;) (f/k/a Zaxis International Inc.) was incorporated in Ohio in 1989, it's fiscal year end is December 31st. On August 25, 1995, The Company merged with a subsidiary of The InFerGene Company (&quot;InFerGene&quot;) and InFerGene changed its name to The Company International Inc. InFerGene was incorporated in California in 1984 and subsequently changed its domicile in connection with the merger into The Company to Delaware in 1985. Operations ceased operations in 2002. In November 2002, the Company and its subsidiaries filed a petition for bankruptcy in the U.S. Bankruptcy Court Northern District of Ohio. On October 13, 2004, the Company emerged from bankruptcy. </p> <p>On July 14, 2015 the closing of the Share Exchange Agreement was held (the &quot;Closing&quot;) and as a result, Emerald Medical Applications Ltd. became a wholly-owned subsidiary of the Registrant. Pursuant to the Closing of the Share Exchange Agreement, the Company issued 5,474,545 shares of its common stock, par value $0.0001 (the &quot;Shares&quot; or &quot;Common Stock&quot;) to Lior Wayn, Emerald's CEO and the sole holder of Emerald Medical Applications Ltd.'s ordinary Shares, representing 40.58% of the company's 13,489,905 outstanding Shares, in exchange for 100% of Emerald Medical Applications Ltd.'s ordinary Shares. </p> <p>Subsequently to the Closing Mr. Lior Wayn has been appointed as the Company's CEO, and has been granted considerable influence on the appointment of new directors thereby creating a new management structure for the company replacing the old management. Additionally Mr. Wayn is to receive additional shares in the future contingent on the Company achieving commercial milestone. Thus the new management, headed by Mr. Wayn, is considered to be in control of more than 50% of the company and with the ability to make all management decisions.</p> <p>Emerald is a company organized under the laws of the State of Israel on February 17, 2010. Emerald is digital health Startup Company engaged in the development, sale and service of imaging solutions utilizing its proprietary DermaCompare software that it developed for use in derma imaging and analytics (&quot;DermaCompare&quot;). Emerald believes that its proprietary DermaCompare software represents an advancement in skin cancer screening that should enable physicians to more readily identify and monitor changes in their patients' skin characteristics. </p> <p>Emerald's DermaCompare solution allows dermatologists and other medical care professionals, using a set of 25 total body photography (&quot;TBP&quot;), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smartphones or tablets. These images are then transmitted online and are remotely analyzed by professionals using our DermaCompare software.</p> <p>Emerald's sales and marketing plan is to sell licenses for our imaging software to: NHSs, HMOs, health insurance companies, hospitals and medical clinics through distributers, health care channel partners or directly through independent salespersons and/or web purchase to dermatologists and other physicians (GPs) that we expect to purchase licenses based on the number of potential numbers of patients.</p> <p><i>Basis of Presentation</i></p> <p>The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred operating losses since inception. Further, as of June 30, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p> <p>The Company elected December 31 as its fiscal year end.</p> <p><i>Significant Accounting Policies</i></p> <p><i>Use of Estimates</i></p> <p>The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Cash and Cash Equivalents</i></p> <p>For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of June 30, 2016 and December 31, 2015.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Other Receivables</i></p> <p>The company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of June 30, 2016 was $8,212.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Currency Translation and other Comprehensive Income</i></p> <p>Balance sheet items are translated using all current translation method for self-contained foreign operations (where functional currency = foreign currency) whereby assets and liabilities are translated using the exchange rate on the date of the balance sheet. It translates revenues, expenses, and net income using the average exchange rate during the period. The foreign exchange adjustment that results from applying the all-current method appears in other comprehensive income, a separate shareholders' equity account, and does not affect net income each period.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Property and Equipment</i></p> <p style='margin:0in;margin-bottom:.0001pt'>New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 5 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes pla</p> <p style='margin:0in;margin-bottom:.0001pt'>ce.</p> <p><i>Valuation of Long-Lived Assets</i></p> <p>We review the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Stock Based Compensation</i></p> <p>Stock-based awards are accounted for using the fair value method in accordance with ASC 718,&nbsp;Share-Based Payments. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company's common stock, the estimated volatility of the Company's common stock, the exercise price of the warrants and the risk free interest rate.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Accounting For Obligations And Instruments Potentially To Be Settled In The Company's Own Stock: </i></p> <p>We account for obligations and instruments potentially to be settled in the Company's stock in accordance with FASB ASC 815,&nbsp;Accounting for Derivative Financial Instruments.&nbsp;This issue addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company's own stock.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Fair Value Measurements</i></p> <p>The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p> <p>As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows.</p> <p>Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p> <p>The Company values its derivative instruments related to embedded conversion features and warrants from the issuance of convertible debentures in accordance with the Level 3 guidelines. For the six-month period ended June 30, 2016 and the twelve month period ending December 31, 2015, the following table reconciles the beginning and ending balances for financial instruments that are recognized at fair value in these consolidated financial statements. The fair value of embedded conversion features that have floating conversion features and tainted common stock equivalents (warrants and convertible debt) are estimated using a Binomial Lattice model. The key inputs to this valuation model as of December 31, 2015, were: Volatility of 143.9% for the six-month period ended June 30, 2016 and 132.4% for the twelve months period ending December 31, 2015, inherent term of instruments equal to the remaining contractual term, quoted closing stock prices on valuation dates, and various settlement scenarios and probability percentages summing to 100%.</p> <p>&nbsp;</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at June 30, 2016</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Level 3 - Derivative liabilities from:</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Balance at June 30, 2016</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>New Issuances</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Settlements</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Change in Fair Value</p> </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Convertible Note</p> </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="276" style='border:none'></td> <td width="20" style='border:none'></td> <td width="9" style='border:none'></td> <td width="163" style='border:none'></td> <td width="9" style='border:none'></td> <td width="10" style='border:none'></td> <td width="60" style='border:none'></td> <td width="9" style='border:none'></td> <td width="12" style='border:none'></td> <td width="70" style='border:none'></td> <td width="9" style='border:none'></td> <td width="9" style='border:none'></td> <td width="91" style='border:none'></td> </tr> </table> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'><b>&nbsp;</b></p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at December 31, 2015</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Level 3 - Derivative liabilities from:</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Balance at December 31, 2015</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>New Issuances</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Extinguishment</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Change in Fair Value</p> </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Convertible Note</p> </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>(20,532)</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="273" style='border:none'></td> <td width="17" style='border:none'></td> <td width="9" style='border:none'></td> <td width="158" style='border:none'></td> <td width="7" style='border:none'></td> <td width="10" style='border:none'></td> <td width="58" style='border:none'></td> <td width="4" style='border:none'></td> <td width="16" style='border:none'></td> <td width="95" style='border:none'></td> <td width="6" style='border:none'></td> <td width="7" style='border:none'></td> <td width="89" style='border:none'></td> </tr> </table> <p>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>Changes in the unobservable input values would likely cause material changes in the fair value of the Company's Level 3 financial instruments. The significant unobservable input used in the fair value measurement is the estimation for probability percentages assigned to future expected settlement possibilities. A significant increase (decrease) in this distribution of percentages would result in a higher (lower) fair value measurement.</p> <p>The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2016 and December 31, 2015:</p> <p>&nbsp;</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at June 30, 2016</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Level 3</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Assets</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Assets</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Liabilities</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative liability</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Liabilities</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> </table> </div> <p style='margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>&nbsp; </b></p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at December 31, 2015</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp; </p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Level 3</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Assets</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Assets</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Liabilities</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative liability</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Liabilities</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> </table> </div> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>The fair values of our debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.</p> <p>There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the year ended December 31, 2015.</p> <p>The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of June 30, 2016 or December 31, 2015.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Earnings per Common Share</i></p> <p>We compute net income (loss) per share in accordance with ASC 260,&nbsp;Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2012.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Income Taxes</i></p> <p>We have adopted FASB ASC 740,&nbsp;Accounting for Income Taxes.&nbsp;Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.</p> <p>We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.</p> <p>Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate.</p> <p>In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be.</p> <p>ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current period and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Uncertain Tax Positions</i></p> <p>When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</p> <p>Our federal and state income tax returns are open for fiscal years ending on or after December 31, 2011. We are not under examination by any jurisdiction for any tax year. At June 30, 2016 we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under FIN&nbsp;48.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Recent Accounting Pronouncements</i></p> <p>In September, 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805) (&quot;ASU 2015-16&quot;). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company's consolidated financial statements.</p> <p>In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (&quot;ASU 2015-14&quot;). The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods with that reporting period.</p> <p>In April 2015, the Financial Accounting Standards Board (&quot;FASB&quot;) issued Accounting Standards Update (&quot;ASU&quot;) No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (&quot;ASU 2015-03&quot;), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Going Concern</i></p> <p>The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. Further, as of June 30, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6609534192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2. Stockholders' Equity.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Note 2. Stockholders' Equity.</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 2. Stockholders' Equity.</b></p> <p>On January 8, 2015 the shareholders approved a resolution to increase the authorized common shares from 100,000,000 to 490,000,000 shares. All other provisions of the common shares remain unchanged. Also on that date, the Company declared a reverse split of common stock at the ration of 1:4. The stock split was effective January 8, 2015 for holders of record as of that date. Except as otherwise noted, all share, option and warrant numbers have been restated to give retroactive effect to this split. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred at January 1, 2012.</p> <p><i>Recent Issuances of Common Stock</i></p> <p>Between January 15, 2015 and March 15, 2015, the Company sold a total of 2,052,000 units for cash consideration of $780,000 at a price of $0.40 (the &quot;Units&quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $351,433 for the common stock and $428,567 for the class A warrants. The warrants were valued using the Black-Scholes model with 153% volatility and discount rates ranging between 0.44% to 0.7%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. </p> <p>Between April 1, 2015 and June 29, 2015, the Company sold a total of 1,012,500 units for cash consideration of $405,000 at a price of $0.40 (the &quot;Units&quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $158,123 for the common stock and $246,877 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between163% - 177% and discount rates ranging between 0.54% to 0.71%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. </p> <p>Between July 1, 2015 and September 30, 2015, the Company sold a total of 140,000 units for cash consideration of $15,000 at price of $0.107 (the &quot;Units&quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $4,294 for the common stock and $10,706 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility of 153% and discount rates of 0.61%. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. </p> <p>Between July 1, 2015 and September 30, 2015, the Company sold a total of 862,500 units for cash consideration of $345,000 at price of $0.40 (the &quot;Units&quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $118,415 for the common stock and $226,585 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between 153% - 182% and discount rates ranging between 0.54% to 0.71%. Of these units $65,000 were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger and $280,000 cash was received subsequent to Closing of the reverse merger. </p> <p>On July 16, 2015 and August 6, 2015, the company issue 517,900 shares to one service provider and 100,000 shares to two service providers, respectively, for services valued at a total value of $617,900, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. </p> <p>On July 16, 2015, 5 Emerald debt holders in amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The Loss on Settlement of Debt recorded was $678,027. </p> <p>On July 14, 2015 the Company issued Emerald's CEO and founder, Lior Wayn, 5,474,545 shares as per the share purchase agreement valued at $877,380, valued on the date of grant for the price of common stock. </p> <p>On July 16, 2015 consultants were issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share The fair value of these warrants is $2,199,507. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class B warrants are fully vested and were accordingly included in expenses as stock based compensation. </p> <p>On July 16, 2015 consultants were issued 2,536,247 Class C Warrants exercisable for a 90 day period, commencing 90 days after the effective date of this Registration Statement, at an exercise price of $0.40 to acquire one (1) share of Common Stock and one (1) Class A Warrant at an exercise price of $0.80. The fair value of these warrants is $3,143,581. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class C warrants are fully vested and were accordingly included in expenses as stock based compensation.</p> <p>On November 17, 2015 the Company sold 250,000 units for cash consideration of $100,000 at price of $0.40 (the &quot;Units&quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $41,304 for the common stock and $58,696 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility ranging between 149% and discount rate of 0.50%. These warrants are fully vested and the fair value and included as stock based compensation on the prior year retained earnings. </p> <p>Between November 5, 2015 and November 16, 2015 the company issue 268,084 shares to three service provider and for services valued at a total value of $268,084, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. </p> <p>On October 1, 2015, the Company granted a total of 534,400 stock options (the &quot;Options&quot;) to three company employees. The options vest over 5 quarters and are exercisable at prices ranging from $0.01 to $0.40 per Share. The options were valued using the Black-Scholes model with 149% volatility and 0.67% discount rate for a total value of $528,857. Of this amount, $397,547 was expensed as of December 31, 2015 and $42,394 as of March 31, 2016. An additional $42,394 was expensed during the three-month period ended June 30, 2016.</p> <p>On January 26, 2016 and March 17, 2016, the Company issued 125,000 shares to one service provider and 50,000 shares to two service providers, respectively, for services valued at a total value of $251,250, arrived at using the stock price on date of grant of $1.75 and $0.65, respectively, per Nasdaq.com. </p> <p>On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. </p> <p>On January 26, 2016, consultants that were previously issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share, exercised the warrants on a cashless basis resulting in 1,928,572 shares issued with no additional related expense booked. </p> <p>On February 11 and 18, 2016, the Company granted a total of 403,333 stock options (the &quot;Options&quot;) to three company employees. The options vest over periods of between 1 and 8 quarters and are exercisable at prices ranging from $0.01 to $0.40 per Share. The options were valued using the Black-Scholes model with 157% volatility and 0.56% discount rate for a total value of $400,914. Of this amount, $231,920 was expensed during the three-months ended March 31, 2016 and $48,711 during the three-months ended June 30, 2016.</p> <p>On March 24, 2016, a convertible note payable was issued to GoldMed Ltd. The warrants were valued at a fair value of $56,030. The note included a beneficial conversion feature which resulted in a $75,000 discount recorded as a reduction of debt and an increase to additional paid in capital.</p> <p>On April 5, 2016, the Company issued 150,000 shares to one service provider for services valued at $105,000 based on the Company's stock price of $0.70 per share on the date of issuance.</p> <p>On May 10, 2016, the Company issued 41,667 shares to one service provider for services valued at $72,911 based on the Company's stock price of $1.75 per share on the date of issuance.</p> <p>On May 18, 2016, the Company issued 150,000 shares to one service provider for services valued at $102,000 based on the Company's stock price of $0.68 per share on the date of issuance.</p> <p>On June 28, 2016, the Company issued 175,000 shares to one service provider for services valued at $122,500 based on the Company's stock price of $0.70 per share on the date of issuance.</p> <p>On June 30, 2016, the Company issued 333,333 shares to one service provider for services valued at $226,666 based on the Company's stock price of $0.68 per share on the date of issuance.</p> <p>On June 6, 2016, a convertible note payable was issued to Alpha Capital. The attached warrants were valued at a fair value of $440,000. The note included a beneficial conversion feature which resulted in a $300,000 discount recorded as a reduction of debt and an increase to additional paid in capital.</p> <p>On April 11, 2016, a convertible note payable was issued to Maz Partner. The attached warrants were valued at a fair value of $80,000. The note included a beneficial conversion feature which resulted in a $46,000 discount recorded as a reduction of debt and an increase to additional paid in capital.</p> <p>On June 30, 2016, a convertible note payable was issued to Ilan Malka. The attached warrants were valued at a fair value of $40,000. The note included a beneficial conversion feature which resulted in a $35,000 discount recorded as a reduction of debt and an increase to additional paid in capital.</p> <p>On April 14, 2016, the Company granted a total of 450,000 stock options (the &quot;Options&quot;) to one Company director. The options vest over periods of between 1 and 3 quarters and are exercisable at $0.60 per share. The options were valued using the Black-Scholes model with 233% volatility and 0.56% discount rate for a total value of $268,839. The Company expensed $89,613 during the three-months ended June 30, 2016 related to these options.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6775559888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3. Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Note 3. Related Party Transactions</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 3. Related Party Transactions </b></p> <p>On July 16, 2015 5 Emerald debt holders in amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The Loss on Settlement of Debt recorded was $678,027. </p> <p>On July 14, 2015 the Company issued Emerald's CEO and founder, Lior Wayn, 5,474,545 shares as per the share purchase agreement valued at $877,380, valued on the date of grant for the price of common stock. </p> <p>The company's CEO, Lior Wayn was owed $3,310 and $3,480 payable as of June 30, 2016 and December 31, 2015, respectively. </p> <p>Following Closing of the reverse merger, $490,000 loan from Zaxis International Inc. to Emerald Medical Applications Ltd. was rendered an intercompany loan and as such was written off.</p> <p>On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph b<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6599585072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4. Employee Payable.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Note 4. Employee Payable.</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 4. Employee Payable.</b></p> <p>For the periods ended June 30, 2016 and December 31, 2015 the Company had $25,867 and $25,612, respectively, in employee payable related to the monthly wages payable to the company's employees. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774896192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5. Notes Payable.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Note 5. Notes Payable.</a></td>
<td class="text"><!--egx--> <p style='margin:0in;margin-bottom:.0001pt'><b><font lang="FR">Note 5. Notes Payable.</font></b></p> <p><i><font lang="FR">Convertible Notes Payable</font></i></p> <p>On March 24, 2016, the Company issued a convertible promissory note to GoldMed Ltd. in the amount of $75,000. The Convertible Note is convertible to 187,500 units at $0.40 (the &quot;Units&quot;), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 months. Since the market price on the date of issuance was higher than the conversion price, a beneficial conversion feature was calculated at $78,750, but only $75,000 was recorded. $20,137 was recorded as amortization expense of for the period ending June 30, 2016, compared to amortization expense of $0 as of December 31, 2015. </p> <p>On June 20, 2016, a $400,000 convertible note payable and 200,000 warrants exercisable at $0.80 per share with a term of 24 months was issued to Alpha Capital. The note included a beneficial conversion feature which resulted in a $300,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $8,219 related to this note. </p> <p>On March 31, 2016, a $80,000 convertible note payable and 200,000 warrants exercisable at $0.80 per share with a term of 24 months was issued to Maz Partner. The note included a beneficial conversion feature which resulted in a $46,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $11,468 related to this note. </p> <p>On May 24, 2016, a convertible note payable was issued to Ilan Malka. The note included a beneficial conversion feature which resulted in a $35,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The Company recorded an amortization expense of $3,548 related to this note. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6604225264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6. Payable - Not Convertible<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note 6. Payable - Not Convertible</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 6. Payable - Not Convertible</b></p> <p style='margin:0in;margin-bottom:.0001pt'>On July 8, 2014 the company issued a convertible promissory note to Axel Springer Plug &amp; Play Accelerator GmbH (the &quot;Holder&quot;), in the amounts of $29,719. The Convertible Notes are convertible at the lessor of a market based discounted and a fixed rate derived from a fixed market cap. The Holders have the right following the Date of Issuance, and until any time until the convertible Promissory Note is fully paid, to convert any outstanding and unpaid principal portion of the Convertible Promissory Note, and accrued interest, into fully paid and non-assessable shares of Common Stock. Holder was not issued warrants with the Convertible Promissory Note. </p> <p>As of December 31, 2015 this note is no longer convertible since pursuant to the loan agreement the in the event that prior to December 31,2015 (the &quot;Maturity Date&quot;), the Company shall consummate a financing round led by unaffiliated investors in the amount of at least Euro 200,000, at a Company pre-money valuation on a fully diluted basis of at least Euro 750,000 (a &quot;Qualified Round&quot;), the Holder shall be entitled (but not obligated) to convert the entire loan amount into the most senior class of shares of the Company issued in such Qualified Round, based on a price per share equal to the lower of the price per share reflected by a Company pre-money valuation on a fully diluted basis calculated at the time of conversion equal to Euro 1,500,000; or - price per share which reflects a 20% discount on the lowest price per share issued pursuant to such Qualified Round. If upon the occurrence of such event the note holder elects not to convert upon receiving notice of such event, then the loan becomes non-convertible. </p> <p>On January 14 and 16, 2015, we issued two promissory notes in the amount of $15,000 each to two different unaffiliated party in consideration for cash transferred to the Company (the &quot;January 2015 Notes&quot;). The January 2015 Notes bears interest at the rate of 1% per annum, are due and payable on January 14 and 16, 2016 and are not convertible to common stock. </p> <p>One of the notes was repaid in full on March 3, 2015 with interest due waived the by the debtor, and the second note was repaid on April 22, 2015 with interest due waived the by the debtor.</p> <p>During the second quarter of 2015, an agreement was reached with the holder of $120,979 advance payable note to settle the full amount due for $30,000 and interest due. The settlement with all note holders resulted in $528 loss on debt settlement due to the payment being higher than principal and accrued interest as of that date as well as a charge of $90,979 considered a contribution of capital due to the fact that note holder, IMWT, was a related party. </p> <p>We concluded that these notes have a stated rate of interest that is different from the rate of interest that is appropriate for this type of debt at the date of the transaction. Accordingly, the company imputed interest at an appropriate rate estimated at 8% as prescribed under FASB ASC 835. The resultant charge of $6,280 for the period ending December 31, 2014 and $4,113 for the period ending March 31, 2015 to interest expense was considered a contribution of capital and was recorded in additional paid in capital. </p> <p>On November 16, 2014 four individuals loaned amount to company, totaling $87,910 with maturity dates of November 16, 2015 and bearing an interest rate of 8% per annum, these notes were fully converted on July 16, 2015 to Company shares of commons stock and warrants as described in Note 3. </p> <p>On March 9, 2016 four individuals lent the company a total of $34,547 with maturity dates of November 16, 2015 and bearing an interest rate of 8% per annum. As of June 30, 2016, the loan was fully repaid.</p> <p>For the periods ended June 30, 2016 and December 31, 2015, the Company has recognized $21,420 and $19,285, respectively, in accrued interest expense related to the stated interest rate on the notes. Interest expense for the periods ended June 30, 2016 and June 30, 2015, respectively, were $21,887 and $11,829, as well as $43,372 and $0 from the amortization of debt discount. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6603325936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7. Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Note 7. Commitments and Contingencies</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 7. Commitments and Contingencies</b></p> <p>The Company received research and development grants from the State of Israel according to guidelines and procedures of the Office of the Chief Scientist of the Ministry of Industry and Trade. According to the agreement, the Company is obliged to pay royalties on the sale of products developed with the participation of the Chief Scientist. The royalty rate is 3.5% and the total royalties will not exceed the amount of the grants. As of June 30, 2016, the Company had an outstanding contingent liability to pay royalties in the amount of $186,335, with $15,795 in accrued interest. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6608333808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8. Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Note 8. Derivative Liabilities</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 8. Derivative Liabilities</b></p> <p>On July 8, 2014 the company issued a convertible promissory note to Axel Springer Plug &amp; Play Accelerator GmbH (the &quot;Holder&quot;), in the amounts of $29,719.</p> <p>The Convertible note is convertible at the lessor of a market based discounted and a fixed rate derived from a fixed market cap. The Holder has the right following the Date of Issuance, and until any time until the convertible Promissory Note is fully paid, to convert any outstanding and unpaid principal portion of the Convertible Promissory Note, and accrued interest, into fully paid and non-assessable shares of Common Stock. The Holder was not issued warrants with the Convertible Promissory Note.</p> <p>The following shows the changes in the derivative liability measured on a recurring basis for the six months ended June 30, 2016 and year ended December 31, 2015.</p> <p>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0;height:.6pt'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Level 3</p> </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative Liability at December 31, 2014</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>20,532</p> </td> </tr> <tr style='height:.6pt'> <td width="71%" valign="bottom" style='width:71.0%;background:white;padding:0in 0in 1.5pt 0in;height:.6pt'> <p style='margin:0in;margin-bottom:.0001pt'>Extinguishment of Derivative Liability</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'></td> <td width="25%" valign="bottom" style='width:25.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>(20,532)</p> </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0;height:.6pt'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative Liability at December 31, 2015</p> </td> <td valign="bottom" style='background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>$</p> </td> <td valign="bottom" style='background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in;height:.6pt'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative Liability at June 30, 2016</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> </table> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p>For the periods ended June 30, 2016 and December 31, 2015 the Company has recognized $0 and $2,013, respectively, in accrued interest expense related to the stated interest rate on the notes. Interest expense for the periods ended June 30, 2016 and December 31, 2015, respectively, were $21,887 and $30,604, of which $0 and $0 is from the amortization of debt discount related to this note The note is no longer considered convertible since the lender elected not to convert, and as such the derivative was written off. </p> <p>As of December 31, 2015 the company has a $0 derivative liability and a $29,719 convertible note payable, net of discount of $0. As of June 30, 2016, the Company has $0 derivative liability and $222,377 of convertible notes payable, net of discount of $412,628. </p> <p style='margin:0in;margin-bottom:.0001pt'>In accordance to ASC #815, Accounting for Derivative Instruments and Hedging Activities, we evaluated the holder's non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the Note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted for as derivative financial instruments. Additionally, since the conversion price of the two notes represented the fair market value of the Company's common stock at the time of issuance, no beneficial conversion feature exists. We believe that the Company's shares of common stock is and have been very thinly traded during the last 3 years and that the fair value of the stock price was deemed not to be a fair value. Management decided that because the Company's ability to continue as a going concern was in question and that it has no revenue sources that the conversion price was a better measure of fair market value. Based on that decision, no beneficial conversion feature was reflected in the financial statements and the $20,165 extinguishment of debt was reflected in the current period earnings and $0 extinguishment of debt was reflected in the current period earnings.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6596250192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9. Other Receivables<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Note 9. Other Receivables</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 9. Other Receivables</b></p> <p>As of June 30, 2016 and December 31, 2015 the Company had other receivables of $8,212 and $25,797, respectively, which represent VAT refunds claimed resulting from excess VAT paid over VAT received. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5066-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5162-111524<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 7<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6603246432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10. Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Note 10. Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 10. Accounts Payable and Accrued Liabilities</b></p> <p>As of June 30, 2016 and December 31, 2015, the Company had Accounts payable and accrued liabilities of $48,204 and $90,705, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6602024464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11. Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Note 11. Subsequent Events</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 11. Subsequent Events</b></p> <p>On August 4, 2016, 31,250 shares were issued to one service provider as per the terms of the service agreement. </p> <p>On July 7, 2016, Emerald entered in a Securities Purchase Agreement and a Registration Rights Agreement with Firstfire Global Opportunities Fund LLC, a New York limited liability company (hereinafter &quot;Firstfire&quot;), pursuant to which the Registrant has issued and sold to Firstfire a secured convertible note bearing interest at 8% per annum in the principal amount of $100,000 with a maturity date on June 19, 2017 (the &quot;Note&quot;). In connection with the Securities Purchase Agreement, the Registrant also granted Firstfire 250,000 Class A and 250,000 Class B Warrants. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774929024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Use of Estimates (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><!--egx--><p><i>Use of Estimates</i></p> <p>The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6601063536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Cash and Cash Equivalents (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Cash and Cash Equivalents</i></p> <p>For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of June 30, 2016 and December 31, 2015.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6610518128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Other Receivables (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Other Receivables</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Other Receivables</i></p> <p>The company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of June 30, 2016 was $8,212.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5212-111524<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3, 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6604134240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Currency Translation and Other Comprehensive Income (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Currency Translation and Other Comprehensive Income</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Currency Translation and other Comprehensive Income</i></p> <p>Balance sheet items are translated using all current translation method for self-contained foreign operations (where functional currency = foreign currency) whereby assets and liabilities are translated using the exchange rate on the date of the balance sheet. It translates revenues, expenses, and net income using the average exchange rate during the period. The foreign exchange adjustment that results from applying the all-current method appears in other comprehensive income, a separate shareholders' equity account, and does not affect net income each period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6601827808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Property and Equipment (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Property and Equipment</i></p> <p style='margin:0in;margin-bottom:.0001pt'>New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 5 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes pla</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6601002848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Valuation of Long-lived Assets (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-lived Assets</a></td>
<td class="text"><!--egx--><p><i>Valuation of Long-Lived Assets</i></p> <p>We review the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51717228&amp;loc=d3e202-110218<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section CC<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6603594432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Stock Based Compensation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Stock Based Compensation</i></p> <p>Stock-based awards are accounted for using the fair value method in accordance with ASC 718,&nbsp;Share-Based Payments. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company's common stock, the estimated volatility of the Company's common stock, the exercise price of the warrants and the risk free interest rate.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6604095808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesEmbeddedDerivatives', window );">Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock:</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Accounting For Obligations And Instruments Potentially To Be Settled In The Company's Own Stock: </i></p> <p>We account for obligations and instruments potentially to be settled in the Company's stock in accordance with FASB ASC 815,&nbsp;Accounting for Derivative Financial Instruments.&nbsp;This issue addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company's own stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesEmbeddedDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49117451&amp;loc=d3e40733-113955<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Embedded Derivative<br> -URI http://asc.fasb.org/extlink&amp;oid=6511375<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56949186&amp;loc=d3e50579-113967<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=28244453&amp;loc=SL5844817-113951<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=58214755&amp;loc=d3e48542-113965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesEmbeddedDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6603594432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Fair Value Measurements (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Fair Value Measurements</i></p> <p>The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p> <p>As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows.</p> <p>Level 1. Observable inputs such as quoted prices in active markets; Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p> <p>The Company values its derivative instruments related to embedded conversion features and warrants from the issuance of convertible debentures in accordance with the Level 3 guidelines. For the six-month period ended June 30, 2016 and the twelve month period ending December 31, 2015, the following table reconciles the beginning and ending balances for financial instruments that are recognized at fair value in these consolidated financial statements. The fair value of embedded conversion features that have floating conversion features and tainted common stock equivalents (warrants and convertible debt) are estimated using a Binomial Lattice model. The key inputs to this valuation model as of December 31, 2015, were: Volatility of 143.9% for the six-month period ended June 30, 2016 and 132.4% for the twelve months period ending December 31, 2015, inherent term of instruments equal to the remaining contractual term, quoted closing stock prices on valuation dates, and various settlement scenarios and probability percentages summing to 100%.</p> <p>&nbsp;</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at June 30, 2016</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Level 3 - Derivative liabilities from:</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Balance at June 30, 2016</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>New Issuances</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Settlements</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Change in Fair Value</p> </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Convertible Note</p> </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="276" style='border:none'></td> <td width="20" style='border:none'></td> <td width="9" style='border:none'></td> <td width="163" style='border:none'></td> <td width="9" style='border:none'></td> <td width="10" style='border:none'></td> <td width="60" style='border:none'></td> <td width="9" style='border:none'></td> <td width="12" style='border:none'></td> <td width="70" style='border:none'></td> <td width="9" style='border:none'></td> <td width="9" style='border:none'></td> <td width="91" style='border:none'></td> </tr> </table> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'><b>&nbsp;</b></p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at December 31, 2015</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Level 3 - Derivative liabilities from:</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Balance at December 31, 2015</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>New Issuances</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Extinguishment</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Change in Fair Value</p> </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Convertible Note</p> </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>(20,532)</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="273" style='border:none'></td> <td width="17" style='border:none'></td> <td width="9" style='border:none'></td> <td width="158" style='border:none'></td> <td width="7" style='border:none'></td> <td width="10" style='border:none'></td> <td width="58" style='border:none'></td> <td width="4" style='border:none'></td> <td width="16" style='border:none'></td> <td width="95" style='border:none'></td> <td width="6" style='border:none'></td> <td width="7" style='border:none'></td> <td width="89" style='border:none'></td> </tr> </table> <p>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>Changes in the unobservable input values would likely cause material changes in the fair value of the Company's Level 3 financial instruments. The significant unobservable input used in the fair value measurement is the estimation for probability percentages assigned to future expected settlement possibilities. A significant increase (decrease) in this distribution of percentages would result in a higher (lower) fair value measurement.</p> <p>The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2016 and December 31, 2015:</p> <p>&nbsp;</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at June 30, 2016</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Level 3</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Assets</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Assets</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Liabilities</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative liability</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Liabilities</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> </table> </div> <p style='margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>&nbsp; </b></p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at December 31, 2015</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp; </p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Level 3</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Assets</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Assets</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Liabilities</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative liability</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Liabilities</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> </table> </div> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>The fair values of our debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.</p> <p>There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2016 or the year ended December 31, 2015.</p> <p>The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of June 30, 2016 or December 31, 2015.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774929024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Earnings Per Common Share (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Common Share</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Earnings per Common Share</i></p> <p>We compute net income (loss) per share in accordance with ASC 260,&nbsp;Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2012.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6602793728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Income Taxes (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Income Taxes</i></p> <p>We have adopted FASB ASC 740,&nbsp;Accounting for Income Taxes.&nbsp;Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.</p> <p>We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.</p> <p>Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate.</p> <p>In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be.</p> <p>ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current period and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6608955344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Uncertain Tax Positions (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesPolicy', window );">Uncertain Tax Positions</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Uncertain Tax Positions</i></p> <p>When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</p> <p>Our federal and state income tax returns are open for fiscal years ending on or after December 31, 2011. We are not under examination by any jurisdiction for any tax year. At June 30, 2016 we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under FIN&nbsp;48.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for tax positions taken in the Company's tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of contingencies related to income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420479&amp;loc=d3e26513-109311<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6597760960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Recent Accounting Pronouncements</i></p> <p>In September, 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805) (&quot;ASU 2015-16&quot;). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company's consolidated financial statements.</p> <p>In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (&quot;ASU 2015-14&quot;). The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods with that reporting period.</p> <p>In April 2015, the Financial Accounting Standards Board (&quot;FASB&quot;) issued Accounting Standards Update (&quot;ASU&quot;) No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (&quot;ASU 2015-03&quot;), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6601378272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><!--egx--><p>&nbsp;</p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at June 30, 2016</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Level 3 - Derivative liabilities from:</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Balance at June 30, 2016</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>New Issuances</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Settlements</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Change in Fair Value</p> </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Convertible Note</p> </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="276" style='border:none'></td> <td width="20" style='border:none'></td> <td width="9" style='border:none'></td> <td width="163" style='border:none'></td> <td width="9" style='border:none'></td> <td width="10" style='border:none'></td> <td width="60" style='border:none'></td> <td width="9" style='border:none'></td> <td width="12" style='border:none'></td> <td width="70" style='border:none'></td> <td width="9" style='border:none'></td> <td width="9" style='border:none'></td> <td width="91" style='border:none'></td> </tr> </table> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'><b>&nbsp;</b></p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at December 31, 2015</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Level 3 - Derivative liabilities from:</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Balance at December 31, 2015</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>New Issuances</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Extinguishment</p> </td> <td valign="bottom" style='padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Change in Fair Value</p> </td> </tr> <tr align="left"> <td width="27%" valign="bottom" style='width:27.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>Convertible Note</p> </td> <td width="2%" valign="bottom" style='width:2.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="16%" valign="bottom" style='width:16.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="6%" valign="bottom" style='width:6.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>(20,532)</p> </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td width="9%" valign="bottom" style='width:9.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td width="273" style='border:none'></td> <td width="17" style='border:none'></td> <td width="9" style='border:none'></td> <td width="158" style='border:none'></td> <td width="7" style='border:none'></td> <td width="10" style='border:none'></td> <td width="58" style='border:none'></td> <td width="4" style='border:none'></td> <td width="16" style='border:none'></td> <td width="95" style='border:none'></td> <td width="6" style='border:none'></td> <td width="7" style='border:none'></td> <td width="89" style='border:none'></td> </tr> </table> <p>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6605889728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1. The Company: Fair Value Measurements: Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><!--egx--><p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>&nbsp;</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Level 3</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Assets</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Assets</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Liabilities</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative liability</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Liabilities</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> </table> </div> <p style='margin:0in;margin-bottom:.0001pt;text-indent:.5in'><b>&nbsp; </b></p> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Fair Value Measurements at December 31, 2015</p> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp; </p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Level 3</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Assets</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td width="78%" valign="bottom" style='width:78.0%;background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Assets</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td width="18%" valign="bottom" style='width:18.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Liabilities</p> </td> <td valign="bottom" style='background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p> </td> <td valign="bottom" style='background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>&nbsp;</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative liability</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'> <p style='margin:0in;margin-bottom:.0001pt'>Total Liabilities</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p style='margin:0in;margin-bottom:.0001pt'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> </table> </div> <p style='margin:0in;margin-bottom:.0001pt'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774310464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8. Derivative Liabilities: Schedule of Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text"><!--egx--><p>&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr style='height:.6pt'> <td valign="bottom" style='padding:0in 0in 1.5pt 0in;height:.6pt'></td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0;height:.6pt'> <p align="center" style='margin:0in;margin-bottom:.0001pt;text-align:center'>Level 3</p> </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 1.5pt 0in;height:.6pt'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative Liability at December 31, 2014</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>20,532</p> </td> </tr> <tr style='height:.6pt'> <td width="71%" valign="bottom" style='width:71.0%;background:white;padding:0in 0in 1.5pt 0in;height:.6pt'> <p style='margin:0in;margin-bottom:.0001pt'>Extinguishment of Derivative Liability</p> </td> <td width="1%" valign="bottom" style='width:1.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'></td> <td width="25%" valign="bottom" style='width:25.0%;border:none;border-bottom:solid black 1.5pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>(20,532)</p> </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0;height:.6pt'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative Liability at December 31, 2015</p> </td> <td valign="bottom" style='background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>$</p> </td> <td valign="bottom" style='background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> <tr style='height:.6pt'> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in;height:.6pt'> <p style='margin:0in;margin-bottom:.0001pt'>Derivative Liability at June 30, 2016</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>$</p> </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0;height:.6pt'> <p align="right" style='margin:0in;margin-bottom:.0001pt;text-align:right'>-</p> </td> </tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41641-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41638-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5580258-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579245-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579240-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41620-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>44
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MD<& % 2DGCUW +YB!0,R$)!Y]K4#\!4HA@DY2,A]/W(0@ 3#B!6(6/G^Q$$
MDH697H.(M>]WIWJ09%;2#G.USE.R$(G9'Z"4BGU0YB85H,D7* N)B_P>5BX%
M>?&@-<D)R192&($YO$/89SEK[#!J\CF+9'F2D(7%C.!T1HG'PMZ6!&B6(H*S
M'OE)C;%+ 30+.Q."4Q_YF8V)2P$TZ0(%SG_DIS?VUAN@6:+ >P#R,QR[&]FH
MF:\W'*.%W1+!&P'RTQQ[ZWK0I'/-VJ%$LQ.P8>)J;P8R./%[:R\BL];I]K&S
M9W3T*2^+CE[9#RJN52N#(U?Z'+:GY85SQ?10XA<]B)N^'TV5FEV4*>:Z+(8;
MPU!1O'M>@*9;6/D74$L#!!0    (  J)%DG>IRMTYP,  +41   8    >&PO
M=V]R:W-H965T<R]S:&5E=#(N>&ULC9C;;N,V$(9?1?!]5IH1*5*!8Z"V4;07
M!19[T5XK-GW ZN!*<KQ]^U*'./+,*+LWD43^0_W#83Z36MZJ^GMS<JX-?A1Y
MV;PL3FU[>0[#9G=R1=9\J2ZN]#V'JBZRUC_6Q["YU"[;]T%%'F(4)6&1G<O%
M:MFW?:U7R^K:YN?2?:V#YEH46?W?VN75[64!B_>&;^?CJ>T:PM4RO,?MSX4K
MFW-5!K4[O"Q^@^<MIIVD5_Q]=K=F<A]TYE^KZGOW\.?^91%U'ESN=FTW1.8O
M;V[C\KP;R;_YWW'0CW=V@=/[]]%_[]/U]E^SQFVJ_)_SOCUYM]$BV+M#=LW;
M;]7M#S?FH+L!=U7>]'^#W;5IJ^(]9!$4V8_A>B[[ZVWHL=$8)@?@&("_&A"/
M ?$] .'3 #4&*!(0#JGT$['-VFRUK*M;4 _5NV3=(H%GY:=ZUS7V,]OW^:EH
M?.O;*HZ6X5LWSBC9#!*<2N!1LA4D>)>$WL#=!8HNL(^/I_&Q'!^+\7$?KZ;Q
MBF0Q2$PO*7L)&F5T2C+A,@"M5"J[4:(;Q=UHXF:0))/76 0D7K@(M4F-;$6+
M5C2WDA KFK_%8FIHB;D,%*!*9#>)Z";A99[)QHCQAF=C23:&VS2&3O^6JQ
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M_)_%4-#X>/P8SG8:J<GPV-\^R/)+RU]02P,$%     @ "HD62?P(016? 0
ML0,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6Q]4]MNW" 0_17$!P0O
MN[EHY;64314E#Y6B/+3/K#VV48!Q *_3OP_@M>.V;E^ &>:<.3,,^8#VS;4
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M_!+.=ARIT?#873[(_$N+OU!+ P04    "  *B19)B*Z!'9X!  "Q P  &0
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MU/\&T4.0DMW<4M*%_[,8"AH?CU_"V4XC-1D>^^L'67YI^0]02P,$%     @
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M_G+3"&W)"9U_V=C_&M&!EY)<[2AI_?^9#0FU"\<;?S;C2(V&P^[R0>9?6GP
M4$L#!!0    (  J)%DFN%-M*HP$  +$#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;&U3P6[<(!#]%>0/"%[6;K<KKZ5LJJ@]5(IR:,^L/;91@'$
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M_O\LAH3&A>-7?S;32$V&P_[V099?6OX#4$L#!!0    (  J)%DD60DI-H0$
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M?Q9#0N/"\9L_FVFD)L-A?_L@RR\M/P!02P,$%     @ "HD62:LT=""B 0
ML0,  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL;5/!;MP@$/T5Q <$
M+^M-JI774C95U1XJ13FT9]8>VRC N(#7Z=\7L-=Q4E^ &>:]>3,,Q8CVU74
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M:&5E=#(V+GAM;&U3P6[<(!#]%<0'!"_K;:*5UU(V5=4>*D4YM&?6'MLHP+B
MU^G?%[#7<5)?@!GFO7DS#,6(]M5U )Z\:67<B7;>]T?&7-6!%NX.>S#AID&K
MA0^F;9GK+8@Z@;1B/,N^,"VDH661?,^V+'#P2AIXML0-6@O[]PP*QQ/=T9OC
M1;:=CPY6%FS!U5*#<1(-L="<Z./N>,YC1 KX)6%TJS.)VB^(K]'X49]H%B6
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M_L]B*&A\/-Z'LYU&:C(\]K</LOS2\A]02P,$%     @ "HD628=84A"A 0
ML0,  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL;5/!;N,@$/T5Q <4
MQW&:5>18:EI5[6&EJH?=,[''-BHP+N"X^_<+.';=UA=@AGEOW@Q#/J!YLRV
M(Q]*:GNDK7/=@3%;MJ"XO<$.M+^IT2CNO&D:9CL#O(H@)5F:)+=,<:%ID4??
MBRER[)T4&EX,L;U2W/P[@<3A2#=T<KR*IG7!P8J<S;A**-!6H"8&ZB.]VQQ.
M68B( 7\$#'9Q)D'[&?$M&,_5D29! D@H76#@?KO /4@9B'SB]ROG9\H 7)XG
M]L=8K5=_YA;N4?X5E6N]V(22"FK>2_>*PQ-<2]@%PA*EC2LI>^M031!*%/\8
M=Z'C/HPWV01;!Z170#H#?B51^)@HRGS@CA>YP8&8L;4=#R^X.:2^$65PQKKC
MG1=JO?=2;/:[G%T"T37F-,:DRY@Y@GGV.46ZEN*4_H"GZ_#MJL)MA&^7V;/=
M.D&V2I!%@NQ+B;??2ER+V7]+PA8]56":.#J6E-CK.*@+[SR==VE\D\_P(N]X
M [^Y:82VY(S.OVSL?XWHP$M);G:4M/[_S(:$VH7CWI_-.%*CX;";/LC\2XO_
M4$L#!!0    (  J)%DES3ZBZI $  +$#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;&U3P6[C(!#]%<0'%,=QVFSD6&JZ6K6'E:H>NF=BCVU48+R
MX^[?%[#CNEU?@!GFO7DS#/F YLVV (Z\*ZGMD;;.=0?&;-F"XO8&.]#^ID:C
MN/.F:9CM#/ J@I1D:9+<,L6%ID4>?<^FR+%W4FAX-L3V2G'S[P02AR/=T*OC
M132M"PY6Y&S&54*!M@(U,5 ?Z?WF<,I"1 QX%3#8Q9D$[6?$MV \54>:! D@
MH72!@?OM @\@92#RB?].G)\I W!YOK+_BM5Z]6=NX0'E'U&YUHM-**F@YKUT
M+S@\PE3"+A"6*&U<2=E;A^H*H43Q]W$7.N[#>+.[G6#K@'0"I#-@GT3A8Z(H
M\R=WO,@-#L2,K>UX>,'-(?6-*(,SUAWOO%#KO9=B<[?/V24033&G,29=QLP1
MS+//*=*U%*?T/WBZ#M^N*MQ&^':9/=NM$V2K!%DDR+Z4^.-;B2LQ^^1;$K;H
MJ0+3Q-&QI,1>QT%=>.?IO$_CFWR&%WG'&_C-32.T)6=T_F5C_VM$!UY*<K.C
MI/7_9S8DU"X<[_S9C",U&@Z[ZP>9?VGQ 5!+ P04    "  *B19)7.6IF:$!
M  "Q P  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6QM4\%NY" ,_164
M#R@)D^E6HTRD3JO5[F&EJH?VS"1.@@HX"V32_?L%,DG3-A? QN_YV9AB1/-F
M.P!'WI74]IATSO4'2FW5@>+V!GO0_J9!H[CSIFFI[0WP.H*4I"Q-;ZGB0B=E
M$7U/IBQP<%)H>#+$#DIQ\^\$$L=CDB6SXUFTG0L.6A9TP=5"@;8"-3'0')/[
M['#*0T0,>!$PVM69!.UGQ+=@_*Z/21HD@(3*!0;NMPL\@)2!R"?^>^7\2!F
MZ_/,_C-6Z]6?N84'E*^B=IT7FR:DAH8/TCWC^ NN)>P#8872QI54@W6H9DA"
M%'^?=J'C/DXWMS-L&\"N +8 [M(H?$H493YRQ\O"X$C,U-J>AQ?,#LPWH@K.
M6'>\\T*M]U[*["XKZ"4076-.4PQ;QRP1U+,O*=A6BA/[!F?;\-VFPEV$[];9
M\_TV0;Y)D$>"_%.)[$N)6S&[+TGHJJ<*3!M'QY(*!QT'=>5=IO.>Q3?Y""^+
MGK?PAYM6:$O.Z/S+QOXWB Z\E/1FGY#._Y_%D-"X</SASV8:J<EPV,\?9/FE
MY7]02P,$%     @ "HD627WTO#F? 0  L0,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL;5/!;N,@$/T5Y \H#G':*G(L-5U5W<-*50_MF=AC&Q48
M+^"X^_<+V''=U!=@AGEOW@Q#/J#YL"V (Y]*:GM(6N>Z/:6V;$%Q>X,=:']3
MHU'<>=,TU'8&>!5!2E*6IK=4<:&3(H^^%U/DV#LI-+P88GNEN/EW!(G#(=DD
M%\>K:%H7'+3(Z8RKA )M!6IBH#XD#YO],0L1,>!-P& 79Q*TGQ _@O&[.B1I
MD  22A<8N-_.\ A2!B*?^._$^94R )?G"_M3K-:K/W$+CRC?1>5:+S9-2 4U
M[Z5[Q>$9IA)V@;!$:>-*RMXZ5!=(0A3_''>AXSZ,-_?I!%L'L G K@!T3!1E
M_N*.%[G!@9BQM1T/+[C9,]^(,CACW?'."[7>>RXV]UE.SX%HBCF.,6P9,T=0
MSSZG8&LICNP'G*W#MZL*MQ&^_:9PMTZ0K1)DD2#[1G![5>):S-U5$KKHJ0+3
MQ-&QI,1>QT%=>.?I?&#Q3;["B[SC#?SAIA':DA,Z_[*Q_S6B R\EO=DEI/7_
M9S8DU"X<[_S9C",U&@Z[RP>9?VGQ'U!+ P04    "  *B19)W[CHK: !  "Q
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6QM4\%NXR 0_17$!Q3'
M2;IIY%AJNJIV#RM5/;1G8H]M5&"\@./NWR]@QW527X 9YKUY,PQ9C^;#-@".
M?"JI[8$VSK5[QFS1@.+V#EO0_J9"H[CSIJF9;0WP,H*49&F2W#/%A:9Y%GTO
M)L^P<U)H>#'$=DIQ\^\($OL#7=&+XU74C0L.EF=LPI5"@;8"-3%0'>CC:G_<
MA(@8\":@M[,S"=I/B!_!^%T>:!(D@(3"!0;NMS,\@92!R"?^.W)^I0S ^?G"
M_ARK]>I/W,(3RG=1NL:+32@IH>*==*_8_X*QA&T@+%#:N)*BLP[5!4*)XI_#
M+G3<^^%FEXRP94 Z M(; !L219D_N>-Y9K G9FAMR\,+KO:I;T01G+'N>.>%
M6N\]YZO=+F/G0#3&'(>8=!XS13#//J5(EU(<TV_P=!F^7E2XCO#UE<+M,L%F
MD6 3"397! \W)2[$/"0W2=BLIPI,'4?'D@(['0=UYIVF\S&-;_(5GF<MK^$/
M-[70EIS0^9>-_:\0'7@IR=V6DL;_G\F04+EP_.'/9ABIP7#87C[(]$OS_U!+
M P04    "  *B19),;3PZ:,!  "Q P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6QM4]MNXR 0_17$!Q2;)+U$CJ6FJVKW8:6J#^TSL<<V*GA<P''W
M[PO8<=VN7X 9YIPY,PS9@.;--@".?&C5V@-MG.OVC-FB 2WL%7;0^IL*C1;.
MFZ9FMC,@R@C2BO$DN69:R);F6?0]F3S#WBG9PI,AMM=:F']'4#@<:$HOCF=9
M-RXX6)ZQ&5=*#:V5V!(#U8'>I_OC-D3$@!<)@UV<2=!^0GP+QI_R0),@ 104
M+C (OYWA 90*1#[Q^\3YE3( E^<+^V.LUJL_"0L/J%YEZ1HO-J&DA$KTRCWC
M\!NF$G:!L$!EXTJ*WCK4%P@E6GR,NVSC/HPW-]<3;!W )P"? ;=)%#XFBC)_
M"2?RS.! S-C:3H073/?<-Z((SEAWO/-"K?>>\_0NS=@Y$$TQQS&&+V/F".;9
MYQ1\+<61_P?GZ_#-JL)-A&^6V6]WZP3;58)M)-A^*Y'_*'$M9O,C"5OT5(.I
MX^A84F#?QD%=>.?IO.?Q3;["\ZP3-?P5II:M)2=T_F5C_RM$!UY*<K6CI/'_
M9S845"X<;_S9C",U&@Z[RP>9?VG^"5!+ P04    "  *B19)O8&%DPU)  !;
M%@$ %    'AL+W-H87)E9%-T<FEN9W,N>&UL[7W9<AO9E>#SS%=D:%1C,B*!
MPLI%93N"HJ2R>K1U2545W1/SD  NR"PE,N',!$DX^N/GK'?)A01EE5UM^\'=
M)2+O=NZY9U]^7U5U=+?)\NH/3Z[K>OOLVV^KY;79)-6PV)H<?ED7Y2:IX9_E
MU;?5MC3)JKHVIMYDWTY&HY-O-TF:/XEV>?KGG;DL=GG]AR?C\]F3/_Z^2O_X
M^_J/+XKE;F/R.DKR5?0RK]-Z'[W.><ZTR*-!]./'%]'1T^/??UO_\???XB >
M>!*]+?+ZNH)!*[-J_OIONWP834=Q-!F-3_I_A%^;/SZPH6?-[^63'\Q56M5E
M @/?)1O3^FICRB1;16_-*ETF672QW6;P'SAC%5T6Y7;8NX]/^VUKNO%H\.^]
M SZ8,BUP[ZOH15*WQNKI_^?_^!]=P/E4)JLTOXH^[C>+(FO^NBFSI/FW"UAU
M12N_RI*KYJ_K)*O:X&"@7<(@  O =V7NHO]C]LWO+G=E21.G%4+M/TQ2]IYK
M,!A/!M/6?>I2Q68#Z/2Q+I:?X^CC=5*:*GJ_JZL:[AG.VS/LPVX!]P0'*Y*Z
MYY-7:6;*Z!)V=%64K1-\W"09_OZ#V19EC8"%G6R3O/6A[E-.[+[_6"?UKFI^
M_A^F]2>9X:<B@U>6E+*SUF?OBIZ!/YLL&WS.BUL DTFJ(C>KZ'55[4S9BVK^
MO;R"/[86:WXIN-GY[;]/'O]J@#X\3[(D7QJX4Z ZK4D#0M!#2EZ8I?UFWO.-
MWDM25;!*BPI<)M4U48PE_H?Y\RZ]23+XOK6?]_4U8$-IE@:^6&0M+/Y4U'#0
M9;!:\YM7Z1U<#?\61[FI6]MI?1$5ZRA9PEWL,D#45;0R0*F7*=-8^.WI>!2?
MSL=TA*<G\7QZ$L,FJZU9UNF-R5K8RMOLWIZ"*DN319JE=6K:\+I8+I$75-$V
MV2,8:&'88+F#S7D#VQBQS8J],3KNH=\!/TK#1]XF9=TZQX4LF>:U@?/6??-^
MO(;7&,$WFR@O:E/U?7=9Y#<&WBTNC1]Z^UB9=;++6E3DGA%R;RMX.@@LNJ?3
M:3P_F? ]C0ZYHV7[-KH_O.<#HIK71;8"<O([/$BZ3-M(]Z$T:P.+K:(*OV_^
M_'_'_Z]]=B+*W9]/6I]?> A<T#M: BTMS;7)*X  7"+\VT1'65%5K0=\L5JE
MB.UPTFV2XHW#6]VF</+[EI&S=D,L! L^>J"B1S*DM0$>\\9!F2XQG.,ES=$<
M^70T'(U&8\3@",C*SGP7P7.%/^'_HHIY6;*K 4?3OYC5=X!'.4 #2?>J)5=T
M3#8[OW>V\7D\.YW%LQ,F#^-Y/)W,X[.S<UF"_EHX5AHE=01DUUBR2Q\ D36;
M!=S9=,R$-D3>UCX/HOW(&PWREPH?Q_LM#*$/FI--#Q<6A?X_C;X56/#_O6_,
M_, QA^[V!W-C\EV;MMV!P%UU$-,?3 4,>,D,: 6#LV*+RS2_^][D"%.FM:M-
MFI/$BO"/C,S=C;0%;Q6NMN^[HS?XYJ)U66STZXZ#,?/39RIS';?.\UJ)L7S1
M(AO727Z%SSU:)ZE@,1%*$"YNZ#QM#N^QNYY9+S8H</T%O^G[Y'O09;Y%ZL('
M!:7 I%>YD-AEZ]V^2G.03%( 8//(W6!^Z*L/97&35G@$6%F_KI.[]G6\ \[1
M30:?)Q7(LX0H:;9#$H=<ALX$U\;H&_U7Y%"Y.<'/<.1K')< VTK@&H1B%/VR
M='O-_^J9_'&/'N_\,N  KP6";[J.WO5D>Y]HW]Q=D$;H]>/H+@>=.$-2VD*8
M"!7&*F.TO +DZKDTX>3!=N[Y_ M()\FOH.7<M@^"OZSQE^!U(YE'TMTCWJU^
MV54USUX7*.X6\!!0PE%D@[_B?Y.XO*M( CMP:O=,<W[TB]J*2&VQC7!3^!2^
MFLJ4-^FRC7GOMPR> SX%1( ;K0RR>OZO8Y8FX"BP&LAX> 0"UI*P &9MVPU>
M ,VB;^Z53U\872O-O;6*![2(HQ?>SF0&&)8TI.XO'/:04-TSC7E =N\99H][
M@"3;?P"2\DTW\_)0G%!QL>]$Q8=>1@J"?/40^M(@$D 1Q=:>GM9%60BGMDCV
M5[ROKC4>VM>:V=#]^WI>E&5Q"Q\!.<CI4;6Y#X TW9+\O!?"T?WE97/773MH
M,<LF;4P<#>D"3=K_"@]6S@&1%^8JS7/<&M"2+5DG'C/<H.C;-_!=D0]H#)%Y
M/'J'_?#YY:MH!;0 ".*R1Q7LVE &0J8,J(02+C- I.AY=)N4:(?L,/S E.-A
M].G:]!FA\)-#QD7ORZLD%RH,&/$\67Z^*H%(K*(#F,_1D]I-]>0X.EI_^_G;
M)/K/Y"ZM(A+^<IT8:.WP&$Y4D;A3;HN2R Y<]/MKD-/@_X_/S\[C**U_!]C.
M-J8]6J/P8F V3^NHZF'T/H\N=E> 5A%H,##T'/ZO?RS8^Q5,?YO6<.-1M5M4
MZ2I%4QJ %[][G;\R)8K1=L31$_LW. EBB?N&J3_L U E3S9TQ_YJ[:-Z@[O.
M? ER!)"-/$WDY#-:$?<): DHF>V#15?%)B6VBP^CR'-#*,C'PRN@XZ(DV=@8
M_/,%$/A;E 5YH?G0TU>B)3ZWE2?HXU>3T6B"!XC>%3<,<_Q+''EW3;O%C5G(
MHAJ\AAT"$81'5).&3I1QD>2?R]VV7B+-HSE^''X< J+9/U\6N[*&Q4ID#GGT
M I69=$F"&^(&7?;[95W@3L93E/I&LW W1JZ;J*1;D$;^VPY@.9ZQL$BCEB"W
M")W ?Y)H$;V\8WA'%U>E8<$1+^[:P LXPL^>7/(P00[X+1$A(;[_J;RI5T.@
M3DO$FR2ZO2ZR;#\H;M$H&^(EKN*\#\/HPZZL=NB'@%NDTQZV[Q T(@;-2?.?
MS^96RE_3_2T]PTWL3 F1&A?XZ"Q]/8G@.I_X]G> !>SM30I__SG9YQ80\(0O
M7[XG..'XJ@#,9=,(KOL@M&!X48+^@7#AI='$ ")S!<=#",Q&P_G9-PJ()1\5
M1@%VS("(G(_F@1E#YT#11<&%J#D>C;[YP@T-HX_^6VW<T-MRZ* 270.N+(P!
MZ66[+= ^2=CC71*#*R9XV8^O$ G@4WCN@".PP04]_S7<#AK)"WY+,J4J.KFY
M!1$:Q,FZ*&F)T@#71J[*H@9]L$ER4/=H"*#:;EGO2H:'!TR$=Y80I\>_PMUY
MPX:1L\'!X?&T=-!4=02#>DWB['2"<_+^USM:$0Z&FZ*=YR%Q65ZGY@;71O0T
M)6G>&R N@*:Y0?ZU8_B%IXGAM28BJ.B>8MR4@A!^@OTME(K699$AT$ / 8H.
M:!'-1TVDHCNQ9);%5;KN3?(9_IUE/C1!?B&M'K!#42I%,J%S%<QK81O 7PW#
M&XAS95\T:G+XC]=5F9@,P?+*+,H=HMWXE"C8*)AZE5ZAW1//G<$687Q9[[:.
M+.97R14S')S>,RC%496(K5Z4(R((F^0*H0[O=<?(#_\/%%[\&Q(+D 2W0.C)
M)?7"E)N$%BKQ@:]KXC$ 11#H:EU*]*\="^\K'&(7(2(*R+&OTV4%W->?\,FQ
M.^;"9( ,IM*Y#]F&)19HF@5$O$&_$ET1;*/Z3-(E_ 4T0W@:)F<LA]FKZV('
M2YJ<'MOV>E\!UP6)CRZ\H(F350HH#]@$R+MF] !RF,)[\W1$!'=: CD%^1@V
M\3M9$UX!R(X@859XYJ%'+1O'8/ C>J'L3W"KBZQ UL#&9M:C-D*OEC@*H+(&
M49(>'-"Z7<4/OF+7PP18']D>%L5J#R<KZ@((#)P0(/_I^8<GQS')K<F6GB9J
M,3B*M@W/#C>#]P:'P[< E K.?"6[@+M&Y3JVV(B<KDS@#_P? Q2TMX@+U0;P
M$];.D?\ ^B.4ZXKD4<007H#1" @@R=J;M"8G09ZEN?B6Z!HV(,IF>T:@O_"3
M#P @YP?)HAM%?.#C4V"PPOX^&Z*40/R4GE4F0Y_*DC1.PF><U;T51?WB6?3N
M3Q_AV']Z^[Z*]4VF>;4KR:W)5"!%2%T7%3DL9%6]1C@COH7Z&@3PJVNTA8 @
MM-@!QKCYZ*X1TW*3D=*>PZ\(32;[R(MD> HT!M3D%=%Y/"((>14^:ECS6QAP
M:Q;1=E?"7!4)M+UHYKV#H^\_5,?\5F[9UKPD\<3.8^&T8,&2*4^^(S$2]2NX
M-W@Y<%K^&Z&9OA.4"JN4_O2!WR\;AU"B1=,%434RR5A[;.6,7]<),!UBG?#X
M\;)70N<QY .I-BL#; *A.V8]&"__B@WJB%'+I=G6CFC^"&_;K)@TT\XN &_@
MNF*0Y-+E-?$1M(<@Y6:.MK,6K8"G(2.X*IBI(>W)0ST,^3ZHBA'P.'@6:75-
M[I@]X!> EJASR<X$UB]O4-K'1VK-&\NB0A>QR*;5;@G/])I5CQWY\MRG:+>#
MP\ +69*OS9#);!B]VI$('N,$L&#@^F&I4DUCM*FJ><9;0VI&M5NCX\RPY+HQ
MALFV6GT6^#11Z<4W%ELAT0$"+=E7[,VX+<K/=#AV\"FI<+BY3EC4*9,4_H[R
M- A]A%^K8K>H@6.#(-B0M3PN+C=F>J_G8;1;%71O ,9LMS)T9TG3:+K.Z)W
M?%L /9D%1 @RZS7\5.E#0?LJ6N-EAV2K0&- NA9YE-S_%=-G%B" %.]R>:_M
M;ST3&S_;3;(7M86UI6!3<#Y9N7&SAX#*2AUX6!/X"7$,HD!#KP<A.KW*:;^
M%Q?N97XH,D2@*OJQ(M1_"0QS0P\0%^+G;8_8>2L=+[_CC7<3@Q(9%LJKGFBG
M$I^Q.^&'5NTV8F\FZ"9TG2A_@#:+"\CEN%O#85G#=8Q&;WB3B ]H_7%R<=\8
MQJ652(LD4[>!8%]6UVZ$F/#<Z@N,5KM2)?[2ABVQ20QD?E 48'Y&'A2J451:
MI7#BTJ&2A<\PLM8V^H^7GK7M%1E,VQO>^D0?6 K@)7)+'Q%5E$=X%_CB,9QC
M@.$<0.W2JVNXW2R%I59B8&5LH/LO2I!/4!N!_<$Y"9($/1 !489#KS)LC.QQ
MK"80M4/!KF$N)'R'RR)ZEQ=M<V('_>QVG0\C]J3^8!T C.*J,=2HN5713Q>?
MD(J UE#A&T]!8F@Z*$"QQ8WCEV24)@[!XT@=(Z[0]#94L> $PO$V[_RD\S!H
M&GEZ%D_&DZ$$NBWWT2?/!^8H=*=?3T.]*, 42(/9B. G4Z"*Q )LY@)??!_;
MQL#]JW<G6P_PT21I[KGF/)O6T2U=%\!O*0JIM4W_H>7*.XYN16WN>WU=^R3<
M5]M"20\S;SW2A7_J8?3:'8FH#K_(V#Y'YHTYF\@1:FXI==F&2WK/5Q\M(I.>
MT'[L^!-3+7W2A$C)=IOM[3I9-E#P"\CA=R#?E>?-Z0C=B4GS("HM?N5F=(V0
M7C[CJC L_0C]],YL$A"R]#0?2KQ588Q(44B9C=Z96U(*[4_&_L3:PK(HT2X
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M;[^8;)I'ZN6RQH]SH?=MZ"C?5I3T_*!/IS,.O?TUP*("?$=T![%\1 2&$W.
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M(?%4 B?@8C885TU.R26\70Q8".,U?]FMKFQ\J/\&A50BP/U4O<X800D+U-Z
M?2NPKUU3%J0ZE1;FD-W9"VZ%+ZFI*<%ZM?SJG8O8RJ"PLE2OE@O3!33#Q(ON
M9&J$"^:=1@WO8"^4+O;O3V2SMHDT=&8[Z<BMZ"QFUD8$R[@J:=WK><0=OBXM
MP+/DEL AQ.I6RUOY>TA\':8NE,0,]1%J8+V3SQK@7'4 )$4H8^2-O57G^*]Z
MT1V#8Q QL%!^,!BE7L3[SJ50?L70'JJ7M94H"HX=JME6C-444HZ7N1/MD#"Z
M\4I(O/&*X. BOP CK5:I%.DG\%! D=(,KY(/P8UKF #2P#4B-0X@G0N+:C_A
M&&G^N_=O8HY?D&?,[Y:(CX=-L&@W]%Q5(D%]?W%;1T$U<3R$3363.T9KN>>A
M1I61S0Q7">J!U"4=2_NP8PTYY;V7$R21T09L;AB:;"6K4J!'%[X(7-;M&=F_
MZ9E^.W9+P2D421/$WG1/6*DZ 5(M)KT4S(&[@$#Z#S(@LF 0;U*5'$7B(%3&
MCTXL%-W:0IFUKM\:ILR\22^T@\,9]%53J!'E,-P@<@5Q0QHKIG1C UH4V?EH
M;8U-0]*.1>UJ$;DUKK*-Z_[>&%D-9]E*2F;<1;L+V:Q/G-+\ILA0GET9+GQ$
M>@/Z\XC.!Q4V7$\ R8S<9N:.CV^N9!U^%98)A]8Q3"S-I0Z)WO-NE4HE [O0
MC\./0R]JK'WZ +3*Q3A]G))NI71<(>)F;;QTF]BO'U637$3(OS!<;@W0$V"*
MT=HX*19KM"F]7.U3JJ;9B"%-34 9&3-@L)!#N6<,Q(E5*L2]A)G5#DH),Q*A
M6O>C8F,_X;1!GKO=#-V);(9>0Q)4T9)28"G#T^40"]LUS1#'!W9C0U)]7*.M
MN?BS6V5K;*P4:/M$@=0'Q^<"]U75Y'+.:>#$(9><SI&>&)&OM0\]H0GD_EV9
M._[92-&49]@(X!'&1$(7<^^D9M.@;870RV2(APP<$WD;QD]8*NCMT0^",WFR
MU,<C$H0&7UKQ(G;>L,W#LPNIY3* 5-Z:-7)/[7;(64FY'R>2+)0_F /CIW]4
MXH+*1?2AJ%()HN_5<'I&'/A9]#-)5MY=4R_L-#.K6.1[27^QPBWYTQ$^6SL)
M1O/F+BJ@ @["Z0 DU9B[1)F"6B!@09(4=Z AEDXR1@1$&L6[ )[]BY@1',T%
MT"\PYI/OKQ3=AQZ@;$=V(W@95EQRWP1A#!Y%LWMO%F:P6(.^4_6^^EKB8-Q6
M%!W4G<KH@!^+YY,I&U40PINPFPQC2N]+X0YID-!((>DNS 'C,RS>&A2;J"Z
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MSF^KJO[C_P=02P$"% ,4    "  *B19)9NIRN*X!  !Y%0  $P
M    @ $     6T-O;G1E;G1?5'EP97-=+GAM;%!+ 0(4 Q0    (  J)%DE(
M=07NQ0   "L"   +              "  =\!  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    (  J)%DDL!2\7>@$  %T4   :              "  <T"  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  J)%DEJ,PTCM0(
M +4)   0              "  7\$  !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ "HD62>"1 (X^ 0  :0,  !$              ( !8@<  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ "HD629E<G",0!@  G"<  !,
M         ( !SP@  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  *
MB19)'5 \*S,"  #G"   #0              @ $0#P  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    (  J)%DD*;_]QF@,  )T+   /              "  6X1
M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  *B19)N)VPZ8D"  "1"0
M&               @ $U%0  >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ "HD62=ZG*W3G P  M1$  !@              ( !]!<  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  J)%DF=PE.R#P0
M "<3   8              "  1$<  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  *B19))"<DK$D"   =!P  &               @ %6
M(   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ "HD62?6V
MCAP;!   ]Q(  !@              ( !U2(  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    (  J)%DG*64X3G@$  +$#   8
M  "  28G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  *
MB19)G'CVU)X!  "Q P  &               @ 'Z*   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ "HD62?P(016? 0  L0,  !@
M         ( !SBH  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   (  J)%DE4S,GLGP$  +$#   8              "  :,L  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  *B19)B*Z!'9X!  "Q P
M&0              @ %X+@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    (  J)%DFY\EJEGP$  +$#   9              "  4TP  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ "HD62:^'((6@
M 0  L0,  !D              ( !(S(  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  *B19)T')/SJ !  "Q P  &0
M@ 'Z,P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  J)
M%DFRR*#XH $  +$#   9              "  =$U  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ "HD624&J4I&> 0  L0,  !D
M         ( !J#<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  *B19)R)Q(;Y\!  "Q P  &0              @ %].0  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  J)%DFJES$>H@$  +$#
M   9              "  5,[  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ "HD62:X4VTJC 0  L0,  !D              ( !+#T
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  *B19)%D)*
M3:$!  "Q P  &0              @ $&/P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    (  J)%DF\!%0ZH $  +$#   9
M  "  =Y   !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M"HD62;!+'36B 0  L0,  !D              ( !M4(  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  *B19)2+L3=:(!  "Q P  &0
M            @ &.1   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    (  J)%DFK-'0@H@$  +$#   9              "  6=&  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ "HD621"R#DR@ 0
ML0,  !D              ( !0$@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  *B19)*N,-9:(!  "Q P  &0              @ $7
M2@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  J)%DF]
MY2:NH@$  +$#   9              "  ?!+  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ "HD628=84A"A 0  L0,  !D
M     ( !R4T  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  J)%DDQM/#IHP$  +$#   9              "
M 0%7  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ "HD6
M2;V!A9,-20  6Q8! !0              ( !VU@  'AL+W-H87)E9%-T<FEN
<9W,N>&UL4$L%!@     I "D $0L  !JB      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>11</ContextCount>
  <ElementCount>107</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - Emerald Medical Applications Corp. - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpBalanceSheets</Role>
      <ShortName>Emerald Medical Applications Corp. - Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - Emerald Medical Applications Corp. - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfOperations</Role>
      <ShortName>Emerald Medical Applications Corp. - Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - Emerald Medical Applications Corp. - Statement of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementOfComprehensiveIncomeLoss</Role>
      <ShortName>Emerald Medical Applications Corp. - Statement of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - Emerald Medical Applications Corp. - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_EmeraldMedicalApplicationsCorpStatementsOfCashFlows</Role>
      <ShortName>Emerald Medical Applications Corp. - Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Disclosure - Note 1. The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompany</Role>
      <ShortName>Note 1. The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Disclosure - Note 2. Stockholders' Equity.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote2StockholdersEquity</Role>
      <ShortName>Note 2. Stockholders' Equity.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - Note 3. Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote3RelatedPartyTransactions</Role>
      <ShortName>Note 3. Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - Note 4. Employee Payable.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote4EmployeePayable</Role>
      <ShortName>Note 4. Employee Payable.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - Note 5. Notes Payable.</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote5NotesPayable</Role>
      <ShortName>Note 5. Notes Payable.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - Note 6. Payable - Not Convertible</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote6PayableNotConvertible</Role>
      <ShortName>Note 6. Payable - Not Convertible</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - Note 7. Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote7CommitmentsAndContingencies</Role>
      <ShortName>Note 7. Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - Note 8. Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilities</Role>
      <ShortName>Note 8. Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - Note 9. Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote9OtherReceivables</Role>
      <ShortName>Note 9. Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - Note 10. Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote10AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Note 10. Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - Note 11. Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote11SubsequentEvents</Role>
      <ShortName>Note 11. Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - Note 1. The Company: Use of Estimates (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUseOfEstimatesPolicies</Role>
      <ShortName>Note 1. The Company: Use of Estimates (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - Note 1. The Company: Cash and Cash Equivalents (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCashAndCashEquivalentsPolicies</Role>
      <ShortName>Note 1. The Company: Cash and Cash Equivalents (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - Note 1. The Company: Other Receivables (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyOtherReceivablesPolicies</Role>
      <ShortName>Note 1. The Company: Other Receivables (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - Note 1. The Company: Currency Translation and Other Comprehensive Income (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyCurrencyTranslationAndOtherComprehensiveIncomePolicies</Role>
      <ShortName>Note 1. The Company: Currency Translation and Other Comprehensive Income (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - Note 1. The Company: Property and Equipment (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyPropertyAndEquipmentPolicies</Role>
      <ShortName>Note 1. The Company: Property and Equipment (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - Note 1. The Company: Valuation of Long-lived Assets (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyValuationOfLongLivedAssetsPolicies</Role>
      <ShortName>Note 1. The Company: Valuation of Long-lived Assets (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - Note 1. The Company: Stock Based Compensation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyStockBasedCompensationPolicies</Role>
      <ShortName>Note 1. The Company: Stock Based Compensation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - Note 1. The Company: Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyAccountingForObligationsAndInstrumentsPotentiallyToBeSettledInTheCompanySOwnStockPolicies</Role>
      <ShortName>Note 1. The Company: Accounting For Obligations and Instruments Potentially To Be Settled in The Company's Own Stock (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - Note 1. The Company: Fair Value Measurements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsPolicies</Role>
      <ShortName>Note 1. The Company: Fair Value Measurements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - Note 1. The Company: Earnings Per Common Share (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyEarningsPerCommonSharePolicies</Role>
      <ShortName>Note 1. The Company: Earnings Per Common Share (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000270 - Disclosure - Note 1. The Company: Income Taxes (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyIncomeTaxesPolicies</Role>
      <ShortName>Note 1. The Company: Income Taxes (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000280 - Disclosure - Note 1. The Company: Uncertain Tax Positions (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyUncertainTaxPositionsPolicies</Role>
      <ShortName>Note 1. The Company: Uncertain Tax Positions (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000290 - Disclosure - Note 1. The Company: Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyRecentAccountingPronouncementsPolicies</Role>
      <ShortName>Note 1. The Company: Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000300 - Disclosure - Note 1. The Company: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables</Role>
      <ShortName>Note 1. The Company: Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000310 - Disclosure - Note 1. The Company: Fair Value Measurements: Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote1TheCompanyFairValueMeasurementsScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTables</Role>
      <ShortName>Note 1. The Company: Fair Value Measurements: Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mrla-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000320 - Disclosure - Note 8. Derivative Liabilities: Schedule of Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://dermacompare.com/20160630/role/idr_DisclosureNote8DerivativeLiabilitiesScheduleOfDerivativeInstrumentsTables</Role>
      <ShortName>Note 8. Derivative Liabilities: Schedule of Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mrla-20160630.xml</File>
    <File>mrla-20160630.xsd</File>
    <File>mrla-20160630_cal.xml</File>
    <File>mrla-20160630_def.xml</File>
    <File>mrla-20160630_lab.xml</File>
    <File>mrla-20160630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001295345-16-000646-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001295345-16-000646-xbrl.zip
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M$W5' KX#<KO*),^*">S[<_;+,,406(^"086TA2TW05V!"P:(F\[;@OP3%P>
M"?]1P![NM$@5]MF8GN")4Z ; 955UW@IR ?+BBF&E00;[',A6&^H4P1CW.NP
M\VESNMKD-8@(P/J8\;WKRR3]0HOCB)Z2/8:IISX;9*D?PO?H1H#A2HP9),4X
M![L"C-DZL] R."39Q$H:;>:]("'B 2ZC(A!$.-\ZIDRVVS2B70;C 009IL"4
MO2:F4_@I4]L,! #25T&(BYW@F;EP*@UKQ+O/9UND;0D"OHCE;E]^-K)2/+3I
MY_ZU=-G8GRP!!>N3,U?(NP%5JW:N-I!P_<"'5N #AT'6J(1'U@N0LW 6T_*
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M:?D$SD$YK7D2B @!Q@503%>-@,P2QJ (,\W %UI>4F18!@99QJM</4=4Z 0
MA77+&[T2U2EG<<NJ]")! [0FL+'FY2M,D66"5J?GO%37([6G&V9?0-@(860%
M6D][YSXKVH'^Y<DX"F=2VQ[180Y,.K)Z/U4!6K ./B7.*^&<@?+'LPOOXM)!
M'+GVDTN9KG[I;%13DF\YAF[!0 <F+!@6%@SL;682AC"NPS]S7 VOOSTZ>T4,
M/_1Z%L-;Z$!0K'*-NDV,C9.F>?/3>9CQ@0#,I0+!,L%ISS .*7A8,O>K$34.
M]I>D'N4\?8SA<3R&XJ !L _*,+:1;6P8/+AUB$#?D9"Q=P["VI,.G]W]Q:Q@
M"P]:A[&#A$)8"#61A0X*@$BS979)@!D\D0&A@\V?R J6+P=BBC%AZTW7BH1C
MK'&:^G.!X6"V36E8HGQ9S8&F]]&M+\>VZ@'**D"@^X1>(N>+6;640G5)#']/
M9*A/NE^DXM!^6J#>R5=-A<"YDK%AL.C:-4Z3&@3QBWGW[: %IDR!)U5(MZRX
M?709PYSE5N44B(D7RPP01=382./0ALJ68?*6#"E<'D9!\$0&NKT8>_.U9TVG
MGGRT[P%ON-?Q$9^/;RF[1,INS'2%6,"%UG.D\A05X.734D/9+&2GB<=&VV-&
M49DJ2\'1FJGEFF6J7*DN>[EZ;;4&_Q$".:9$%G*CBMA1(E$:<@H&5[I[DFJE
M] X'YAIY6+9ASN$S]A:_5CDF ##!:-X?6DJ1%BTR%J7UFP%!HQ1U[0K>XYD!
M/)1Y,L8S"?((# TK5^!@HADF(!;*6"R3<&5\9C\Z/ :=H\,77;EER,K=\+)K
MY&1B ! A9ZA5"A3=SUA]^I'V-\_9:3J?XV0)<IB&$4;'<Y"5@((Y^YEQHA@A
M\'.=O5-;KQQZQHW"GH8\6L&IMLL2<VW,=Q =.+\1&-5D*TA+9&+,- CX4)*L
ME.!,A<_>.'DCRNC03@WJ+U)2K'_4O2J8; RC%ZG">UF7XIL2B<ZL *[%  3L
MQ;?2),O"JP9%BI4WC:GGH";0BP_#WHXN9&39>AYQN!0'YHW /$EBB"B'7DV,
MQSZ9L\>JN H+<QY**F/>:R:H;F-2<Y/E)56$8JS<#*!=$H4!.TDU21P9>3.O
M G[7DH<FI^PS>"\J&5M/Q=P/Y=$S8VJ6PNK/2L9EA:SY<UJC'1WB<R2OPCB9
MXRK>^WF.EBI9X;R0+^):[0\Z4 >[PIC=;*US2+J&8AC]?^G\NV0X>]U.<_2#
M-N&WYA>OTVYVS7LVZV2;>2>,<4NC!@"!3WZF17U (*Q='A<$30%(ED0@HXQ^
MI/2)E$KJ)"RC7\JH)+;P@MPA@[@7H&:3(I,V&Y_MFX@8OV4B@5TP5HH0UC'!
M] X&4D!2S(G1$SHL61\YTB;IDJ7G@V$=__P7.NZ#8XJ4_[Z1"?@C'MMOT% O
MY2#:*%QA"^*^*5%O7S;HJJ6R(!B3]2#7VY)+G8 5DBWHL&3-+PL\![GTRV48
MY.?R.\1[#=;HD9?P8[/UPX\\<6,"@LE?9.*E^L- SE"F)8I$8IKS7^8)Y!7K
M$49$S?0\X\LXB86:72*-!),S1O\:=',/Z"?7^+)5 6=7*BC1W[#=)3M%@NKE
M985"+_+@YJM<#?F=<_9*5JLL!$@-W*5 :4LH[I.(=XX*E:W;L*D/%/YJ*8S9
MJ7?2%,P.9/U6R'JFS8T#4;\9HG(+&/1%C/&U!BDO\O1F]H=M^[0'/]P(A6P4
MM0=D$^F+EB_!3\[%WLT0JPZ(@]=#UW-&:5D[K>I>%K4MHY<LU%V6XQF[=3N6
MO_.E/[G!BOL[+;E_AVNVX4CQ5,8MMSV/H6=IW L['+C[,7#W3LQ]X.T#;Q]X
M^\#;!]Y^^*6/=EGZZ-MD\EOZ'_WUCEKY>,(ZD[^UIX%&>QK'ZW<>&T3[0E'_
MT>&ZO:>!!H]M97L;Q]MU('M_OZ TS+W&A2)9'ZHBIFO+0CUH.FPI'[D$W2$E
M=DB)'8*P7T<0UDJ);=K8!RI_M50^I,6^2;*^N<+S5468G>NK?@>Z?@-T/63&
M#IFQ;S(&=<B,'2*L!^Y.#MF# V\?>/M;X>UG[9;;Z[2?'UC\ZV;Q0X+L01-D
M^\HB>8-'EI+P>L,]C;2OE>TM0;:WE77WM;)]I5E'O3T-M"^ ]D7[X<YLO2Y!
MME9^[NS]EVI8.\72)5=UJY0O,$?A%RRK//'Q)C->"4SQ$F"Y$';E)F--N0&5
M *F]6BEOG5LU-VN 4C>1EZJ7F)O;86:7XU"=,U;=G<-Z"[-85A.015)5#1_K
M(MZ"Z@;)/$W3.2K!&<98G1\0\RP0_-=SAI%JN<N:S+)6DSTWHU:61\4;M%1U
M4:3.LRBY%.GS%2M<>1_87'G-)N<B*")!5P/]5-_G-O<.2W5%[2N.Y<NL>,T=
MK[H6:<H79/$FNL1_J73%#>HT5C-<7^_]Q(>+V^[=#@O"BY7+,>+N[K+%PS7)
MXN$#Y8JU)0@,C_^1P8A_W;-1_!U$Y:5FV*<%O"5^=C/_[P0)5O&^6Z::'HT_
M=Z=$N ,?;*MUW3LKWI'\H;; SAZY[C%%'#8$U1YT15]3(.&1\NY]":!O'?SO
M4IX^@'UC3OD=]/LWI]]+L:3A+F'KP7!]!N*.Q%#-.=3K[RXW<9.#$SL1UQL>
MDA+[U&;M.[&#]RVB5Y(;^T5A&(7HW6ZV'P.3/_":'@D35R+O+X+P8D?$,S A
M-=-[V>S9K(J#56ZC\&S?XW44YQL.0]HCG ODR)?-OHV&NS+RZV>[!^]BWQ/O
M16.NP?TAL'D(;!X<G^_1\=D^]'EP> X.S^,1U5^94/O*P/TJ9?#79PX<@J$'
M?OP*0IV'I.=!;Q\"E8= Y2-DXOT%*K?0!H]FP'*WE$SU*L5^)=SG,!!BSD=Y
M_<4B3:ZH>8DS3I(OJM47-;5/A6ZD)%2CG[9J7>)GLD<8"+IKZ@7W*5F$$V?8
M;C6\5J.SW&9<@F;U,%>MJ[+R,5O92=5J^H1%7U3C*MDHR=4 65V(JNT,L_!*
M-32IZX(BG\)6O?+WS<W2%8)54Z%S/\"ER.9DM9 33JOM;RHGAJDA4MRH'B&N
M.RQ,G?7NNJ?[&S_%EBW4" ;7BLUQJ)\E3;2N&:'LK6RWG'Z&+5.?TU#4Z7)5
M^\QVOV5U$Y0@T&LT=5,]9!J9RBYJ^JPVK.N<4#?A-MAA1&V>A;T:!N'9F].S
MYZJQ^-0WS20ES+K]4!.[B\)X\'RI=31P/8B3D/KC+*_5O_##B.+OL,M4<R&K
M=[?S+"[FV*4V29_C4-3&D@*PR"FR(SD\@D16#4*!%X"YL7$9SODL$-AC*.8A
M:MJ5OY:+1\!GU*Y:<#-PW/=1Q,A!.T\W0BP!6IYM:7RK/6J>4C[DVN'V/:JW
M>:5=$I *MCI*$G[,O!]2RWE\D)K+X=O8PDRBFOH/F:6XI9[M5L,@O>DE?*'I
MQZ:ZTJD)E_!*7<18(HYA@"*=G%/W.JM?L>P[6NW#BKM1=8@JHUQ<4:/4;!6N
MY=0A<1V(!4D<ZA68APWU!C ]O&_XUO11Q'9E>9IP'[?H6K7EKJ,>]FW#TCO<
M;=K!-LJS<]F<"=MB 2(7(*Q(F%%W:233/_RXP":U+&+:>Q<Q[WC#?/*OQ.9.
MW-3-2_6ZU.U'!]W6ZO:C]OA6J]'3(L4B1+0-U!BP]62S,I(K@=RT),>P+35W
M(1R+&#2>5"^XY4W?<]ST@'/LZ1QR^V#L*LQ7=0S)]0# 1;7OTRJY0S=H.JMU
MFFZ65M<?#9[F"T?652( )9:MOI&Y<4TA,=<\P>;7?$V)&@/B4_ 3M2<OL*O8
M'SS0-@M$N.1M(.YWOX)Z\R++N<WT!'8YMIXW[:913OQ6!#->2F6W2J&*-,#K
M1G$F*CWG-!9PUP*+";X?E8F5,W#W]%#U_8XF1:35AX).TYQ?MI2YZE/HIR@-
M2#Z8IM_ZR@_,3-MNJFBH)L#M%IO.J'I!-&%<V_[.+*P.N:^54%T-LC3YEAMS
MECN6&PO+ &$Z,.H&@S -FR:PFA7S69H!GDXU#2+_DC D)1VUNZ_"X-L7RZBS
M/,FGIMJJ>$$-E*XP-EX%PT$-0D)$/#@2?VA"F^[NV<I- ;,3KS2=C^67T9C&
MW5$[%9K%"T$'&IQB@2_ TS/8^'(C9<5T&DY"ZISG7\DK>\3DE;U$1A*:YZ#=
M?"F'?@,MG 7A1#933>2RA)(L1F$QWH"$:-6(.9 117D)T['4;\L;W46%\>'D
MO<M-ZN5FYY[C)*(L;H))Z[&'/1A99LG=8$].T@8?4W<D<1$($0TO:8P-6:V&
MY'AIC^L$SGR\B0>H'*.&DRV<4<VN)4[3^<6TO2< L!]AB-L1^WWR3*KS*!%\
M7&I.OCPB-]BV^H;60 N6# .%;V29ZD]=/V"F7!*PC4&' _N0^JY# OE0J*;H
M;BEI,'5/$@UKN0P&RP]^ P',_7H3Q6[+%IWNUGHI6%@SD$QJGYM$8_=ZM:OA
M(41[EF!+QFLC5W"U?%O3=&2?@R=&32)I;G20@,](VL-GD-1LKP.G@0T<U_"Z
M#1LSZW(W=S8JL($X20.W3L(G$GY;7H7Q11*A?1P@V0$GY)!@8VG2!O(9MCNQ
M(_7$Z M0MI&X8HR(F9R'-XK6WN72I;!T9%GL>YPKTA<!Z>:L,!-];IXU"26R
MA>\20DK85KH.80*QBJ^P#R];<(JK7!*?D.AJ'&$C3K2/>#]@ ^>".1;0#/2C
M06%OZ?W.VWKA7UM\G*GNU23]BC@&YS3+@".8*7%@964B+*9)-0)HL.2S;I&"
M;#UW5N I#QMB$V_@+]@6* HD,$03"0QM$#^VL0#;*.5R=XA/$D"9NA/-&)*$
MV0X:GD/2MP1:!."PE+Q4FHYOEDMLVW*"W)'Z?M=2&Y::)F=576CZTAH["IUF
M_YKT3H+;=%K$ 7^*;6L+7(LBC8V6)9\ C1%>OMRL]@URM I9?9&UQCK>S_E6
MM_*$5ZLBTC0-HVJL,W8EM6[!&%J[0,3^1.TG:6>@^T4\I(P0US1<GF\>70KD
ML< QX+=BPDZ_Y=D;?N6^\;;A,E9:1 1[]YP^*]&$SHUSFF1$\4U.%)E;%FG1
MU)J&D0A<Z1K@K7HL7J",8&KMCNA8J!G@_2\PBFY0GX%:\<D,(%-'7/E*4ZB8
M!DQ(YF,!/F=J+&CD-Y12# 4H\M]D8,)(7<#T&'Q82:Y4NDVT!24X$AK)ABR#
MEI_!56B +9FF8:=80UU7;NS&K?IYVRYGPP./L>)L&I(8M]-0QI6]M%FVH>5,
ME-! AMFRLU?OZI6ED)224JCKS8"FD&%3@;84@.>"OM;VSUA$H;B@;NBK#6 E
MS32<2DNLIKMK;SP2A%D2Z:H.H#YA3\@ :1[.F%5 VJ*01M8 2QV<UR9AK\IU
M?LJ^<3*=HNV%BG0V ZU+HH>(QKI2O[<T#*YG+H3D*5AR@Y?<P"4W<&Q;@.;G
M #R&ZVAF*3$"CI\ LE!?@!%JL9VEOF@JA5=":*^E:EHH/&.X4@H7EA.,3*N:
MAN9$:79(H6-OJ&L58T@5CBU.H\!6,@D-AO(:O!*LXFHB1)#9.\E>,3A<$Q#D
M^&&<7& M"[6C9-2)'_,M78>[HH@MMBZ)2V5/328<KPBY/;AI!%^MFH'ZG->
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M^4"5'>2*&2OXFJ;?2DKJVR2;9CJVS/?2;,N3K;QS4A/JJQ$E95<!G.LY_)"
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MUE'J[=-T?D4;DTMDE1OE\!-4]@X7P'US &!< #6C4"-\HHJ08 5D>J>9:G[
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MVVGWW.%P9,>[2B5 \IM?+ZG!6N4;5-%__?-/+W"Y?_WS_P-02P,$%     @
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MF>6!3,LE?9ZWR==JSB,0M+B8H1\>LQR7,9_;H.L/)E7M].LC(8K&\"<V=#(
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MP4_Y=[B8VD+PA^'65S!5O9;@H*W'.?WIQ\^;W]!_W48$__CY_P%02P,$%
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M]+G@WI42W/AHI !Z];U=0*_)I@;Z=$= QUQ?"FX8\F_%4.7E,YZ!_>8ZG5W
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MZV,+D,P"C6R*5DU<9-O>8V[EVLXCH;$ ]C6AR@N1J#N &^\%NW&;]SC0]
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M-=:XD?P -<^U*-?9'ITQ=D,?=X>+UW$X^9RD-]_.B[A=(DPP9$R@<(&X%Q\
MLJ,%RW)8K=N%52A:/7GO*T? /(93H7LI4X;_RRQ64PRY!$5D;N@MM8UZ7:BI
M]E<"T.5B;)VC78:F4D'26Y*ZAFA^=2;RDYG/HL9Z_&T)'#?<[98@X=[[ENA]
MM]*'L?\MIQ6;/7!).#?$!ZO/.\R0MDR7N@T##3HATHSAO<.KVN%MZ<G^CUW4
M]KYG_D+^,T <__3J?U!+ 0(4 Q0    (  J)%DEJ%REWG&8  ,K" @ 1
M          "  0    !M<FQA+3(P,38P-C,P+GAM;%!+ 0(4 Q0    (  J)
M%DG!>=\IO L   IM   1              "  <MF  !M<FQA+3(P,38P-C,P
M+GAS9%!+ 0(4 Q0    (  J)%DGH\<M =P(  !,(   5              "
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8;6Q02P4&      8 !@"* 0  @:D

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
